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With respect to existing methods of treatment strategies and response monitoring in 
rheumatoid arthritis (RA), there is clearly a need for improvement. The aim of this thesis 
was to explore new treatment strategies and to develop noninvasive molecular imaging 
methods for early response monitoring in experimental arthritis. 
RHEUMATOID ARTHRITIS
RA is a chronic systemic autoimmune disease affecting 0.5% - 1% of the population of the 
western world1. RA is characterized by inflammation of multiple joints, which causes pain, 
swelling and stiffness of the affected joints. On the longer term, this results in detrimental 
and disabling joint erosion and irreversible bone damage. The course of the disease is 
characterized by exacerbations and more quiescent periods. Comorbidities such as 
cardiovascular diseases, asthma or infection, limit the quality of life and the life-span of 
patients with RA2. The pathogenesis is not yet fully understood, but the symptoms are the 
results of an immune response attack on joint tissues. RA is classified as a multifactorial 
autoimmune disease in which several components of the immune system play a role in 
the diverse debilitating processes in the joints. 
Synovium
Healthy diarthrodial joints are covered by intimal and subintimal soft tissue layers, called 
the synovium. The intimal layer consists of macrophages and fibroblast-like synoviocytes 
(FLS), while the subintimal layer contains few inflammatory cells3-5. The synovium forms 
a natural barrier, produces synovial fluids to lubricate the joints to enable smooth 
movement, enables chondrocyte nutrition and cells in the synovium remove unwanted 
debris from the synovial fluid that can contribute to joint damage.
During chronic inflammation, local production of chemoattractants results in recruitment 
and proliferation of macrophages and FLS6, 7. Additionally, inflammatory cells, including 
lymphocytes, monocytes, neutrophils, dendritic cells and plasma cells infiltrate into the 
synovium8, 9. Abnormal proliferation in the synovium can lead to pannus formation, which 
is a pivotal event in the progress of cartilage damage10. The activated macrophages in the 
pannus produce pro-inflammatory cytokines, such as tumor necrosis factor-α (TNFα) and 
interleukin-1 (IL-1)11. IL-1 can also stimulate FLS in the pannus to produce pro-inflammatory 
cytokines and proteolytic enzymes, such as interleukin-6 (IL-6) and matrix metallo-
proteinases (MMPs)12-14. Besides MMPs, FLS also express fibroblast activation protein 
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(FAP). The peptidase and collagenase activity of FAP and MMPs causes extracellular matrix 
degradation and destruction of the collagen type II network in the cartilage13, 15, 16. Overall, 
these processes result in the characteristic progressive destruction of the cartilage layers 
and erosion of the bone in RA patients.  
DIAGNOSIS AND THERAPY
Diagnosis 
To diagnose RA, various methods are used. Besides physical examination, the diagnosis 
can be confirmed by the detection of autoantibodies. The most important autoantibodies 
in RA patients are rheumatoid factor (RF), which are antibodies of any isotype of 
immunoglobulins that are directed against the Fc region of IgG, and anti-citrullinated 
protein antibodies (ACPA) which are directed against citrullinated proteins. Additionally, 
the level of the inflammation marker C-reactive protein can be determined. Unfortunately, 
these methods are not conclusive, which makes it difficult to diagnose patients in the 
early phase of the disease. Early diagnosis is of importance to prevent development of 
irreversible cartilage and bone destruction17-19.
Treatment of RA
Current treatment strategies often involve a combination of disease-modifying 
antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drug (NSAIDs) and/or 
glucocorticoïds (GC), which are administered systemically or intra-articularly. DMARDS, 
e.g. methotrexate, are most commonly used in the early phase of the disease. These 
drugs decrease inflammation by killing inflammatory cells in the joints and thus prevent 
further joint damage. NSAIDs, such as ibuprofen, have a pain-killing effect and an anti-
inflammatory effect when given at high doses. Furthermore, biologicals that neutralize 
a single pro-inflammatory target, such as TNFα and IL-6 can be administered20, 21. It is 
recommended that GC be given at low dose at the start of treatment with DMARDs, since 
DMARDs do not have an immediate effect. However, GC can also be given at high doses 
to obtain a fast and strong effect during strong exacerbations22. Although the treatment 
is often effective, not all patients respond to these drugs, and in some patients severe side 
effects occur. Moreover, treatment can take several months before therapeutic effects are 
observed23, 24. 
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Liposomal drug delivery
Enhanced accumulation of a drug at the target site can be achieved using a drug delivery 
approach. The enhanced accumulation of the carrier-associated drug as compared to the 
free drug can lead to an increased therapeutic effect and could reduce side effects. Several 
drug carriers have been investigated, such as plasma proteins, micelles, antibodies, 
nanoparticles and liposomes. 
Liposomes are small lipid vesicles that can be loaded with antirheumatic drugs and can 
be used for drug delivery to inflamed tissues in RA. To enable efficient drug targeting, 
enhanced permeability and retention (EPR) of the liposomes at the target side is essential. 
In inflamed tissue the local vasculature shows increased permeability. To allow for EPR-
mediated accumulation a long circulation time of the liposomes is crucial. To prevent 
rapid and premature uptake of liposomes by phagocytic cells in the liver, spleen and bone 
marrow upon injection, liposomes can be coated with polyethylene glycol (PEG) polymer, 
which hampers opsonisation of the liposomes and thereby recognition by phagocytes of 
the mononuclear phagocyte system. This results in so-called long-circulating liposomes 
(LCL). The high drug-loading capacity, good biocompatibility, low toxicology and their 
long circulation time, make these LCL attractive drug carriers for EPR-mediated targeting 
in RA.
Therapeutic effects of liposomal drugs have been extensively studied in animal models of 
RA. These preclinical studies have shown that treatment with liposome-formulated anti-RA 
drugs can result in increased and faster anti-inflammatory effects, slower clearance of the 
drug, decreased synovial cell infiltration and reduced cartilage damage25-30. EPR-mediated 
delivery of liposomal prednisolone, methotrexate and indomethacin has shown to result 
in increased uptake in inflamed joints, prolonged therapeutic effects and reduced side 
effects compared to non-encapsulated drugs27, 31, 32. However, the increased therapeutic 
effect of antirheumatic drugs when encapsulated in long-circulating liposomes does not 
solve the issue of non-responsiveness to these drugs as observed in some patients. 
To prevent that unsuccessful and expensive treatments are given to unresponsive patients 
or that patients are treated longer than necessary, there is a need for noninvasive molecular 
imaging techniques that can predict and monitor treatment effects. Molecular imaging 
with radiolabeled PEG-liposomes can be used to evaluate whether a patient has vascular 
permeability to select patients that are amenable for liposomal treatment, emphasizing 
the theranostic properties of PEG-liposomes. Additionally, molecular imaging of specific 
biomarkers of RA (e.g. increased glucose metabolism, protein expression) can determine 
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severity of disease and can be used to follow the development of disease early after 
treatment. Due to the fact that the response to therapy often varies significantly among 
patients, personalized treatment accompanied by accurate therapy response monitoring 
would be optimal. 
OUTLINE OF THE THESIS
The scope of this thesis is to explore and evaluate sensitive techniques to image drug 
delivery realised by PEG-liposomal drugs. In addition, the studies aim to explore the 
potential value of molecular imaging techniques for early diagnosis, and monitoring of 
the therapeutic effects of antirheumatic drugs in experimental arthritis. To achieve these 
objectives, we have used positron emission tomography (PET) and single photon emission 
computed tomography (SPECT). 
The use of liposomes as EPR-mediated drug delivery vehicles and the use of radiolabeled 
liposomes to noninvasively track them in vivo have been described in chapter 2. In 
this chapter, the theranostic application of radiolabeled PEG-liposomes for using them 
simultaneously for diagnosis and for therapy is addressed. 
In the study described in chapter 3, 3 different methods to radiolabel liposomal 
formulations with radionuclides are compared in terms of labeling efficiency and radiolabel 
retention in time. In chapter 4 the feasibility of 18F-FDG-PET to monitor the development 
of arthritis and to monitor the therapeutic effect of prednisolone-containing liposomes 
is investigated in an antigen-induced arthritis model in mice. Chapter 5 presents the 
specific targeting of radiolabeled anti-FAP antibodies and the sensitivity of SPECT using 
radiolabeled anti-FAP antibodies as a tracer to monitor that targeting process. Here, we 
also introduce the potential use of SPECT imaging with radiolabeled anti-FAP antibodies 
for early diagnosis and therapy monitoring in mice with collagen-induced arthritis. The 
potential of this imaging method to monitor the therapeutic effects of prednisolone-
containing liposomes in mice with collagen-induced arthritis is investigated in chapter 6. 
In chapter 7, we used anti-FAP-SPECT/CT imaging to explore the therapeutic potential of 
neutralizing anti-IL-22 antibodies in mice with collagen-induced arthritis. 
Finally, the results and the future perspectives of the studies are discussed in chapter 8.
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ABSTRACT
Introduction: Ever since their discovery, liposomes have been radiolabeled to monitor 
their fate in vivo. Despite extensive preclinical studies, only a limited number of 
radiolabeled liposomal formulations have been examined in patients. Since they can 
play a crucial role in patient management, it is of importance to enable translation of 
radiolabeled liposomes into the clinic. 
Areas covered: Liposomes have demonstrated substantial advantages as drug delivery 
systems and can be efficiently radiolabeled. Potentially, radiolabeled drug-loaded 
liposomes form an elegant theranostic system, which can be tracked in vivo using single 
photon emission computed tomography (SPECT) or positron emission tomography 
(PET) imaging. In this review, we discuss important aspects of liposomal research with a 
focus on the use of radiolabeled liposomes and their potential role in drug delivery and 
monitoring therapeutic effects. 
Conclusions: The developments in the field of liposomes lead to several different 
radiolabeling approaches, resulting in increased labeling efficiency, radiochemical 
purity, and stability in vitro and in vivo.  By in vivo tracking of these radiolabeled liposomes 
using noninvasive imaging, the therapeutic efficacy of the liposomal drug formulation 
could be predicted and could thus be used to steer treatment in the individual patient.
Keywords: Drug delivery, liposomes, PET, radionuclide imaging, SPECT, theranostics
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INTRODUCTION
Ever since their discovery by Bangham et al., liposomes have been studied extensively for 
their diagnostic and therapeutic potential1, 2. Liposomes consist of negatively charged, 
positively charged, non-charged and/or zwitterionic phospholipids. These phospholipids 
are amphiphilic molecules that form the main component of biological membranes. 
After dispersion in aqueous media they spontaneously form multilamellar vesicles of 
varying diameters, which can be sized via extrusion or ultrasonication. The small lipid 
vesicles enclose an aqueous core, which can be used to carry hydrophilic drugs, while 
lipophilic drugs are carried in the lipid bilayer. Amphiphilic drugs consist of a lipophilic 
element and a hydrophilic element. The lipophilic part of these drugs resides in the lipid 
bilayer, while the hydrophilic part is located in the aqueous core or the exterior of the 
liposomes3. Liposomes can potentially be used for delivery of their therapeutic cargo to 
diseased tissues. The targeting of these lipid vesicles is based on the increased vascular 
permeability found in tumours and infected/inflamed tissue, also known as the enhanced 
permeability and retention (EPR) effect4. Additionally, targeting properties are dependent 
on factors that affect in vivo behaviour, such as size, composition, charge and surface 
modification5-7. The size of the liposomes ranges from 50 nm to several micrometers, 
but the most stable liposome range in size from 90-250 nm8.  When smaller than 70 
nm, liposomes are primarily taken up by the liver, while an increase of splenic uptake is 
observed when liposomes are used that are larger than 200 nm. In both cases, circulation 
time of the liposomes is relatively short and biodistribution of the liposomes is altered. 
Liposomes with a diameter of 100-200 nm show up to 4 fold higher tumour uptake rate 
compared to larger or smaller vesicles. Emphasizing the importance of sizing liposomes 
during preparation9. Apart from size, composition of the liposomes is important to obtain 
acceptable stability in vivo. For example, the addition of ample amounts of cholesterol to 
the phospholipids may result in increased rigidity and chemical stability of liposomes in 
physiological conditions. Several liposomal formulations are FDA-approved drug carriers 
carrying anticancer drug, such as vincristine (Marqibo®) or cytarabine (Depocyt®) (Figure 
1.1)10-13. When administered intravenously, conventional liposomes will be coated with 
serum proteins. These serum proteins can act as opsonins, which results in recognition of 
the liposomes by phagocytic cells of the mononuclear phagocyte system and subsequent 
rapid clearance of the liposomes14-16. To increase their circulation time, the liposomal 
surface can be coated with polyethylene glycol (PEG) (Figure 1.2)17, 18, 19, 20. The first FDA-
approved PEGylated liposomal formulations were liposomes loaded with doxorubicin 
(Doxil®/Caelyx®/Myocet®) in 199521. To obtain specific targeting, the liposomal surface 
can be modified with antibodies, peptides or proteins (Figure 1.3)22-25. Ahmad et al. 
demonstrated that immunoliposomes carrying monoclonal antibodies or their fragments 
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(Fab’) at the distal ends of their PEG chain showed specific targeting to solid tumours. 
Additionally, they showed the enhanced therapeutic effects of the targeted liposomes 
containing doxorubicin, compared to non-targeted liposomes26-28. 
Besides being a drug carrier, liposomes can also be labeled with radionuclides to allow 
for in vivo tracking using noninvasive radionuclide imaging techniques, which enables 
a theranostic approach (Figure 1.4). Several methods have been developed to produce 
efficiently labeled and radiochemically stable liposomal formulations. The combination of 
diagnostic and therapeutic capabilities in a single agent can be used to develop specific 
and personalized therapies. This so-called theranostic approach has several advantages. 
Figure 1. Schematic overview of four types of modifications of liposomal formulations. Conventional 
liposomes are composed of cationic, anionic, or neutral phospholipids and cholesterol, and enclose and 
aqueous core (1). These liposomes can be loaded with hydrophobic as well as hydrophilic agents. PEGylated 
liposomes to prolong the circulation time of conventional liposomes (2). Targeted liposomes to which proteins, 
peptides, antibodies, carbohydrates or small molecules can be attached to enable specific targeting of the 
liposomes and their content (3). Theranostic liposomes consist of a liposome, an imaging agent, a therapeutic 
component and a targeting ligand (4) (Reproduced with permission from Sercombe et al.30).
Radionuclide imaging of liposomal drug delivery
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The in vivo biodistribution behaviour of radiolabeled liposomes can be monitored by 
radionuclide imaging. Radiolabeled liposomes could function as a companion diagnostic, 
which is administered prior to therapy to predict accumulation at target sites. This would 
be beneficial to predict the potential therapeutic response and to determine the dose to 
obtain an optimal therapeutic response, while lowering the side effects. If accumulation 
of the radiolabeled liposomes is considered sufficient, the therapeutic liposomes can be 
administered. Additionally, drug-loaded liposomes can also be radiolabeled to verify the 
delivery of their encapsulated drugs to the tissue of interest and for diagnosis of disease. 
Insufficient accumulation of the liposomes could explain a lack of therapeutic response 
or imaging could visualize possible increased immune responses29. Liposomes can be 
adapted when inadequate targeting is observed or the treatment strategy can be altered. 
So, imaging results could have an impact on patient management by protecting patients 
from unnecessary side effects and costs if the treatment does not reach target sites. Thus, 
radionuclide imaging of liposomes and liposomal drugs can play an important role in the 
management of the individual patient.
LIPOSOMES AS DRUG DELIVERY SYSTEM 
To enable sufficient uptake in target tissue and drug delivery, it is of importance to 
obtain physiological and radiochemical stable formulations. To accomplish this, several 
characteristics have been shown to play a crucial role, such as size, composition, charge 
and surface modification31-33. The size of liposomes ranges from 50 nm to several 
micrometers, but the most stable liposome size ranges from 90-250 nm. Additional to 
stability, tissue uptake is also size dependent, with a 4 fold higher uptake rate of liposomes 
with a diameter of 100-200 nm, compared to smaller or larger vesicles. This emphasizes 
the importance of homogenization of size, which can be achieved via ultrasonication or 
extrusion through filters with the desired pore size9. 
Several lipid compositions can be used to successfully prepare liposomes. The choice of 
phospholipids and amount of cholesterol influences liposomal characteristics, such as 
bilayer fluidity, size, zeta potential and the ability of encapsulating drugs or radionuclides. 
Currently, liposomes containing saturated phospholipids, high levels of cholesterol (>5%) 
and that are neutral in charge are well accepted for preclinical and clinical purposes. In vivo 
properties of liposomes are strongly affected by the serum proteins that surround them. 
These serum proteins act as opsonins, which results in recognition of macrophages14-16. 
To avoid rapid clearance of the liposomes it is known to be essential to avoid recognition 
by mononuclear phagocytising cells from the reticuloendothelial system (RES). The well 
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studied method to protect liposomes from serum proteins and increase circulation time is 
the addition of PEG on the surface of liposomes17, 18. Another external surface modification 
that resulted in increased circulation time is the addition of N1-(2-aminoethyl)-N4-
hexadecyl-2-tetradecylsuccinamide conjugated with superhydrophilic polymer (HDAS-
SHP). This method also increased the encapsulation of Doxorubicin and the induction 
activation of complement was less prominent, indicating the significant effects of surface 
modification34.
The first liposome-based radiotracer formulation was called Vescan, which was loaded 
with an 111In-based ionophore within the lipid structure of the liposomes35. Clinical 
trials with Vescan showed that liposomes containing phospholipids and cholesterol 
(DPSC: chol 2:1) were well tolerated and, when radiolabeled, were able to image a wide 
variety of tumours. The compound showed to be highly specific (>95%), but due to lack 
of sensitivity to detect known malignancies (~70%), this diagnostic tool was never FDA 
approved36-38. Although never commercialized, Vescan provided a lot of understanding 
of in vivo behaviour of liposomes, which allowed for the development of other liposomal 
drug loaded formulations. Doxorubicin encapsulated liposomes (Doxil), daunorubicin-
encapsulated liposomes (DaunoXome), vincristine encapsulated liposomes (Marqibo) and 
cytarabine-encapsulated liposomes (DepoCyt) are examples of liposomal formulations 
that have been developed for the treatment of ovarian cancer, breast cancer, Kaposi’s 
sarcoma, acute lymphoblastic leukemia and lymphomatous meningitis39, 40.
RADIONUCLIDE IMAGING
Positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) image acquisition can be used to determine the in vivo behaviour of radiolabeled 
compounds. With these imaging techniques the in vivo distribution of the radiolabeled 
liposomes can be monitored quantitatively during days or even weeks, depending on the 
half-life of the radionuclide used. SPECT imaging is based on the measurement of single 
photons emitted by γ–emitting radionuclides, such as 99mTc (t½ = 6 h), 111In (t½ = 2.8 days) 
or 123I (t½ = 13.2 h). These photons are registered by detectors that acquire multiple two-
dimensional (2D) projections. These 2D images, obtained from different angles, can be 
reconstructed into 3D images (Figure 2A).
PET imaging is based on the emission of positrons by radioisotopes such as 18F (t½ = 110 
min), 68Ga (t½ = 68 min) or 64Cu (t½ = 12.7 h). These positrons annihilate with an electron 
that results in a pair of γ-photons, each of 511 keV, directed in opposite direction. The 
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scintillator converts these photons into visible light, which is detected by a photomultiplier 
and the signals can be is reconstructed into 3D images (Figure 2B)41. 
In a clinical setting, PET imaging outperforms SPECT imaging in terms of sensitivity and 
spatial resolution (PET = 2 - 4 mm vs. SPECT = 4 - 6 mm). In contrast, preclinical microSPECT 
imaging systems have a higher spatial resolution than microPET systems (microSPECT = 
0.3 – 0.5 mm vs. microPET = 1.5 – 2.5 mm)42. Using PET images, uptake of the radionuclides 
in tissues of interest can be determined quantitatively, which remains a challenge for 
(clinical) SPECT images due to the low resolution of these images. Both SPECT and PET 
can be combined with other modalities such as computed tomography (CT) or magnetic 
resonance imaging (MRI) to obtain additional anatomical information43. Here we focus on 
imaging of radiolabeled liposomes using SPECT and PET. 
 
Figure 2. A: SPECT image acquisition. The radionuclide emits γ-rays. The photons are collimated by the lead 
collimator and reach the sodium-iodine (NaI) crystal, which produce scintillation. The scintillation is converted 
into an electronic signal, which is stored digitally to be processed to form the actual image.
B: Coincidence principle of PET. A radionuclide emits a positron, which annihilates with an electron. This 
results in two γ-photons of 511 keV that are emitted in opposite direction. These photons are detected in the 
ring of detectors and the activity distribution can be reconstructed into an image.
A B
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RADIOLABELING OF LIPOSOMES
The choice of radionuclide for radiolabeling of liposomes is dependent on the aim of the 
application. To study the in vivo behaviour of the liposomes, 14C-labeled lipids and 3H-labeled 
cholesterol have been used. Since carbon and hydrogen are present in the original 
molecules of the lipids and cholesterol, the in vivo behaviour will not change upon isotope 
substitution. However, 14C and 3H are pure ß-emitters with long half-lives (5730 years and 
12.33 years, respectively), which makes it unfeasible to use these isotopes noninvasively for 
imaging in live animals or human subjects44, 45. To allow for noninvasive in vivo imaging with 
PET and SPECT, positron and γ-emitters are used. Alternatively, high-energy ß- or α-emitters 
can be used for therapeutic purposes. Radionuclides can be entrapped in the aqueous core 
of the liposomes, entrapped in the lipid bilayer or attached to the surface of the liposomes. 
The radiolabeled formulation should have high radiochemical stability in an in vitro and 
in vivo environment to prevent injection or release of the free radiolabel. Release of the 
radiolabel in vivo alters the biodistribution of the radiolabel and would no longer reflect the 
fate of the liposomes in vivo. Additionally, the physical half-life of the radiolabel should be 
compatible with the circulatory half-life of the liposomes. To obtain radiolabeled liposomal 
formulations, several methods have been developed. Three main approaches for the 
radiolabeling of liposomes can be distinguished (Figure 3): Liposomes can be radiolabeled 
during preparation by (1) passive encapsulation of the radionuclide, or by (2) labeling of the 
liposomal membranes. After preparation of the liposomes, the preformed liposomes can be 
radiolabeled by (3) loading of the radionuclide into liposomes either via an ionophore, using 
a lipophilic chelator, or by labeling the liposomal surface after inclusion of a chelator on the 
surface of the liposomes46.
Encapsulation of radionuclides into liposomes
The first method that was used to radiolabel liposomes is often referred to as ‘passive 
encapsulation’. Using this method, the radionuclide is encapsulated into the internal 
compartment of liposomes during preparation of the lipid vesicles47. To achieve 
encapsulation, the radionuclide (either free or chelated) is added to the aqueous 
solution in which the liposomes are formed. During formation of the lipid vesicles, the 
radionuclide is trapped in the aqueous core of the liposomes. This method has been used 
to entrap 2-Deoxy-2-[18F]fluoro-D-glucose (18F-FDG), 3-[18F]fluoro-1,2-dipalmitoylglycerol 
18F-fluorodipalmitin (18F-FDP) and 99mTc  into liposomes (Table 1). However, the loading 
efficiency is low, often less than 10%, which is far from optimal for the use in (pre)clinical 
studies48-51. 
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Radiolabeling of the liposomal membrane
The second approach involves labeling of the liposomal membrane. Radionuclides can be 
coupled to components of the liposomal membrane prior to the formation of liposomes, 
or a radionuclide containing a hydrophobic molecule can be added to the formulation, 
which would then be incorporated in the lipid bilayer. Although higher labeling efficiency 
can be obtained with this method, stability of the radiolabeling is a risk. Upon i.v. injection, 
the radiolabel could be transchelated to serum proteins in the blood, such as transferrin, 
particularly if no chelating agent is incorporated in the liposomal bilayer and neither in 
the aqueous core. This can result in loss of radioactivity from the liposomes, which can 
affect image quality negatively and may lead to an erroneous impression of the liposome 
distribution. This makes this method less attractive for the in vivo evaluation of the 
biodistribution profile.
Membrane labelling
Passive encapsulation
Ionophore-mediated
Surface chelation
Lipophilic chelator
Remote labelling
Figure 3. Schematic overview of three radiolabeling approaches. Passive encapsulation of the radionuclides 
during preparation using a chelator (DOTA), liposomal membrane labeling during preparation of the 
liposomes, remote loading of radionuclides into preformed liposomes via ionophores or using lipophilic 
chelators (2-hydroxyquinoline), and surface labeling after incorporation of a chelator (DOTA)  to the lipid 
bilayer or PEG are shown. In this figure, radionuclides are represented by the open circles. 
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Radiolabeling of preformed liposomes
For application in the preclinical or clinical setting, it is important to use a fast (0.5 - 2 
h) method to produce a radiolabeled product. Additionally, high incorporation efficiency 
(preferably >50%) and good retention of the radiolabel are mandatory. Most efficient 
labeling and the best radiolabel retention of liposomal formulations can be obtained with 
remote loading methods. These methods attach the radiolabel to preformed liposomes. 
Various remote labeling methods have been developed, which use transmembrane pH, 
osmotic or a concentration gradient. Recently, it has been demonstrated that 64Cu can 
cross the liposomal membrane of preformed liposomes unassisted, when these liposomes 
contain a high affinity copper chelator, such as 1,4,7,10-tertraazacyclotetradecane-
1,4,7,10-tetraacetic acid (DOTA). The chelator binds free copper in the aqueous core, 
resulting in copper depletion and establishes a steep transmembrane copper gradient. 
Upon incubation with 64Cu, 64Cu diffuses spontaneously across the bilayer to be trapped 
in the liposomal core. The high loading efficiency (>95%) and high radionuclide retention 
after incubation in mouse serum (>95% after 18 h at 37 °C), demonstrate that this easy 
remote labeling method has great potential for future use in (pre)clinical settings52. 
Nevertheless, most remote labeling methods require the use of ionophores or lipophilic 
chelators to assist the radionuclide to accumulate in the liposomes.
Radiolabeling of preformed liposomes using ionophores
The use of hydrophilic ion transport molecules can be used to actively transport the 
radiolabel into the aqueous core of preformed liposomes, where the radionuclide can 
subsequently be trapped by encapsulated chelators. Ionophores form a hydrophilic 
channel through the lipid bilayer, which allows radionuclides to pass through the 
membrane without interaction with the lipophilic bilayer. For example, the ionophore 
A23187 can be incorporated in the lipid bilayer to label liposomes with 111In3+ at 60-80 °C. 
After crossing the bilayer, the 111In3+ is chelated by the encapsulated chelator nitrilotriacetic 
acid (NTA). A high, up to 90%, labeling efficiency can be achieved; however radiolabel 
retention was not checked53. Unfortunately, the incorporation of an ionophore in the lipid 
bilayer and the need to radiolabel at high temperatures might alter the behaviour of the 
liposomes in vivo. 
Radiolabeling of preformed liposomes using lipophilic chelators
To obtain radiolabeled liposomes lipophilic chelators, such as 8-hydroxyquinoline 
(oxine), can be used for the remote loading of radionuclides such as 67Ga, 68Ga, 111In or 
99mTc. Radionuclides can form complexes with lipophilic chelators, and these complexes 
can diffuse through the lipid bilayer. For example, liposomes can be incubated with 111In-
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Oxine. The hydrophilic oxine is incorporated into the lipid bilayer of the liposomes. After 
crossing the liposomal membrane, the chelated radionuclide can be transchelated to a pre-
incorporated hydrophilic chelator such as diethylenetriaminepentaacetic acid (DTPA)54-56. 
Pre-incorporation of a chelator in the core of the liposomes increases the radiolabeling 
efficiency and radiochemical stability significantly55. The advantage of transchelation to 
encapsulated chelators such as desferal or DTPA, is that after release from the liposomes, the 
radiolabeled complex is rapidly cleared via the kidneys, while non-chelated radionuclides 
can bind to serum proteins, resulting in accumulation in tissues like liver, spleen, lymph 
nodes and bone marrow. The most widely known labeling procedure to label liposomes 
makes use of the lipophilic chelator hexamethylpropyleneamine oxime (HMPAO). 99mTc 
forms a lipophilic complex with HMPAO and crosses the lipid bilayer. After crossing the 
liposomal membrane, HMPAO is converted into membrane impermeable hydrophilic 
complex by interaction with the encapsulated glutathione, resulting in the entrapment 
of the complex in the aqueous core57, 58. This strategy can exceed 90% labeling efficiency 
and shows good in vivo radiolabel retention. This method has been used to prepare 99mTc-
labeled liposomes to detect infection and inflammation in patients59. Using a similar 
approach, liposomes have also been labeled with PET radionuclides, such as 64Cu. 64Cu 
is transported across the lipid bilayer by the lipophilic chelator 2-hydroxyquinoline and 
trapped by encapsulated DOTA, resulting in stably radiolabeled liposomes60. 99mTc can also 
form a complex with N,N-bis(2-mercaptoethyl)-N’,N’-diethyl-ethylenediamine (BMEDA), 
which is transported across the membrane in the same manner, but entrapment of the 
radioactive complex is based on a pH gradient. The amino groups of the complex are 
protonated in the acidic aqueous core of the liposomes, which traps the complex inside 
the liposomes5. 
Radiolabeling of preformed liposomes using surface chelators
The surface of liposomes can be radiolabeled by exposure of chelators on the lipid 
bilayer. In this convenient method, a phospholipid is derivatized with a chelator and is 
incorporated in the lipid bilayer during preparation of the liposomes. Phospholipids such 
as distearoylphosphatidylethanolamine (DSPE) have been derivatized with chelators such 
as DOTA, hydrazinonicotinamide (HYNIC) or DTPA. Subsequently, these liposomes can be 
incubated with 64Cu, 99mTc or 111In, respectively, which results in > 95% labeling efficiency 
and excellent radiolabel retention55, 61. 
To use a radiolabeled liposomal formulation for diagnostic or therapeutic purposes, 
efficient and stable labeling of the liposomes is required. Preferably, the method to 
label the liposomes is a one-step procedure and can be carried out within one hour, 
with minimal radiation exposure for the technical personnel during preparation. 
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Nowadays, passive encapsulation of the radionuclide into the liposomes during 
preparation is barely used. Low labeling efficiencies, the necessity of a purification 
step, radioactive contamination of the equipment and the need of a fresh batch of 
liposomes makes this a laborious method. Although labeling efficiency is higher 
when the liposomal membrane is labeled, it is still not optimal because purification 
of the radiolabeled product is necessary, and a fresh batch of liposomes should 
be prepared each experiment. Therefore, remote labeling methods are preferred. 
In remote labeling methods preformed liposomes are used, making the method less 
time-consuming and laborious. Efficient labeling has been shown for all remote labeling 
methods. However, labeling of liposomes with a chelator incorporated in the lipid bilayer, 
can be labeled most efficiently and with high specific activity (up to 15 GBq/mmol for 
111In-DTPA-PEGylated liposomes), radiochemical stability without affecting the in vivo 
behaviour or biodistribution. The simplicity of the preparation, efficient labeling and 
sufficient radiochemical stability make the use of surface chelation the most convenient 
method to use.
RADIONUCLIDE IMAGING WITH RADIOLABELED LIPOSOMES
SPECT and PET imaging allows noninvasive monitoring of the in vivo pharmacokinetics 
and tissue distribution of the liposomes. Radionuclide imaging allows for longitudinal 
monitoring of their behaviour in animals, as well as in patients. In addition to tracking 
radiolabeled liposomes, the liposomal payload can be radiolabeled to monitor the fate of 
encapsulated drugs. Potentially, these techniques may play an important role in translating 
liposomal drug formulations into clinical practice. In addition, the approach could be used 
to predict target localization and possibly therapeutic effects of liposomal drugs which 
could help personalize therapy for individual patients. SPECT and PET imaging studies 
with radiolabeled liposomes are discussed below. 
SPECT imaging with radiolabeled liposomes
SPECT imaging with radiolabeled liposomes has been applied in a broad range of animal 
models: multiple types of cancers, imaging of infection, inflammation, artherosclerotic 
plaques and blood pool imaging72, 73. With their half-life of respectively 6 h and 2.8 d, 99mTc 
and 111In are well-suited to monitor the fate of liposomes in vivo using SPECT imaging, since 
liposomes usually have a half-life of less than 24 h in rodents and 48 h in humans32, 74-76. 
The only liposome-based radiotracer formulation that was used in late-stage clinical trials 
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was a liposomal formulation radiolabeled with 111In, which was enabled by incorporation 
of the ionophore A23187 in the lipid bilayer and encapsulation of NTA as chelator35. 
Clinical studies with this formulation showed that liposomes containing phospholipids 
and cholesterol were well tolerated and that a wide variety of tumours could be imaged. 
Imaging studies in cancer patients showed high specificity (>95%). However, due to lack 
of sensitivity (~70%) to detect known tumour lesions, this diagnostic tool was never 
approved by the Food and Drug Administration (FDA)36-38. Although never commercialized, 
it provided in-depth insight in the in vivo behaviour of liposomes in cancer patients and 
paved the road for the development of new radiolabeled liposomal formulations. SPECT 
imaging of polyethyleneglycol (PEG) coated and 111In-labeled liposomes was performed 
to visualize tumour lesions in different types of locally advanced cancer (head and neck, 
breast, bronchus and cervix cancer and glioma patients). Uptake in the tumours was highest 
in patients with head and neck cancers (33.0 ± 15.8% ID/kg (percentage of injected dose/
kg)), while uptake in long tumours was 18.3 ± 5.7% ID/kg, and the breast cancers showed 
relatively low uptake levels (5.3 ± 2.6% ID/kg). They showed that radiolabeled PEGylated 
liposomes accumulate in solid tumours and remain there for prolonged periods77. 
Besides studies focusing on cancer imaging, SPECT imaging with radiolabeled liposomes 
was also applied to image infectious and inflammatory foci. As early as the late 1980s, 
radiolabeled liposomes were shown to localize preferentially in inflamed tissues59, 78-82. 
99mTc-labeled PEGylated-liposomes showed superior performance as vehicles for 
scintigraphic imaging of inflamed joints in rats with experimental arthritis and showed 
increased targeting compared to non-PEGylated liposomes79, 83. PEGylated liposomal 
formulations have also been used to detect inflammatory foci in patients. These studies 
showed that the use of radiolabeled liposomes for scintigraphic imaging of infection and 
inflammation was safe, sensitive and specific. In addition, such radiolabeled liposomes 
were used to image arthritic lesions in patients with RA59, 77, 79-81. These studies indicated 
that radiolabeled liposomes can be used to predict their potential for drug delivery by 
determining their accumulation in arthritic joints.   
Liposomes were efficiently labeled with 99mTc with high specific activity using HYNIC as a 
surface chelator. This allowed the use of a very low lipid dose. Interestingly, scintigraphic 
imaging showed that these liposomes were rapidly cleared from the circulation when 
these very low lipid doses were administrated. This was shown in rats and mice with a 
focal E. coli infection as well as in 4 patients suspected of infection or inflammation and 
would not be clear without SPECT imaging84. SPECT imaging with 111In-labeled PEG-
liposomes was used to visualize S. Aureus infection in mice (Figure 4) and rabbits55, 72. 
The latter study demonstrated that the accumulation of the liposomes in the infected 
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tissue could be visualized with SPECT up to 72 h after administration of 111In-labeled PEG-
liposomes (Figure 4D). 
Figure 4. MicroSPECT/CT images of a mouse with a S. Aureus abscess in the left thigh muscle. Images were 
acquired at 1 h, 4 h, 24 h, 48 h and 72 h after injection of 111In-labeled PEGylated liposomes. At all time points, 
uptake in the abscess and the characteristic splenic and hepatic uptake is visualized (arrows) (Reproduced 
with permission from van der Geest et al.55). 
More recently, SPECT imaging contributed to gain insight in the in vivo behaviour of 
newly developed liposomal formulations32, 73. Artherosclerotic plaques are characterized 
by infiltrating macrophages. These macrophages recognize phosphatidylserine (PS). In 
an attempt to visualize vulnerable plaques, 111In-labeled PS-modified liposomes were 
investigated. SPECT imaging with PS-coated liposomes visualized artherosclerotic 
plaques in apolipoprotein E-deficient (apoE2/2) mice as well as in Watanabe heritable 
hyperlipidemic (WHHL) rabbits. Surprisingly, in this study, imaging showed that PEGylation 
of the liposomes did not improve targeting properties and that larger liposomes showed 
higher accumulation in the macrophages as compared to smaller vesicles73.
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PET imaging with radiolabeled liposomes
PET imaging with radiolabeled liposomes has been studied less frequently as compared to 
SPECT imaging and has only been carried out in animal models. The well-known positron 
emitters for PET imaging, 18F and 68Ga, have been used successfully to radiolabel liposomes 
and to image different types of cancers. 18F- and 68Ga-labeled liposomes showed stable 
radiolabel retention in vivo and their accumulation in tumour lesions was sufficient to 
visualize tumour lesions with PET imaging85-87. However, the biological half-life of PEGylated 
liposomes is generally between 24 and 48 h. Even though tumours could be visualized 
with 18F- and 68Ga-labeled liposomes, the short half-life of these radionuclides (110 min 
and 68 min, respectively) limits the duration of examination with PET. To be able to image 
at later time points to evaluate the dynamics of the accumulation in tumours, liposomes 
labeled with radionuclides with longer half-lives should be used. Liposomes labeled with 
64Cu (t½ = 12.7 h) and 89Zr (t½ = 78.4 h) have been developed. These liposomes allow for 
tracking of liposomes for a longer period of time, up to 2 weeks after injection for 89Zr-
labeled liposomes. PEG-liposomes labeled with 64Cu were used to evaluate PET imaging of 
cancer lesions and tumour-associated macrophages33, 60, 88. In these studies, 64Cu-labeled 
PEGylated liposomes appeared stable in the circulation and accumulated efficiently in 
tumour lesions. Additionally, it was shown that after mannosylation of these liposomes, 
the liposomes were actively taken up by tumour associated macrophages (Figure 5). This 
resulted in high quality images up to 24 h post injection. Dosimetric analysis indicated an 
effective dose of 3.3 • 10-2 mSv/MBq for 64Cu-labeled PEGylated-liposomes, which would 
be acceptable for using these liposomes as a diagnostic imaging agent in patients33. 
Liposomes have been labeled with 89Zr to evaluate their pharmacokinetics over a week 
with PET6. Recently, PEGylated-liposomes labeled with 89Zr as well as with gadolinium ions 
have been developed. This resulted in a liposomal formulation that enabled combined 
PET and MR imaging. Additionally, these liposomes were surface-coated with octreotide, a 
peptide targeting the human somatostatin receptor type II, for specific tumour targeting89. 
In vitro serum protein studies and bone uptake of 89Zr uptake indicated limited stability of 
these radiolabeled liposomes. Still, dual PET/MR tracking of the liposomes was feasible 
and specific tumour uptake was observed. This provided proof of principle for ability 
to monitor the targeting properties of the liposomal formulation using this multimodal 
approach.
Only preclinical studies demonstrated the potential of using radiolabeled liposomes for 
PET imaging. So far, to our knowledge, no clinical studies have yet been published that 
include PET imaging to monitor radiolabeled liposomes.
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Figure 5. MicroPET/CT-images of a mouse bearing human colon adenocacinoma (HT29, arrows) on their right 
and left flank. Image acquisition was performed 24 h post injection of 64Cu-labeled PEGylated liposomes A: 
Coronal PET image showing both tumours (arrows). The characteristic uptake of liposomes in spleen and liver 
is also visualized (arrowheads). B: Axial PET image (top) and PET/CT image (bottom), showing both tumours 
(arrows) (Reproduced with permission from Petersen et al.60). 
THERANOSTIC LIPOSOMES
Radiolabeled drug-loaded liposomes can be applied simultaneously for drug delivery 
and radionuclide imaging. The combination of a diagnostic agent and a therapeutic 
agent results in a theranostic compound. The most obvious way to conceive theranostic 
liposomes is to radiolabel a drug containing liposomal formulation to monitor the 
liposomes and their content using imaging methods. Besides radiolabeling of drug-
loaded liposomes, liposomes can be labeled with beta-emitting radionuclides such as 
90Y, 166Ho, 177Lu, 186Re and 188Re or with alpha-emitters such as 225Ac or 213Bi and directly 
function as radiopharmaceutical or enable the combination of chemotherapy and 
radionuclide therapy. Liposomes can be labeled with these radionuclides using similar 
methods as described above (2: radiolabeling methods). However, in vivo behaviour of 
these theranostic agents has not been widely examined. 
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Chow et al. demonstrated that accumulation of 111In-labeled vinorelbine-liposomes 
in human colorectal carcinoma HT-29/luc xenografts in mice could be visualized using 
scintigraphy. Additionally, they showed that tumour growth could be inhibited by the 
combination therapy of 111In-labeled vinorelbine-liposomes and unlabeled vinorelbine-
liposomes. They demonstrated the possibility to provide diagnostic and therapeutic 
efficacy evaluation using a single theranostic liposomal formulation90.
The first and only clinical study including radiolabeled drug-loaded liposomes was 
performed with 99mTc-DTPA-labeled doxorubicin loaded PEGylated liposomes to image 
uptake in patients with glioblastomas and metastatic brain tumours91. The authors 
claimed successful accumulation of the radiolabeled drug in tumour tissue suggesting 
that doxorubicin loaded PEGylated liposomes may increase the effectiveness of the (radio) 
therapy for brain tumours. However, there are some major concerns about the labeling 
methods that have been used in this study92. The method is based on the assumption that 
adding 99mTc-DTPA to PEGylated liposomes results in radiolabeled liposomes. However, 
due to the lack of any driving force to escort 99mTc-DTPA through the lipid bilayer, this 
method might reveal an unstable radiolabeled product. Additionally, the applied quality 
control method did not distinguish between 99mTc-DTPA and 99mTc-DTPA-liposomes59, 
77. A control scan with 99mTc-DTPA could show that the scan with 99mTc-DTPA-labeled 
doxorubicin loaded PEGylated liposomes represent the accumulation of the liposomes 
instead of free 99mTc-DTPA. 
The same doxorubicin loaded PEGylated liposomes have been radiolabeled with 99mTc via 
the direct labeling method using BMEDA as a chelator for noninvasive imaging studies. 
They showed that the in vivo biodistribution and pharmacokinetics of 99mTc-labeled 
doxorubicin loaded PEGylated liposomes could be determined using scintigraphic 
imaging. In this study, the therapeutic effects were not examined, since only healthy 
animals were used. Nevertheless, they showed that this labeling method results in a 
radiochemical stable 99mTc-labeled product, which may be extended to 186Re and 188Re5. 
This method has been used in preclinical studies that show that 188Re-labeled PEG-
liposomes inhibit the growth of human non-small cell lung carcinoma (NCL-H292) and 
glioma xenografts93, 94. Additionally, Soundararajan et al. labeled liposomal doxorubicin 
with 186Re, showing that the combination therapy was more effective in inhibiting growth 
of head and neck tumours than liposomal doxorubicin alone95. PEGylated-liposomes were 
also radiolabeled with 177Lu. Based on preclinical dosimetric studies in mice with human 
tumour xenografts, the authors estimated that a high radiation dose could be delivered 
to tumour lesions (114 mGy/MBq). Since, 177Lu, 186Re and 188Re emit both ß-particles as well 
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as γ-photons, labeling of liposomes with these radionuclides results directly in theranostic 
agents96. 
The use of α-emitting radionuclides to deposit highly focused energy can cause efficient 
elimination of particularly single cells and micrometastases with limited toxicity to 
surrounding normal tissues. Immunoliposomes labeled with 213Bi have shown to be 
effective in mice with early-stage breast cancer metastases. Median survival times were 
similar to those obtained with antibody-mediated delivery of 213Bi. Although the tumour 
absorbed dose (1.9 ± 0.6 Gy) induces a therapeutic effect, the radiation dose in other 
organs was disturbing, e.g. the spleen (28 ± Gy)71.
Proper evaluation of the potential risks of the radiotherapeutic liposomes labeled with 
high-energy ß- and α-emitters is mandatory. Dosimetry studies are essential to estimate the 
radiation doses to various non-target organs, such as liver and spleen, in which significant 
uptake of liposomes is expected. Liposomal delivery of high-energy ß- and α-emitters for 
therapeutic purposes merits further consideration prior to clinical implementation.
CONCLUSION
The developments in the field of liposomes lead to several different radiolabeling 
approaches, resulting in increased labeling efficiency, radiochemical purity, and stability 
in vitro and in vivo. Which method is optimal depends on the application, the choice of 
radionuclide and the type of liposome. In general, labeling of liposomes via a chelator 
incorporated in the lipid bilayer, results in efficient labeling with high specific activity, good 
in vivo stability and unaltered in vivo behaviour. Several types of cancer, infectious foci and 
inflammatory tissue have been successfully visualized using SPECT and PET imaging after 
administration of the radiolabeled liposomes. Studies with radiolabeled liposomes have 
provided important insights in the in vivo behaviour and targeting properties of liposomal 
drug formulations. Most importantly, radiolabeled liposomes could be used to predict 
the therapeutic efficacy of drug-loaded liposomes. However, the theranostic applications 
of liposomes have not been clinically exploited yet. Noninvasive imaging of the in vivo 
targeting of the radiolabeled liposomes could predict the therapeutic efficacy of the 
liposomal drug formulation and could thus be used to steer treatment in the individual 
patient. 
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ABSTRACT
Introduction: Long-circulating liposomes (LCL) are often used as a drug carrier system 
to improve the therapeutic index of water-soluble drugs. To track these LCL in vivo, 
they can be radiolabeled with 111In-oxine. For this labeling method, generally DTPA is 
encapsulated in the aqueous phase of LCL (DTPA-LCL). Alternatively, LCL can be labeled 
with 111InCl
3 
after incorporation of DTPA-conjugated DSPE in the lipid bilayer (DTPA-DSPE 
LCL). Here, we compared the in vitro properties of DTPA-DSPE LCL with those of DTPA 
LCL and empty LCL. Additionally, we compared the in vivo performance of DTPA-DSPE 
LCL with those of DTPA LCL in mice.
Methods: DTPA LCL (88 nm) and empty LCL (84 nm) were labeled with 111In-oxine, and 
DTPA-DSPE LCL (83 nm) were labeled with 111InCl
3
. Labeling efficiency at increasing 
specific activity was determined. In vitro stability of 111In-labeled LCL was determined 
in human serum at 37°C. The in vivo properties of 111In-labeled LCL were determined in 
mice with a S. Aureus infection in the thigh muscle. Image acquisition, blood sampling 
and biodistribution studies were performed 1, 4 (blood sampling only), 24, 48 and 72 h 
p.i. of 111In-labeled LCL.
Results: DTPA-DSPE LCL could be labeled efficiently at a much higher specific activity 
compared to DTPA LCL and empty LCL: >90% at 15 GBq/mmol, >90% at 150 MBq/
mmol and 60-65% at 150 MBq/mmol, respectively. 111In-labeled DTPA-DSPE LCL and 
DTPA LCL were stable in human serum, regarding label retention, for at least 48 h at 
37°C (>98% retention of the radiolabel). In contrast, only 68% radiolabel was retained 
in empty LCL after 48 h. In vivo targeting of 111In-DTPA-DSPE LCL to the abscess was 
comparable to targeting of 111In-DTPA LCL (3.5 ± 0.9 %ID/g and 3.4 ± 0.9 %ID/g abscess 
uptake respectively, 48 h p.i.). 
Conclusions: Labeling of DTPA-DSPE LCL with 111InCl
3
 represents a robust, easy and fast 
procedure which is preferred over the more laborious conventional labeling of DTPA-
LCL with 111In-oxine. 
Keywords: DTPA-DSPE-PEG liposomes, DTPA-PEG liposomes, Staphylococcus Aureus, 
targeting, microSPECT/CT imaging
Radiolabeling of LCL
51
3
INTRODUCTION
Liposomes are small lipid vesicles with an aqueous core, which have been extensively 
studied since their discovery in the early 60’s1, 2. Coating with polyethylene glycol (PEG) 
sterically hinders binding of proteins that could act as opsonins, which enables them to 
escape recognition by macrophages of the reticuloendothelial system, thereby increasing 
their blood circulation time if given intravenously3. These long-circulating liposomes (LCL) 
have been extensively studied as a drug carrier system to increase the therapeutic index 
of drugs and reduce their systemic side effects4-6. By virtue of increased permeability 
of local vascular endothelium and their small size (80-120 nm in diameter), liposomes 
preferentially access pathological sites, such as inflamed, infectious or cancerous tissue, a 
phenomenon referred to as ‘passive targeting’7-9. Retention of liposomes and drug delivery 
at target sites can also be enhanced by the attachment of antibodies, small molecules 
or peptides to the surface of the liposomes (‘active targeting’)10-13. To evaluate the 
pharmacokinetics and biodistribution of liposomes and their content in vivo, noninvasive 
imaging methods, such as positron emission tomography (PET) and single photon 
emission computed tomography (SPECT), are used7, 14. For this end, liposomes have been 
radiolabeled with 111In, 99mTc, 89Zr, 67Ga and 64Cu and several remote labeling methods have 
been described15-19. Radioactivity is sequestered in the aqueous core, the lipid bilayer or 
on the surface of the liposomes. Entrapment of the radionuclides in the aqueous core 
and insertion in the lipid bilayer may require higher temperatures20, 21. Because this might 
influence the liposomal properties and because the related labeling procedures are 
more laborious, surface labeling is the most convenient method to efficiently radiolabel 
liposomes, although firm attachment of the incorporated radionuclide after surface 
labeling has not always been determined. Since the half-life of 111In (2.8 days) is sufficient 
for tracking the radiolabeled formulations during several days and the blood half-life of 
liposomes is also in the order of days (typically about 48 h), the use of 111In is preferred 
in our experiments. To allow surface labeling with 111InCl3, DTPA can be derivatized with 
a phospholipid that can be inserted in the lipid bilayer. Here, we used DTPA conjugated 
to 1,2-distearoyl-phosphatidylethanolamine (DSPE), which was incorporated in the lipid 
bilayer. Conventional 111In-labeling of liposomes was achieved by the entrapment of 
111In in the aqueous core. In this method the soluble chelating agent diethylenetriamine 
pentaacetate (DTPA) is encapsulated in the liposomes and allows entrapment of the 
radionuclide by incubating the liposomes with the lipophilic chelator 111In-oxine that can 
pass through the lipid bilayer. 
In the present study we determined the labeling efficiency, maximal specific activity and 
the stability of radiolabeling of 3 types of 111In-labeled LCL: (1) DTPA-DSPE LCL surface-
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labeled with 111InCl3 were compared with those of conventionally labeled liposomes 
containing (2) DTPA in their aqueous core and (3) empty LCL (without DTPA) labeled 
with 111In-Oxine. Additionally, we compared the in vivo performance of 111In-DTPA-DSPE 
LCL with those of 111In DTPA LCL in female NMRI mice with a focal Staphylococcus Aureus 
infection.
MATERIALS AND METHODS
Preparation of liposomes
DTPA-DSPE LCL, DTPA LCL and empty LCL (without DTPA) were prepared by injection of an 
ethanolic lipid solution into an aqueous dispersion medium (water for injection or saline), 
followed by extrusion, as described previously22. Briefly, dipalmitoylphosphatidylcholine 
(DPPC), 1,2-distearoyl-phosphatidylethanolamine-methyl-polyethyleneglycol conjugate- 
2000 (mPEG2000-DSPE) (both from Lipoid GmbH, Ludwigshafen, Germany) and 
cholesterol (BUFA, Uitgeest, The Netherlands) (1.85: 0.15: 1 molar ratio) were dissolved 
in ethanol by heating to 70°C with continuous stirring. For the preparation of DTPA-DSPE 
LCL also 1.3 mM DTPA-DSPE (Avanti Polar lipids, Alabaster, AL, USA) was dissolved in the 
ethanolic lipid solution. In the case of DTPA LCL, 6 mM DTPA (Sigma Aldrich, St. Louis, MO) 
was dissolved in saline (B. Braun, Melsungen, Germany) as an aqueous dispersion medium. 
After dispersion of the ethanolic lipid solution in the aqueous solution the resulting coarse 
dispersion was passed through polycarbonate filter membranes with pore sizes of 200, 100 
and 50 nm, to adjust the size of the liposomes to 100 nm diameter. Size distribution and 
polydispersity were determined by dynamic light scattering (triplicate measurements) 
on a Malvern 4700 system (Malvern Ltd, Malvern, UK). Ethanol was removed by dialysis 
against saline using Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, Etten-Leur, 
The Netherlands) with a molecular weight cut-off of 10 kDa and repeated changing of the 
dialysis medium (phosphate buffered saline (PBS)). 
Radiolabeling procedure
Surface labeling of DTPA-DSPE LCL was performed by incubation of the liposomes (24.7 
pmol total lipid - 24.7 µmol total lipid) with 3.7 MBq 111InCl3 (Malinckrodt Pharmaceuticals, 
‘s Hertogenbosch, The Netherlands) in 0.5 M 2-(N-morpholino) ethanesulphonic acid 
buffer (MES buffer, twice the volume of 111InCl3), pH 5.4, for 30 min at RT. The amount 
of activity that was added during the labeling procedure ranged from 0.15-15000 GBq/
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mmol total lipid. After incubation, 50 mM EDTA was added to a final concentration of 
5 mM to chelate unincorporated 111In. Labeling efficiency was determined using instant 
thin layer chromatography (ITLC) on ITLC-SG strips (Agilent Technologies, Amstelveen, The 
Netherlands), using 0.1 M citrate buffer, pH 6.0, as mobile phase and gel filtration on PD-
10 Columns (GE Healthcare Life Sciences, Buckinghamshire, United Kingdom). 
Labeling of DTPA-DSPE LCL and empty LCL was performed by incubation of the liposomes 
(247 nmol total lipid - 24.7 µmol total lipid and 2.47 µmol total lipid - 24.7 µmol total lipid, 
respectively) with 3.7 MBq 111In-oxine (Mallinckrodt Medical B.V., Petten, The Netherlands) 
in 0.2 M Tris buffer (50 % of the total volume), pH 8.0, for 30 min at RT. So, specific activity 
ranged from 0.15-150 GBq/mmol total lipid. After incubation, 50 mM EDTA was added to 
a final concentration of 5 mM. The labeling efficiency was determined by gel filtration on 
a disposable PD-10 column.
For the in vivo imaging and biodistribution experiments both liposomal preparations 
were labeled with 350 MBq 111In, in order to obtain preparations with a specific activity 
of 150 MBq/mmol total lipid. The radiochemical purity of both radiolabeled preparations 
used in this experiment exceeded 95%. 
All radiolabeling procedures were performed under metal-free conditions to prevent the 
interference of contaminating metals with DTPA. 
In vitro stability of the radiolabeled liposomes
To examine the in vitro stability regarding label retention, radiolabeled liposomal 
preparations, DTPA-DSPE LCL were labeled with 111InCl3 and DTPA LCL were labeled 
with 111In-oxine with a specific activity of 150 MBq/mmol total lipid. The radiolabeled 
preparations were purified by gel filtration chromatography on a PD-10 column. These 
samples, with a radiochemical purity of 100%, were incubated in human serum (1:1) at 
37 °C. At 24 h and 48 h, retention of the radiolabel to the liposomal preparations was 
determined by gel filtration chromatography on a PD-10 column. In case of 111In-DTPA-
DSPE LCL, retention of the radiolabel was also determined using instant thin layer 
chromatography (ITLC) on ITLC-SG strips, using 0.1 M citrate buffer, pH 6.0, as mobile 
phase.
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DTPA – challenge assay
DTPA-DSPE LCL, DTPA LCL and empty LCL were radiolabeled with 111In (specific activity 
of 150 MBq/mmol total lipid), diluted to a volume of 500 µl with saline and subsequently 
500 µl DTPA solution, pH 7.4 was added. The final concentration of DTPA in the solutions 
was 10-5, 10-4, 10-3 and 10-2 M. Samples were incubated at 37°C for 24 h and analysed by 
ITLC (111In-DTPA-DSPE LCL) and by gel filtration chromatography on a PD-10 column (111In-
empty LCL and 111In-DTPA LCL).
Animals
Female NMRI Mice, 4-6 week of age were purchased from Harlan (Horst, The Netherlands). 
Mice were housed in individually-ventilated cages (IVC) under standard laboratory 
conditions (temperature, 20-24°C; relative humidity, 50-60%; 12 h light-dark cycle) 
and food (SNIFF Voer, Soest, The Netherlands) and water were available ad libitum. All 
animals were accustomed to the environment for at least one week before experiments 
were initiated. All in vivo experiments were approved by the institutional animal welfare 
committee of the Radboud University, Nijmegen, and were conducted in accordance with 
the principles laid out by the revised Dutch Act on Animal Experimentation (1997).
Murine thigh muscle infection model 
To compare the in vivo properties of 111In-DTPA-DSPE LCL with those of 111In-DTPA LCL, both 
preparations were injected i.v. in mice with an intramuscular S. Aureus abscess in the thigh 
muscle23. To induce the infection, mice were kept under anaesthesia (1-3% isoflurane in 
O2), shaved and injected i.m. with 50 µl of bacterial suspension into the left thigh muscle 
(1.28 x 108 colony-forming units (CFU) per ml, mixed 1 : 1 with autologous blood). 
Bacterial suspension was prepared by overnight incubation of S. Aureus (ATCC 25923) 
in Brain Heart Infusion (BHI) broth (OXOID Deutschland GmbH, Wesel, Germany). The 
bacteria were centrifuged (10 min, 2000 x g), the pellet was washed and resuspended in 
0.9% NaCl solution and diluted to a final concentration of 2 x 109 CFU/ml. Infection dose 
was prepared by dilution, controlled by optical density, and verified by plating dilutions 
on agar plate. Colonies were counted after incubation for 24 h at 37°C. 111In-DTPA-DSPE 
LCL and 111In-DTPA LCL were injected 24 h after induction of the infection, followed by 
microSPECT/CT imaging, blood sampling and biodistribution after dissection. 
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SPECT/CT imaging 
NMRI mice were injected i.v. with 15 ± 0.6 MBq 111In-DTPA-DSPE LCL (specific activity 150 
MBq/mmol total lipid, 100 µmol total lipid/mouse in 200 µl, n = 20) or with 17.1 ± 0.3 
MBq 111In-DTPA LCL (specific activity of 150 MBq/mmol total lipid, 100 µmol total lipid/
mouse in 200 µl, n = 20) 24 h after induction of S. Aureus infection. Groups of 5 mice were 
euthanized at 1 h, 24 h, 48 h and 72 h p.i. by CO2/O2 suffocation. Subsequently, mice were 
placed prone in the U-SPECT-II/CT scanner (MILabs, Utrecht, The Netherlands)24. Mice 
were scanned for 45 min using a 1.0-mm-diameter cylindrical pinhole mouse ultra-high 
sensitivity collimator (UHS-M). SPECT scans were followed by CT scans for anatomical 
reference (spatial resolution of 160 µm, 65 kV, 615 µA). Scans were reconstructed with 
MILabs reconstruction software, which uses an ordered-subset expectation maximization 
algorithm, with a voxel size of 0.4 mm, 16 subsets and 1 iteration). Images were processed 
using Inveon Research Workplace 4.1 Software (Siemens Preclinical Solutions, Knoxville, 
TN, USA). After image acquisition, mice were dissected to determine the biodistribution 
and blood clearance of the radiolabel. At 1 h, 24 h, 48 h and 72 h p.i., tissues of interest 
(blood, heart, lung, abscess, muscle, spleen, pancreas, kidney, liver, stomach and 
duodenum) were dissected, weighed and radioactivity was measured in a shielded 
3’’-well-type gamma counter (Perkin-Elmer, Boston, MA, USA). For the determination of 
the blood clearance profiles, an additional blood sample was taken via a tail cut at 4 h p.i.. 
Injection standards (1%) were counted simultaneously with the tissue samples to correct 
for physical decay and to allow calculation of percentage of the injected dose per gram 
tissue (%ID/g). 
Statistical analysis
Statistical analysis was performed using the non-parametric, Mann-Whitney U tests using 
GraphPad Prism software (version 5.03; GraphPad Software). All mean values are given 
± standard deviations. All tests were two-sided and a p-value of 0.05 was considered 
significant. 
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RESULTS
Size distribution of DTPA-DSPE LCL, DTPA LCL and empty LCL
For direct comparison of in vivo characteristics, the liposomal preparations should 
have similar diameter and size distribution. As determined by dynamic light scattering, 
mean particle sizes of DTPA-DSPE LCL (83 ± 2 nm), DTPA LCL (89 ± 1 nm) and empty LCL 
(85 ± 2 nm) did not differ significantly (Kruskal-Wallis test p = 0.08). In addition to the 
mean particle size, polydispersity index was reported. This is a value between 0 and 1, 
0 indicating monodispersity, whereas 1 indicates maximal variation in particle size. All 
preparations used had a polydispersity index < 0.11 (0.054 ± 0.003 for DTPA-DSPE LCL, 
0.054 ± 0.009 for DTPA LCL and 0.109 ± 0.001 for empty LCL).
Labeling efficiency
Labeling efficiencies of DTPA-DSPE LCL, DTPA LCL and empty LCL with 111In were 
determined. Increasing amounts of activity per mmol total lipid were added, ranging from 
0.15 GBq/mmol total lipid to 15,000 GBq/mmol total lipid (Figure 1). Labeled at a specific 
activity of 0.15 GBq 111In per mmol total lipid, the labeling efficiency for DTPA-DSPE LCL as 
well as for DTPA LCL was >95%. The labeling efficiency of DTPA-DSPE LCL was >90% up to 
a specific activity of 15 GBq/mmol total lipid, while the efficiency of the labeling of DTPA 
LCL markedly dropped when labeled at specific activities higher than 0.15 GBq/mmol 
total lipid. The labeling efficiency of empty LCL was least efficient (62%) when labeled at 
a specific activity of 0.15 GBq/mmol total lipid. The labeling efficiency further decreased, 
when labeled at higher specific activities. The maximum specific activity which can be 
achieved by surface labeling is more than two orders of magnitude higher than that of 
LCL with encapsulated DTPA or without DTPA (13.65 GBq/mmol, 0.14 GBq/mmol and 0.09 
GBq/mmol total lipid, respectively). 
Radiolabel retention in vitro
Since we aim to use these formulations in vivo, we assessed their stability toward retention 
of the radiolabel in vitro by incubation of 111In-labeled LCL in 50% human serum (Figure 2). 
This analysis showed that more than 95% of the label remained associated with the 
liposomes after 48 h of incubation, indicating that both DTPA-DSPE LCL and DTPA LCL 
were stably labeled with 111In. In case of the empty LCL, 88% of the label was associated 
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with the liposomes after 24 h and only 68% after 48 h, indicating that the 111In-labeling of 
this formulation yielded inferior results.
Figure 1. Labeling efficiency after labeling of DTPA-DSPE LCL (red circles), DTPA-LCL (Blue squares) 
and empty LCL (black triangles) with 111In as a function of added activity (0.15 – 15,000 GBq/mmol 
total lipid). 
Figure 2. Stability of DTPA-DSPE LCL (red circles), DTPA-LCL (Blue squares) and empty LCL (black 
triangles) in 50% human serum at 37 °C. 
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To further characterize the stability of the 111In-labeled liposomal preparations, the 
radiolabeled formulations were exposed to increasing DTPA concentrations (10-5 M to 10-2 
M). We evaluated the transchelation of the radiometal from labeled LCL to DTPA in the 
solution after 24 h of exposure at 37°C (Figure 3). At the maximum DTPA concentration 
tested (10-2 M), the amount of 111In transferred to DTPA in solution was high for all labeled 
formulations. The amount of 111In that remained associated with the DTPA-DSPE LCL was 
high (93%) up to a DTPA concentration of 10-3 M. This was significantly higher as compared 
to 111In associated with DTPA LCL (46%) and empty LCL (2%).
Figure 3. DTPA challenge assay in which 111In-labeled LCL (DTPA-DSPE LCL = red bars, DTPA-LCL = 
blue bars and empty LCL = black bars) were incubated in DTPA solutions for 24 h at 37 °C. Activity 
that retained to the LCL was measured and is shown as a percentage of total activity.
MicroSPECT/CT imaging
To investigate the in vivo targeting properties of the liposomal formulations, 111In-labeled 
liposomes were injected i.v. into NMRI mice with a focal S. Aureus abscess in the left thigh 
muscle. 111In-labeled LCL were injected 24 h after induction of the infection and SPECT/CT 
imaging was performed 1 h, 24 h, 48 h and 72 h after injection. 111In-DTPA-DSPE LCL and 
111In-DTPA LCL accumulated in abscess, liver and spleen, but little background activity in 
other tissues (Figure 4). Image acquisition at 1 h p.i. also visualized the larger vessels and 
the heart (Figure 4 A and E). Whole body distribution of both preparations was comparable, 
with exception of the hepatic uptake, which was higher for the 111In-DTPA-DSPE LCL.    
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Biodistribution studies
Biodistribution studies of mice that were injected with 111In-DTPA-DSPE LCL and 111In-
DTPA-LCL showed that the abscess targeting capabilities were comparable for both 
formulations at all time points, which is in line with the SPECT/CT imaging results (Figure 
5A). The most striking difference in uptake of the formulations was observed in the 
liver. Hepatic accumulation of 111In-DTPA-DSPE LCL was significantly higher at all time 
points (p = 0.008, Figure 5B), while the uptake in the spleen was comparable (Figure 5C). 
Additionally, blood levels, based on quantification of the radiolabel, decreased at later 
time points, which was reflected by visualization of the large vessels and heart (Figure 5D).
Figure 4. MicroSPECT/CT imaging with 111In-DTPA-DSPE LCL (A-D) and 111In-DTPA-LCL (E-H) at 
1 h, 24 h, 48 h and 72 h p.i to visualize the targeting properties of the radiolabeled liposomal 
formulations in mice infected with S. Aureus. Representative images at all time points are shown. 
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Figure 5. Tissue uptake in abscess (A), Liver (B), Spleen (C) and Blood (D) after injection of 111In-
DTPA-DSPE LCL (red) and 111In-DTPA LCL (blue) expressed in percentage injected dose per gram 
tissue. Due to differences in tissue uptake per organ, the y-axes vary in range. Biodistribution 
studies were determined at 1 h, 24 h, 48 h and 72 h p.i. Blood samples were taken 1 h, 4 h, 24 h, 
48 h and 72 h p.i.
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DISCUSSION
In the present study we demonstrated that both DTPA-DSPE LCL and DTPA LCL could be 
efficiently labeled with 111In, though the maximal specific activity of DTPA LCL might be a 
limited factor. Empty LCL were labeled less efficiently. We also showed that 111In-labeled 
DTPA-DSPE LCL and DTPA LCL, retained the label quantitatively in human serum for at 
least 48 h at 37 °C. Additionally, we demonstrated that both 111In-DTPA-DSPE LCL and the 
conventionally labeled 111In-DTPA LCL showed efficient targeting to the S. Aureus infection 
in vivo. 
We showed that the surface labeling procedure of DSPE-DTPA LCL with 111InCl3 allows 
for efficient labeling at high specific activities. The maximum specific activity that can be 
achieved by surface labeling is two orders of magnitude higher than that DTPA-LCL, 13.7 
GBq/mmol total lipid and 0.14 GBq/mmol total lipid respectively. This might be explained 
by the higher concentration of activity in 111InCl3 during the labeling procedure (370 MBq/
ml) compared to the activity in 111In-oxine (37 MBq/ml). The smaller reaction volume results 
in a faster reaction, and might influence the labeling efficiency. Additionally, instability of 
111In-oxine before it enters the liposomes might also play a role25, 26. 111In may dissociate 
from the oxine and will be chelated by EDTA in solution. This is also the case for empty LCL, 
for which the labeling efficiency and maximum specific activity that could be achieved 
was even lower (0.09 GBq/mmol total lipid). Due to the absence of a chelating agent in the 
empty liposomes, 111In-oxine which has crossed the lipid bilayer, is not efficiently trapped 
in the aqueous core, which results in a less efficient 111In-labeling.
While both the surface labeling and the conventional labeling procedure resulted in a 
stable preparation in human serum, labeling of empty LCL was not. Since there is no DTPA 
present in the core of the empty liposomes, the 111In-oxine and the 111In that dissociates 
from the oxine may leak out of the liposomes and transchelate to serum proteins.
Additionally, the excellent stability of the 111In-DTPA-DSPE LCL was confirmed in a DTPA 
challenge assay. Most of the incorporated 111In was still associated with the 111In-DTPA-
DSPE LCL at DTPA concentrations up to 10-3 M. Interestingly, we found that, despite the 
presence of DTPA, the 111In-labeled DTPA LCL were also less stable than the 111In-DTPA-
DSPE LCL. We hypothesize that part of the 111In does not transchelate to DTPA in the 
hydrophilic core, but is non-specifically bound to the lipid bilayer. This part of the 111In-
oxine may leak out of the liposomes and transchelate to DTPA in the solution. Again we 
found that 111In-labeled empty liposomes were not stable. These results imply that in vitro 
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111In-DTPA LCL are less stable than 111In-DTPA-DSPE LCL regarding 111In label retention. This 
might also be the case in vivo. 
To further characterize the radiolabeled liposomal preparations, in vivo experiments were 
performed. Based on the results of the in vitro stability assays with empty LCL, we decided 
not to use this formulation in the in vivo experiments. 
DTPA-DSPE LCL and DTPA LCL were similarly PEGylated, both were cleared mainly via 
the hepatosplenic mononuclear phagocyte system (MPS) and they were comparable in 
size. Based on these characteristics, a comparable biodistribution of intact 111In-labeled 
formulations is expected. However, we slightly altered the outer layer of the liposomes 
by addition of DTPA-DSPE. This might change the interaction with serum proteins and 
increase the propensity of DTPA-DSPE LCL for MPS macrophages, as has also been 
observed after injection of actively targeted LCL (i.e., LCL with surface-attached targeting 
ligands)27. 
Additionally, the difference we found in in vitro stability of 111In-labeled formulations might 
also affect the biodistribution of 111In due to label release in the circulation. We found that 
the tissue distribution of both liposomal formulations was comparable except for hepatic 
uptake. Accumulation in the liver was significantly higher for 111In-DTPA-DSPE LCL. Part 
of this uptake might be blood level-driven, since the blood levels of 111In-DTPA-DSPE LCL 
were higher and the liver is highly vascularised. However, also a higher degree of label 
release in case of DTPA LCL may have contributed. 
When 111In or 111In-oxine is released from the liposomes, transchelation to serum proteins 
(i.e. transferring) can take place. Both 111In chelated to serum proteins (transferin, albumin) 
as 111In-DTPA dissociated from the liposomes, will accumulate in excreting organs, leading 
to rapid clearance of the radionuclide28. In contrast, 111In-DTPA-DSPE is released from the 
111In-DTPA-DSPE LCL during degradation of the liposomes which have ended up in the 
MPS cells, like Kupffer cells29. Our data show that 111In-labeled DTPA LCL are less stable in 
vivo and as a result, the injected 111In label is cleared faster from the body, leading to lower 
hepatic uptake at all time points. Splenic uptake was not affected since this uptake is size 
related and the formulations did not significantly differ in size. Targeting properties of 
both formulations to the S. Aureus abscess were comparable.
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CONCLUSIONS
Labeling of DTPA-DSPE LCL with 111InCl3 is a robust, easy and fast procedure which is 
preferred over the more laborious conventional labeling of DTPA-LCL with 111In-oxine. In 
addition, the DTPA-DSPE LCL could be labeled more efficiently and at a higher specific 
activity. The in vivo targeting properties to the S. Aureus infection were comparable for 
both formulations. Regarding the detachment of 111In label from circulating liposomes, 
111In-DTPA-DSPE LCL were extremely stable in vitro and may be also more stable in vivo 
compared to the 111In-DTPA LCL. Therefore, 111In-DTPA-DSPE LCL are to be preferred in 
future imaging studies of the biodistribution and targeting capability of LCL. 
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ABSTRACT
Introduction: Current treatment of rheumatoid arthritis includes systemic administration 
of glucocorticoids. To improve joint targeting and anti-inflammatory efficacy, these 
glucocorticoids are encapsulated in long-circulating liposomes. The present study 
aimed to monitor therapeutic effects of prednisolone (PLP)-containing PEG-liposomes 
in murine antigen-induced arthritis (AIA) using 18F-FDG PET/CT.
Methods: Mono-articular arthritis was induced in male C57Bl6/J mice. At 0, 3, 7 and 
12 days after arthritis induction, inflamed joints were macroscopically scored (0 = 
unaffected – 4 = immobile) and 18F-FDG PET/CT images were acquired. In a second 
experiment, to study the feasibility to monitor therapeutic effects of PLP encapsulating 
PEG-liposomes, mice were treated with a single i.v. injection of PLP-containing PEG-
liposomes (10 mg/kg) or empty PEG-liposomes 3 days after arthritis induction. Inflamed 
joints were macroscopically scored and images were acquired at -3, 0, 4 and 9 days after 
treatment. PET images were analyzed quantitatively, and mice were dissected to allow 
histological analysis of the joints. 
Results: With progression of arthritis, 18F-FDG uptake in inflamed joints increased 
significantly (day 0: 2.5 ± 0.9 %ID/ml, day 7: 4.4 ± 0.4 %ID/ml, p = 0.0159), while no 
changes were observed in unaffected paws (day 0: 2.5 ± 1.1 %ID/ml, day 7: 2.7 ± 0.8 %ID/
ml, p = 0.3466). In the second experiment, macroscopic scoring revealed suppression 
of joint swelling after treatment with PLP-containing PEG-liposomes. In line with that, 
18F-FDG uptake did not change in the treated mice (day -3: 1.9 ± 0.3 %ID/ml, day 4: 2.2 
± 0.2 %ID/ml, p = 0.3466), while it increased in mice that developed arthritis (day -3: 
2.0 ± 0.2 %ID/ml, day 4: 3.1 ± 0.6 %ID/ml, p = 0.0225). Histological analysis confirmed 
therapeutic efficacy, which showed less inflammation (p = 0.0354) and bone erosion (p 
= 0.0298) in treated mice. 
Conclusions: These data show that 18F-FDG PET/CT could be used to monitor the 
progression of AIA and confirmed rapid and profound anti-inflammatory effects of PLP-
containing PEG-liposomes that were also observed macroscopically and microscopically. 
Keywords: Antigen-induced arthritis, 18F-FDG PET/CT, liposomes, glucocoticoids, 
therapy monitoring
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INTRODUCTION
Rheumatoid Arthritis (RA) is one of the most common autoimmune disorders, affecting 
approximately 1% of the adults in the western world1. It is a chronic, systemic and 
progressive disease, characterized by joint inflammation and cartilage destruction2. 
Though effective medication has gradually become available since the middle of the 
previous century, RA is still incurable3. Glucocorticoids (GC) were among the first and 
most important and still retain a prominent place in the therapy of RA4. However, the 
issue of poor accumulation at target sites and awareness of potential side effects has 
limited the application in the field. High and frequent dosing is often required to treat 
severe chronic inflammation, which might lead to well-known severe adverse effects as 
Cushing syndrome, induction of diabetes, osteoporosis, muscular atrophy and thinning 
of the skin5, 6.
To enhance local therapeutic activity and reduce systemic side effects, various approaches 
have been developed to improve GC targeting to inflamed joints. A local strategy is intra-
articular therapy, where GC are directly injected in the inflamed joint. This approach is 
effective, but not applicable when targeting multiple afflicted joints, as is the case in 
polyarthritis, where systemic delivery would be preferable. A systemic approach is delivery 
of GC by encapsulation in liposomes. These lipid vesicles can encapsulate hydrophilic 
agents in their aqueous core. Encapsulation of GC in liposomes has proven to result in 
improved pharmacokinetics, better targeting to inflamed sites, reduced metabolism of 
the GC, and less side effects.  
Long-circulating liposomes (LCL) are small (ca. 100 nm diameter) vesicles that consist of a 
lipid bilayer of phospholipids, cholesterol and are coated with polyethylene glycol (PEG). 
PEG sterically hinders plasma protein binding which protects them from being opsonized 
and prematurely phagocytised by macrophages, and therefore exhibit prolonged 
circulation times and limited hepatic excretion7. It has been shown that the leaky vessels 
in inflamed and cancerous tissue are permeable for colloidal formulations with diameters 
up to 200 nm8, 9. 
In arthritis, the inflamed synovial area contains activated macrophages. These 
macrophages can process drug-containing LCL, which leads to local drug release. Local 
drug release prevents non-target effects and widens the therapeutic window of the 
drug10. Prednisolone (PLP) is an immunosuppressive drug used to treat RA. It has been 
shown in preclinical as well as in clinical studies that treatment of experimental arthritis 
with PLP-containing LCL, is markedly more effective than pulse therapy or intra-articular 
injections of free PLP11-14. 
Chapter 4
72
Typically, progression of experimental arthritis and therapeutic effects on the model are 
assessed by clinical scoring (visual) and histopathological evaluation of the joints. However, 
with imaging modalities such as positron emission tomography (PET) or single-photon 
emission computed tomography (SPECT) the severity of inflammation may be assessed 
in a novel noninvasive way and potentially the therapeutic effect can be monitored15, 
16. It has been demonstrated that the accumulation of 18F-fluorodeoxyglucose (FDG) 
increases with the progression of joint swelling and reflects the characteristic changes 
in pathological progression17, 18. There is early evidence that 18F-FDG positron emission 
tomography/computed tomography (18F-FDG PET/CT) imaging can be used to assess 
disease activity in RA. In the present study we provide more evidence that this is also the 
case for disease progression in mice with antigen-induced arthritis (AIA). Additionally, we 
investigated whether the therapeutic effect of PLP-encapsulating LCL can be monitored 
in mice with AIA. 
MATERIALS AND METHODS
Preparation of liposomes
Empty LCL and LCL containing 2.1 mg/ml PLP were prepared by injection of an 
ethanolic lipid solution into an aqueous dispersion medium, followed by extrusion, 
as described earlier11. Briefly, dipalmitoylphosphatidylcholine (DPPC), 1,2-distearoyl-
phosphatidylethanolamine-methyl-polyethyleneglycol conjugate-2000 (mPEG2000-
DSPE) (both from Lipoid GmbH, Ludwigshafen, Germany) and cholesterol (BUFA, Uitgeest, 
The Netherlands) (1.85: 0.15: 1 molar ratio) were dissolved in ethanol. The aqueous drug 
solution contained 100 mg/ml PLP (BUFA, Uitgeest, The Netherlands) in water for injection 
or, in case of the empty LCL, saline (B. Braun, Melsungen, Germany). The ethanolic lipid 
solution was injected in the aqueous solution and the resulting coarse dispersion was 
downsized by multiple extrusion steps through polycarbonate filter membranes with 
decreasing pore sizes of 200, 100 and 50 nm. Size (about 110 nm) and mean polydispersity 
(about 0.07) were determined by dynamic light scattering using a Malvern 4700 system 
(Malvern Ltd, Malvern, UK). The polydispersity index is a measure for the heterogeneity 
of particles in solution. Unencapsulated PLP was removed by dialysis against saline using 
Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, Etten-Leur, The Netherlands) 
with a molecular weight cut-off of 10 kD and repeated changing of the dialysis medium 
(PBS). 
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Animals
Male C57Bl/6J mice (8-12 weeks old) were purchased from Janvier Labs (le Genest-Saint-
Isle, France). Mice were housed under standard laboratory conditions (temperature, 20-
24°C; relative humidity, 50-60%; 12 h light-dark cycle) and had food (SNIFF Voer, Soest, 
The Netherlands) and water available ad libitum. All animals were accustomed to the 
environment for at least one week before experiments were initiated. All in vivo experiments 
were approved by the Institutional Animal Welfare Committee of the Radboud university 
medical center, Nijmegen, and were conducted in accordance with the principles laid out 
by the revised Dutch Act on Animal Experimentation (1997).
Antigen-Induced Arthritis (AIA)
AIA was induced as described previously19. Three weeks prior to induction of arthritis, 
mice were immunized with 100 µg methylated bovine serum albumin (mBSA, 1 mg/
ml, Sigma-Aldrich, St. Louis, USA), emulsified in Complete Freund’s Adjuvant (CFA, Difco 
Laboratories, Detroit, USA), which was injected intradermally into the flanks and the 
footpad of the forelegs. Heat-killed Bordetella Pertussis (RIVM, Bilthoven, The Netherlands) 
was administered intraperitoneally as an additional adjuvant. After 7 days, two intradermal 
booster injections of 50 µg mBSA/CFA (1 mg/ml) were administered in the neck region 
of the mice. Finally, arthritis was induced by a single intra-articular injection of 60 µg of 
mBSA in PBS (10 mg/ml) into the right knee joint. The left knee joint remained untreated 
and served as an internal control. 
Monitoring progression of arthritis 
AIA was induced in four groups of male C57Bl6/J mice (n = 6 per group). At 0, 3, 7 and 
12 days after induction of arthritis one group underwent 18F-FDG PET/CT imaging. Mice 
were anesthetized using 1.5-3% isoflurane in air during injection of the tracer, during the 
uptake phase of the tracer and during image acquisition. During anaesthesia, mice were 
placed on a heating pad to maintain their body temperature, and eye drops (Opthtosan, 
AST Farma b.v., Oudewater, The Netherlands) were administered to prevent dehydration 
of the eyes. Mice were euthanized after image acquisition by CO2/O2 suffocation.
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Monitoring therapeutic efficacy of PLP-containing LCL
AIA was induced in two groups of male C57Bl6/J mice (n=6 per group) as described 
above. Mice were treated 3 days after arthritis induction. One group of mice received PLP-
containing LCL in PBS (10 mg/kg body weight, 200 µl i.v.), while the other group received 
empty LCL in PBS (200 µl i.v.). Effect of the treatment was monitored using 18F-FDG PET/CT 
at 3, 7 and 12 days after induction of arthritis. Severity of inflammation was evaluated at 
each time point. Knee joint swelling was macroscopically scored, scores ranged from 0-4: 
0 = joint is unaffected, 1 = joint is mildly swollen, but the mouse shows no difficulties in 
mobility, 2 = joint is swollen, and the mouse shows impaired mobility, 3 = joint is severely 
swollen, mouse did not use the affected paw, 4 = joint severely swollen, the mouse 
becomes immobile.
After image acquisition mice were euthanized and knee joints were isolated and fixed for 
4 days in 10% buffered formalin, decalcified in 5% formic acid for 1 week, dehydrated and 
embedded in paraffin for histological analysis.
18F-FDG PET/CT image acquisition
PET/CT imaging was conducted with an Inveon small-animal PET/CT system (Siemens 
Preclinical Solutions, Knoxville Tennesse, USA). Whole body PET images were obtained 
45 min after i.v. administration of 10 ± 2.5 MBq 18F-FDG via the tail vein. PET scans were 
performed for 15 minutes followed by a CT scan for anatomic reference (spatial resolution, 
113 μm; 80 kV; and 500 μA). Acquired data were reconstructed iteratively in a 256 x 256 
x 159 matrix using an attenuation-weighed 3-dimensional ordered-subsets expected 
maximization/fast maximum a posterior (OSEM3D/fMAP) algorithm using Inveon 
Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions, Knoxville 
Tennessee, USA. Scans were analyzed using Inveon Research Workplace 4.1 Software 
(Siemens Preclinical Solutions, Knoxville Tennessee, USA). Spherical isocontours were set 
at 50% of the maximal pixel value to measure uptake values (Bq/ml) in inflamed (right) 
and unaffected (left) knee joints. Bq/mlmean in inflamed joints and unaffected joints were 
used to calculate the %ID/ml. To determine the %ID/ml. Bq/mlmean was corrected for 
the amount of injected activity and time between injection and image acquisition, in 
which the radionuclide decayed. Quantification of the PET signal was performed by an 
independent technician not aware of the treatment groups.
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Histology 
Standard frontal knee sections (7 µm) were mounted on Superfrost slides (Menzel-
Gläser, Braunschweig, Germany) and stained with haematoxylin and eosin (HE). Synovial 
inflammatory activity and bone erosion was examined in HE-stained frontal sections of 
whole knee joints of mice that were dissected at day 7. Severity of inflammation was 
determined as described previously20, by scoring the cellular infiltration into the synovium 
using an arbitrary scale between 0 and 3, 0 = no cells, 1 = mild cellularity, 2 = moderate 
cellularity, 3 = maximal cellularity. Three representative sections per knee joint were 
scored and scoring was performed by two blinded observers.
Statistical analysis
Statistical analysis was performed using SPSS software version 20 (IBM, Chicago, IL, USA). 
Mean values are given ± standard deviations. Statistical analysis of 18F-FDG uptake in the 
joints and histological evaluation were calculated using nonparametric, Mann-Whitney U 
tests. Statistical analysis of arthritis scores was performed using nonparametric, Wilcoxon 
matched-pairs signed ranked tests. All tests were two-sided and a p-value of 0.05 was 
considered significant.
RESULTS
Monitoring progression of arthritis
Antigen-induced arthritis (AIA) was induced by an intra-articular injection of mBSA in the 
right knee joint of pre-immunized mice, the left knee joint served as a negative control. 
Macroscopic scoring of the joints, which was based on joint swelling and mobility of 
the mice, showed the 7-day course of AIA. Arthritis scores of arthritic joints increased 
significantly from day 0 and peaked at day 7, while no changes were observed in 
unaffected control joints (Figure 1, score day 0 = 0, day 3 = 0-2, day 7 = 2-3, day 12 = 1-2, 
Wilcoxon matched-pairs signed rank test p = 0.002).
18F-FDG PET/CT images were acquired of all mice at day 0, day 3, day 7 and day 12 after 
the intra-articular induction of arthritis. A representative set of microPET/CT images is 
shown in Figure 2A-D. All images were analyzed quantitatively to determine the 18F-FDG 
accumulation. Activity values in volumes of interest (VOI) drawn around the inflamed 
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joints and control joints at day 0, day 3, day 7 and day 12 after induction of arthritis, were 
converted to %ID/ml and are presented in Figure 2E. 18F-FDG PET/CT imaging revealed 
increased accumulation of 18F-FDG up to day 7 in the right knee (arthritic joint) of the 
mice, while no increase in 18F-FDG uptake was seen in the left knee (control joint, Figure 2). 
Additionally, activity was seen in heart, kidneys, bladder and brain. Quantification of this 
18F-FDG accumulation confirmed increased uptake in inflamed joints with progression of 
arthritis. Maximum uptake was measured at day 7 (Mann Whitney U, p = 0.0159), while no 
changes were observed in control joints (Mann Whitney U, p = 0.3466).  
Figure 1. Arthritis scores in time of arthritic joints (right knee, grey lines) and control joints (left 
knee, black lines) of C57Bl6/J mice during the development of arthritis. Knee joint swelling was 
macroscopically scored, scores ranged from 0-4: 0 = Unaffected, 1 = Mild swelling, no difficulties 
in mobility, 2 = Swollen knee, impaired mobility, 3 = Severe swelling, no use of affected paw, 4 = 
Severe swelling, immobility. Score in arthritic knee day 0 = 0, day 3 = 0-2, day 7 = 2-3, day 12 = 1-2, 
in control joints all time points = 0  (Wilcoxon matched-pairs signed rank test, p = 0.002).
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Figure 2. 18F-FDG PET/CT imaging (45 min p.i.) demonstrated 18F-FDG accumulation in the 
affected knee joint during the development of AIA. Representative 18F-FDG PET/CT images of a 
mouse at day 0 (A), day 3 (B), day 7 (C) and day 12 (D) after induction of arthritis in the right knee 
joint (arrows). Radioactivity was seen in heart, kidneys, bladder and brain. E: Quantification of the 
tissue uptake of 18F-FDG (%ID/ml) in arthritic joints and control joints, based on 18F-FDG PET/CT 
images, during the progression of arthritis. A significant increase in 18F-FDG uptake was found at 
day 7 after induction of arthritis at day 0 (p = 0.0159). Graph values represent mean ± SD, n = 6 
mice per group. The significance of difference was tested by the Mann-Whitney U test.
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Monitoring therapeutic effect PLP-containing LCL with 18F-FDG PET/CT
Mice with AIA were injected i.v. at day 3 after induction of arthritis, prior to imaging, either 
with a single injection of 10 mg/kg PLP-containing LCL in PBS or empty LCL in PBS. Joint 
swelling was macroscopically monitored during the course of arthritis and was completely 
suppressed in the treated group, while empty LCL did not have a suppressive effect on 
joint swelling (Figure 3). 
At day -3, 0, 4, and 9 after treatment, 18F-FDG PET/CT images were acquired. 18F-FDG PET/
CT imaging showed no uptake in the right knee, in which arthritis was induced, of treated 
mice, while 18F-FDG uptake increased up to day 4 in arthritic knees of mice that received 
empty LCL. Figure 4 shows images acquired at day -3 and day 4 of mice that were treated 
with PLP-containing LCL (A and B) and mice that received empty LCL (C and D). In addition 
to the 18F-FDG uptake in the arthritic knees, 18F-FDG accumulated in the front paws. This 
18F-FDG uptake also decreased after treatment with PLP-containing LCL. Activity was also 
seen in heart, kidneys, bladder and brain.
Quantitative analysis of the 18F-FDG PET/CT images, showed that 18F-FDG accumulation 
in the arthritic joints increases in concordance with the development of arthritis in both 
groups until day 0. After treatment with PLP-containing LCL, a strong reversal in joint 
uptake was seen at day 4, compared to the joint uptake at day 0. In mice that received 
empty LCL, joint uptake significantly increased at least for 7 days after induction of 
arthritis. No change in tissue uptake was seen in the internal control joints in time or after 
receiving PLP-containing LCL or empty LCL (Figure 4E).
The knee joints were analyzed histologically to assess therapeutic effects on inflammatory 
activity and bone erosion of a single injection of 10 mg/kg PLP-containing LCL (Figure 5). 
Histological examination showed that inflammatory activity in the synovium was reduced, 
although more abundant than in healthy joints, after PLP-LCL treatment (Figure 5D). 
Additionally bone erosion was significantly lower in mice that received treatment with 
PLP-containing LCL compared with arthritic joints of untreated mice, but bone erosion 
was also present in healthy control joints. 
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Figure 3. Arthritis scores in time of arthritic joints (right knee) of mice that received either 
PLP-containing LCL (black lines) or empty LCL (grey lines) at day 0. Knee joint swelling was 
macroscopically scored, scores ranged from 0-4: 0 = Unaffected, 1 = Mild swelling, no difficulties 
in mobility, 2 = Swollen knee, impaired mobility, 3 = Severe swelling, no use of affected paw, 4 = 
Severe swelling, immobility. Score in arthritic knee of treated mice: all time points: 0 and mice that 
received empty LCL: day -3: 0, day 0: 0-2, day 4:  1-3, day 9: 1-2 (Wilcoxon matched-pairs signed 
rank test, p = 0.0310).
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Figure 4. 18F-FDG PET/CT imaging (45 min p.i.) to visualize the 18F-FDG accumulation in the course 
of AIA after treatment with 10 mg/kg PLP-containing LCL. Representative 18F-FDG PET/CT images 
of a mouse that was treated with PLP-containing LCL (A-B) and a mouse that received empty 
LCL (C-D) at day -3 and day 4 after treatment are shown. Note that the 18F-FDG accumulation in 
the front paws also decreased after treatment with PLP-containing LCL. Also activity was found 
in heart, kidneys, bladder and brain. Arrows indicate 18F-FDG uptake in joints in which arthritis 
was induced. E: Tissue uptake (%ID/ml) in arthritic joints (right knee joint) and control joints (left 
knee joints) after treatment with PLP-containing LCL or empty LCL, 3 days after intra-articular 
induction of arthritis. Note that a strong reversal is seen after treatment with PLP-containing LCL 
and no significant difference in tissue uptake is observed compared to day -3 (p = 0.3466), while a 
significant increase in tissue uptake was found in mice that received empty LCL (p = 0.0225). The 
control joints of both groups did not show any difference between uptake after receiving therapy 
or Empty LCL (p = 0.8248 and p = 0.4857, respectively). Graph values represents mean ± SD, n = 6 
mice per group. The significance of difference was tested by Mann-Whitney U test.
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Figure 5. Histological cross sections of whole knee joint from the control joints of an untreated 
mouse (A), of the arthritic knee of a mouse that received 10 mg/kg PLP-containing LCL (B), and of 
whole knee joint from the arthritic knee of a mouse that received empty LCL (C). Note the swelling 
and the abundant inflammatory infiltrate (stars) and that there is more inflammatory infiltrate in 
the untreated joint than in the joint of mice treated with PLP-containing LCL (B). D: Quantification 
of the synovial infiltrate. Inflammatory activity in arthritic joints was reduced after treatment with 
PLP-containing LCL (p = 0.0354), and no inflammation was observed in the untreated control 
joint (p = 0.0027). E: Quantification of bone erosion of patella, femur and tibia. Bone erosion was 
suppressed after treatment with PLP-containing LCL (p = 0.0298), but, in less extend, also present 
in healthy joints (p = 0.0059). Graph values represents mean ± SD, n = 6 mice per group. The 
significance of differences between groups was tested by Mann-Whitney U test.
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DISCUSSION
The present study demonstrates that 18F-FDG PET/CT imaging can be used to visualize the 
progression of AIA in mice. Moreover, we showed that 18F-FDG PET/CT imaging is a useful, 
noninvasive tool to monitor therapeutic effects of PLP-containing LCL in murine AIA. 
18F-FDG uptake in the inflamed joints, as a measure of inflammation severity, could also be 
determined quantitatively and reflected therapeutic efficacy noninvasively. Therapeutic 
effects were tracked closely by macroscopic scoring of the mice and by histological 
evaluation of affected joints. We were able to monitor the therapeutic effect of PLP-
containing LCL with 18F-FDG PET/CT imaging. Although macroscopically no swelling of 
the joints in treated mice was observed (Figure 3), joint uptake of 18F-FDG at initiation 
of treatment was shown (Figure 4E, day 0). The tissue uptake in the contralateral joint 
remained the same. This indicates that even mild inflammation in the arthritic joint can be 
detected with 18F-FDG PET/CT. Histology of the knee joints confirmed that treatment with 
PLP-containing LCL suppressed the synovial inflammation. The suppressed inflammation 
also explains the inhibited bone erosion, since it is correlated with bone erosion and 
osteoclast activation21. 
Previous studies, which assessed the use of PLP-containing LCL as a treatment of 
experimental arthritis, reported a rapid, profound and more sustained effect of liposomal 
drugs, compared to administration of the free drugs. They showed that inflammation 
in treated animals was decreased and as a result, bone erosion reduced11, 13. Others also 
evaluated the use of 18F-FDG PET (or PET/CT) as a noninvasive tool to examine RA and 
reported that this method can be used to assess disease activity and response monitoring 
in experimental arthritis15, 22, 23. Here, we have demonstrated in vivo quantification of 
progression of AIA and response monitoring after treatment with PLP-containing LCL, 
using 18F-FDG PET/CT.
Since therapeutic effects were observed within 4 days after treatment and FDG uptake was 
assessed longitudinally, 18F-FDG PET/CT imaging potentially is superior to conventional 
methods to score arthritis, such as macroscopic or histological scoring. Therapeutic effects 
were already seen macroscopically within one day after treatment, but this method is not 
quantitative as is 18F-FDG PET/CT, while longitudinal assessment is not possible using 
histology. 
The possibility to study the same animal at multiple time points during the progression of 
the disease or during therapy, can increase statistical power as a result of continues values, 
which would allow parametric testing. Additionally, the mice are kept alive to analyze 
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all joints simultaneously and at different time points, which may take out some of the 
variation compared to histological assessments after dissection. Also extra information 
can be acquired, because the results that are obtained are not limited to joints or organs 
of interest. As shown in the present study, in which 18F-FDG uptake in the front paws of the 
mice was observed. Although not assessed as these joints were not analyzed histologically, 
this is most likely due to an inflammatory reaction against mBSA in CFA which was injected 
in the footpad during the immunization procedure. But also here, a therapeutic effect of 
the treatment was found, emphasizing that i.v. administration of PLP-containing LCL leads 
to accumulation of PLP in multiple inflamed joints. Considering that 18F-FDG accumulates 
in inflamed joints due to molecular changes, rather than due to anatomical changes, 
18F-FDG PET/CT imaging might also be able to detect early arthritis onset, especially in 
subclinical arthritis without symptoms. Potentially this could be used for the treatment 
in the earlier phases of exacerbations, which could prevent chronic effects, such as bone 
loss, and could suppress flare-ups.
It is of utmost importance to interpret 18F-FDG uptake in inflamed joints using the baseline 
uptake as a reference (day 0 when monitoring the progression of the disease, or day -3 
when monitoring the therapeutic effect of PLP-containing LCL). 18F-FDG uptake (in terms 
of %ID/ml) in the mouse joints varied considerable, which hampers the analysis and the 
detection of changes in tissue uptake. 18F-FDG cannot differentiate between arthritis or 
other processes with enhanced metabolic activity. To improve the use of noninvasive 
imaging tools in arthritis, other more specific tracers might be more valuable. Specific 
targeting of activated macrophages might increase the value of noninvasive imaging 
methods. Other studies show already promising results with targeting of the folate 
receptor and TSPO, which are both overexpressed by activated macrophages found in 
RA24, 25. The use of radiolabeled antibodies against other targets that are (over)expressed 
in RA, such as fibroblast activation protein or TNFα, might increase the specificity of the 
method22. As for now, these agents are not that well accepted in the clinic compared to 
18F-FDG PET/CT. 
CONCLUSIONS
We showed that treatment of arthritis with PLP-containing LCL reduced 18F-FDG 
accumulation in arthritic joints, which was confirmed with suppression of joint swelling 
and decreased inflammatory activity and bone erosion. It showed that therapeutic effects 
can be monitored noninvasively with whole body 18F-FDG PET/CT, even in an early stage 
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after treatment initiation. This study shows the potential application of 18F-FDG PET/CT for 
early liposomal drug response monitoring in RA. 
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ABSTRACT
Introduction: One of the most prominent cell populations playing a role in rheumatoid 
arthritis (RA) is activated fibroblast-like synoviocytes (FLSs). Among many other proteins, 
FLSs dominantly express fibroblast activation protein (FAP). Due to high expression 
of FAP in arthritic joints, radioimmunoimaging of activated fibroblasts with anti-FAP 
antibodies might be an attractive noninvasive imaging tool in RA. 
Methods: Single photon emission computed tomography (SPECT) and positron 
emission tomography (PET) with 111In- and 89Zr-labeled anti-FAP antibody 28H1 was 
performed in mice with collagen-induced arthritis. Radioactivity uptake in joints was 
quantified and correlated with arthritis score.
Results: Both 111In-28H1 and 89Zr-28H1 showed high uptake in inflamed joints, being 
3-fold higher than that of the irrelevant isotype-matched control antibody 111In-DP47GS, 
clearly indicating specific accumulation of 28H1. Uptake of 111In-28H1 ranged from 
2.2 %ID/g in non-inflamed joints to 32.1 %ID/g in severely inflamed joints. DP47GS 
accumulation ranged from 1.6 %ID/g in non-inflamed tissue to 12.0 %ID/g in severely 
inflamed joints. Uptake of 28H1 in inflamed joints correlated with arthritis score 
(Spearman’s ρ 0.69, p<0.0001) and increased with severity of arthritis. 
Conclusions: SPECT/CT imaging with the anti-FAP antibody 111In-28H1 specifically 
visualized arthritic joints with high resolution, and tracer accumulation correlated with 
the severity of the inflammation in murine experimental arthritis. Background uptake of 
the radiolabeled antibody was low, resulting in excellent image quality. 89Zr-28H1 was 
less favorable for RA imaging due to an elevated bone uptake of 89Zr. Future studies will 
focus on the potential role of 28H1 as a tool to monitor therapy response early-on.
Keywords: Fibroblast activation protein (FAP), SPECT imaging, PET imaging, collagen-
induced arthritis, monoclonal antibody
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease that results in chronic and 
systemic inflammation in synovial joints. RA is characterized by hyperplasia and chronic 
inflammation of synovial membranes that invade into articular cartilage and bone. Many 
cell types that play a role in joint destruction are present in the synovial lining layer. One of 
the most prominent cell populations is activated fibroblast-like synoviocytes (FLSs) which 
is involved in pannus formation1. Among many other proteins, FLSs dominantly express 
fibroblast activation protein (FAP)2. It has previously been shown that the area where 
these FAP-expressing FLSs are present corresponds with the center of high inflammatory 
activity2.
FAP is a cell surface-bound, type II transmembrane glycoprotein, belonging to the family 
of serine prolyl oligopeptidases, has a molecular weight of 95 kDa and is abundantly 
expressed in granulation tissue of healing wounds3, 4. It has been shown that FAP is closely 
related to dipeptidylpeptidase IV (DPP IV), also known as CD265. Besides peptidase activity, 
it was demonstrated that FAP has collagenase activity in vitro6. FAP is also found in more 
than 90% of human epithelial carcinomas3, 7, where its expression is limited to fibroblasts 
in the tumor stroma8. We hypothesized that, due to high expression of FAP in arthritic 
joints, radioimmunoimaging of activated fibroblasts with anti-FAP antibodies might be an 
attractive noninvasive imaging tool in RA. 
Since FAP is expressed in tumor stroma, various anti-FAP antibodies have been studied 
for radioimmunotargeting of malignancies. Amongst these are 131I-labeled murine F19 
and 131I-labeled sibrotuzumab, a humanized version of the F19 antibody9, 10. More recently, 
two new anti-FAP antibodies, ESC11 and ESC14, were labeled with 177Lu, which showed 
excellent targeting in melanoma xenografts11. 
In the present study, we investigated the potential of a radiolabeled anti-FAP antibody 
for specific positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) of activated fibroblasts in an experimental model of RA. While PET 
is generally better for quantification purposes, preclinical SPECT imaging has a higher 
resolution. 
Fischer et al. grafted the human anti-FAP Fab fragments into the human IgG1 framework, 
resulting in fully human anti-FAP IgG1 antibodies11. Here we used the 28H1 antibody, 
which is an non-internalizing anti-FAP antibody with high pM affinity for both murine and 
human FAP and bearing mutations in the Fc part, preventing binding to the Fcγ receptors. 
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In brief, the antibody was conjugated with desferal for 89Zr labeling and with diethylene 
triamine pentaacetic acid (DTPA) to allow 111In labeling. PET/CT and SPECT/CT imaging 
studies as well as biodistribution studies were performed in mice with collagen-II-induced 
arthritis (CIA) to correlate the radioactivity concentration in the joints with the severity of 
arthritis.
MATERIALS AND METHODS
Animals
Male DBA/1J mice were obtained from Janvier-Elevage (Le Genest Saint Isle, France). 
All mice were housed in filter-top cages under specific pathogen-free conditions and a 
standard diet and water were provided ad libitum. The mice were used between 10 and 
12 weeks of age. All animal procedures were approved by the institutional animal welfare 
committee and carried out according to their guidelines.
Antibody conjugation and radiolabeling 
The monoclonal anti-FAP antibody 28H1 has high avidity for murine (< 1 pM) and human 
FAP (268 pM) and has the P329G LALA mutations in the Fc part to make it Fc effector silent. 
The monoclonal antibody DP47GS with the P329G LALA mutations served as an isotype-
matched control antibody with no known binding specificity and no affinity for murine or 
human FAP. The 28H1 anti-FAP antibody is a fully human FAP antibody that was generated 
by phage display using recombinant FAP12. In order to abolish FcγR and C1q binding a 
P329G LALA mutation was introduced that completely abolishes FcγR and C1q binding, 
but does not affect FcRn binding and pharmacokinetics13. 
Both 28H1 and DP47GS were conjugated with isothiocyanatobenzyl–diethylene-
triaminepentaacetic acid (p-SCN-Bz-DTPA) (Macrocyclics, Inc., Dallas, TX) according to 
standard procedures. Labeling with 111InCl3 (Mallinckrodt BV, Petten, The Netherlands) was 
performed as described previously14. Labeling efficiencies were >99% and 89% for 111In-
DTPA-28H1 and 111In-DTPA-DP47GS, respectively.  111In-DTPA-DP47GS was purified on a 
PD-10 column (GE Healthcare Biosciences, Uppsala, Sweden), and eluted with phosphate-
buffered saline (PBS), containing 0.5% bovine serum albumin (BSA), to provide two 
preparations with a radiochemical purity of ≥ 99%. 
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In addition, the 28H1 antibody was modified with succinyl-desferal-iron-tetrafluorophenol 
ester (VU University Medical Center, Amsterdam) as described previously15. The 28H1-
desferal conjugate (1 mg) was radiolabeled with 110 MBq of 89Zr (PerkinElmer, Boston, 
MA) in 0.5 M HEPES, pH 7.2, for 60 min at 37°C. Labeling efficiency was 97% as determined 
by ITLC. The reaction mixture was purified on a PD-10 column eluted with gentisic acid (5 
mg/ml). The radiochemical purity of 89Zr-N-succinyl-desferal-28H1 (89Zr-28H1) was >99%. 
18F-FDG was purchased as ready-to-use product (GE Healthcare, Eindhoven, The 
Netherlands).
Binding assay of 28H1
Human fibroblast cell line GM05389 and murine 3T3 fibroblasts stably transfected 
with murine FAP were detached with Cell Dissociation Buffer and resuspended in FACS 
buffer. Cells (200,000) were seeded into a 96-well round bottom plate. The plate was 
centrifuged at 400xg for 3 min to pellet the cells. The supernatant was removed and cells 
were resuspended in 40 µl of Alexa647-labeled anti-FAP 28H1 or DP47GS at 10 µg/ml. 
The plate was incubated for 30 min at 4°C to allow binding of the antibodies. To remove 
unbound antibodies the cells were centrifuged again and washed twice with FACS buffer, 
resuspended in 200 µl FACS buffer and the fluorescence was measured by flow cytometry.
Animal experiments
For the induction of collagen-induced arthritis, Freund’s complete adjuvant (FCA) and 
Mycobacterium tuberculosis (strain H37Ra) were obtained from Difco, Detroit, MI. 
Bovine collagen type II (CII) was prepared as described previously16. DBA/1J mice were 
immunized intradermally at the base of the tail with 100 µg of CII. Three weeks later, mice 
received an intraperitoneal booster injection of 100 µg CII dissolved in PBS. The onset of 
arthritis occurred a few days after the booster injection. Clinical onset and progression 
was monitored by macroscopic scoring of the paws, on a scale of 0 to 2 for each paw, in 
a blinded fashion by two independent observers. Cumulative scoring based on redness, 
swelling, and, in later stages ankylosis was as follows: 0=no changes; 0.25=1-2 toes red 
or swollen; 0.5=3-5 toes red or swollen; 1=swollen ankle; 1.5=swollen footpad; 2=severe 
swelling and ankylosis. Naïve mice, i.e. not immunized, were used as control. Mice were 
injected with the radiolabeled antibodies at day 24-26 after start of the immunization. 
SPECT/CT imaging with 111In-28H1 and 111In-DP47GS was performed as follows. Mice (n=3/
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group) received an intravenous (i.v.) injection of 15-18 MBq of 111In-28H1 or 111In-DP47GS 
(injected dose 50 µg). At 1 and 3 days post injection (p.i.), images were acquired with the 
U-SPECT-II/CT (MILabs)17. Mice were scanned under general anesthesia (isoflurane and 
air) for 60 min (4x 15 min frames) using a 1.0-mm-diameter pinhole Ultra High Sensitivity 
mouse collimator (UHS-M). One mouse was scanned using a 0.35-mm-diameter pinhole 
Ultra High Resolution mouse collimator (UHR-M). SPECT scans were followed by CT scans 
(65 kV, 615 µA). SPECT scans were reconstructed with software from MILabs, which uses an 
ordered-subset expectation maximization algorithm, with a voxel size of 0.375 mm. Using 
Inveon Research Workplace software (IAW 4.0, Siemens Preclinical Solutions, Knoxville, 
TN) a 3D volume of interest was drawn around the arthritic joints, and the uptake was 
quantified as percentage of the injected dose (%ID). For PET/CT imaging with 89Zr-28H1 
and 18F-FDG, mice (n=3/group) received an i.v. injection of 5-7 MBq of 89Zr-28H1 (injected 
dose 50 μg) or 5 MBq 18F-FDG. For 89Zr-28H1, PET/CT images were acquired with the 
Inveon animal PET scanner18 (Siemens Preclinical Solutions, Knoxville, TN) under general 
anesthesia (isoflurane and air) for 20 min at 1 and 3 d p.i.. 18F-FDG-PET scans (20 min) were 
acquired 45 min p.i., while mice remained under general anesthesia during time between 
injection and imaging. PET scans were followed by CT scans (80 kV, 500 µA). PET scans 
were reconstructed using Inveon Acquisition Workplace software (v 1.5, Siemens) using 
an ordered-set expectation maximization 3-dimensional maximum a posteriori (OSEM-
3D MAP) algorithm with the following parameters: matrix, 256 × 256 × 159; pixel size, 
0.43 × 0.43 × 0.8 mm; and a uniform-variance maximum a posteriori prior, 0.5 mm. For 
the biodistribution studies after dissection, mice (n=5/group) with various macroscopic 
scores of arthritis received an i.v. injection of 370 kBq 89Zr-28H1, 111In-28H1 or 111In-DP47GS 
(injected dose 50 μg) or 10 MBq 18F-FDG. At 72 h p.i (89Zr-28H1, 111In-28H1 or 111In-DP47GS) 
or 1 h p.i. (18F-FDG), mice were euthanized by CO2/O2 asphyxiation, a blood sample was 
drawn and tissues of interest were dissected, weighed and counted in a gamma counter. 
The percentage of the injected dose per gram tissue (%ID/g) was calculated for each 
tissue. Joints were dissected with minimal residual bone/muscle. Uptake in the joints was 
correlated with the individual arthritis scores of the joints prior to dissection.
Immunohistochemistry
To demonstrate FAP expression in arthritic murine joints, frozen sections of ankle joints 
from mice with CIA were stained with monoclonal anti-FAP antibody 28H1 and isotype-
matched control DP47GS. Frozen sections of 5 µm were dried overnight at RT and then 
fixed with ice-cold acetone for 10 min. After drying for at least 1 h at RT the primary 
antibody 28H1 or DP47GS was applied and incubated for 1 h at RT. After three washing 
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steps with 50 mM PBS, pH 7.4, the secondary antibody goat-anti-human IgG-peroxidase 
was applied. After 30 min at RT, slides were washed three times with PBS. Finally, the 
sections were stained for 10 min with diaminobenzidine (DAB) and subsequently for 5 
seconds with hematoxilin.
Statistical analysis
All mean values are given ± standard deviation (S.D.). Unless state otherwise, statistical 
analysis was performed using a Welch’s corrected unpaired Student’s t-test or one-way 
analysis of variance using GraphPad Prism software (version 5.03 GraphPad Software). The 
level of significance was set at P<0.05.
RESULTS
Immunohistochemistry with 28H1 demonstrated abundant expression of FAP in an 
inflamed knee joint from a CIA mouse (Supplemental Figure 1A). Staining with DP47GS 
was negative (Supplemental Figure 1B). Staining with 28H1 on knee tissue from a 
healthy mouse was also negative (Supplemental Figure 1C). An in vitro binding assay 
on both human and murine fibroblasts demonstrated high and specific binding to FAP 
(Supplemental Data, Figure 2).
SPECT/CT imaging
To investigate the feasibility of imaging with anti-FAP antibodies in arthritis, collagen-
induced arthritis was induced in DBA/1J mice, and SPECT/CT and PET/CT imaging with 
anti-FAP antibody 28H1 were performed after clinical onset of arthritis. 111In-28H1 SPECT/
CT scans of mice with arthritic joints clearly demonstrated strong accumulation of the 
anti-FAP antibody in the inflamed joints, with little background activity in other tissues. 
SPECT with 111In-28H1 delineated all inflamed joints, even joints with minimal arthritic 
scores (0.25 on a scale of 0-2) as well as small, inflamed joints, such as those in the feet 
and toes. Lungs were also visible on the SPECT scans at 24 h p.i. (Figure 1A), however, this 
accumulation had disappeared at 72 h p.i. (Supplemental Figure 4A).
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Figure 1. 3D SPECT/CT scans of mice with collagen-induced arthritis, injected with 15 MBq 111In-
labeled antibody (50 µg). 111In-28H1 at 24 h p.i. (A) with joints scores of 1.75, 0, 0.25 and 1.5 (front 
right, front left, hind right, hind left, respectively). Radiotracer uptake is clearly visible in the 
inflamed joints. Panel B: 111In-28H1 at 72 h p.i. in a healthy mouse. Some bone marrow uptake is 
visible. Panel C: 111In-DP47GS at 24 h with joints scores of 0, 0, 2 and 0.5 (front right, front left, hind 
right, hind left, respectively). R and L indicate right and left side of mice, respectively. All images 
are scaled similarly.
The SPECT/CT scan of 111In-28H1 in a healthy mouse at 72 h p.i. showed that the majority of 
the radioactivity was cleared from the circulation with little bone marrow uptake (Figure 
1B). Whole body distribution of the isotype-matched control antibody 111In-DP47GS was 
similar (Figure 1C), with the exception of a slower clearance from the circulation, resulting 
in some residual activity in the heart region at 72 h p.i (Supplemental Figure 4B). With 
the non-FAP-binding control antibody 111In-DP47GS the inflamed joints could also be 
visualized (Figure 1C), however, to a much lesser extent than with 111In-28H1.  
A strong correlation was found between tracer uptake and arthritis severity as 
demonstrated by quantitative analysis of the SPECT/CT scans at both 1 and 3 d p.i. (Figure 
2). Analysis revealed that at both time points the uptake (%ID) correlated well with the
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Figure 2. Joint uptake vs score of inflammation based on quantitative analysis of the SPECT scans 
of 111In-28H1 after 1 d (A) and 3 d (B), and of 111In-DP47GS after 1 d (C) and 3 d (D). 
arthritis score (Spearman’s ρ 0.87, p=0.007 and 0.89, p=0.005, 1 and 3 d, respectively). 
There was good retention of radioactivity in the inflamed joints over the 3 d period. For 
111In-DP47GS, no correlation between uptake and arthritis score was found (Spearman’s ρ 
0.51, p=0.20 and 0.42, p=0.30, 1 and 3 d, respectively).
PET/CT imaging
PET/CT images of healthy mice injected with 89Zr-28H1 showed a similar whole body 
distribution as the SPECT/CT scans with 111In-labeled 28H1. Excellent targeting of 89Zr-28H1 
to inflamed joints was observed, as illustrated by the PET/CT scans (Figure 3). Healthy mice 
only displayed accumulation in the heart region as well as in the bone (Supplemental 
Figure 5).
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PET/CT imaging was also performed with the clinically established radiotracer 18F-FDG, a 
radiolabeled glucose analog, which accumulates in cells with increased glucose uptake 
such as tumor cells and inflammatory cells (mainly neutrophils). PET/CT imaging with 
18F-FDG showed low uptake in inflamed joints (Figure 3B). Only severely inflamed joints 
with a score above 1.25 were visualized, and signal intensity was much lower as compared 
to that found with the radiolabeled anti-FAP antibodies. 
Figure 3. PET/CT scans (3D) of a mouse with collagen-induced arthritis, injected with 5 MBq 89Zr-
28H1 and scanned at 72 h p.i. (A). Joints scores were 1.75, 1.5, 0.25 and 2 (front right, front left, hind 
right, hind left, respectively). Right panel (B) shows a PET/CT scan of mouse with collagen-induced 
arthritis, injected with 10 MBq 18F-FDG and scanned at 1 h p.i. Joints scores were 0, 0.25, 1.25 and 
0.25 (front right, front left, hind right, hind left, respectively). R and L indicate right and left side of 
mice, respectively.
Biodistribution studies
Biodistribution studies of mice that received 111In-labeled 28H1 revealed that the whole 
body distribution of the radioactivity in arthritic mice was similar to that in healthy mice. 
In line with the quantitative SPECT imaging data, accumulation of 111In-28H1 in the 
inflamed joints correlated well with the arthritis score as shown in Figure 4A (Spearman’s 
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ρ 0.69, p<0.0001). Highest joint uptake of the radiolabeled anti-FAP antibody was found in 
mice with severely inflamed joints with the maximum arthritis score of 2 (mean 25.9 ± 4.2 
%ID/g, range 19.0 – 32.1 %ID/g), whereas uptake in non-arthritic joints was significantly 
lower (mean 4.5 ± 1.1 %ID/g, range 2.2 – 6.5 %ID/g; P<0.0001) (Figure 4A).
Figure 4. Joint uptake vs macroscopic score of arthritis of 111In-28H1 (A), 111In-DP47GS (B), 89Zr-
28H1 (C) and 18F-FDG (D). Joint uptake was measured in dissected tissues, 3 days p.i. of the 
radiolabeled antibodies.
Dissection revealed that uptake of 111In-DP47GS in inflamed joints increased only slightly 
with increasing arthritis scores up to 0.75, but did not increase further in arthritic joints 
with scores from 0.75 – 2 (Figure 4B). Uptake of 111In-DP47GS in non-arthritic joints ranged 
from 1.6 – 8.4 %ID/g (mean 3.5 ± 1.4 %ID/g). Highest accumulation was found in joints with 
arthritis scores from 0.75 – 2 but never exceeded 12.0 %ID/g (range 6.5 – 12.0 %ID/g, mean 
9.8 ± 1.6 %ID/g). The higher joint uptake of 28H1 as compared to the isotype-matched 
control antibody DP47GS, strongly indicates that the uptake in the arthritic joints was 
FAP-mediated.
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Similar to the 111In-labeled anti-FAP compound, uptake of 89Zr-28H1 in inflamed joints also 
correlated with the arthritis score (Figure 4C, Spearman’s ρ 0.060, p<0.0001). Joint uptake 
of 89Zr-28H1 in both normal and inflamed joints was higher than that of 111In-labeled 28H1. 
This may partly be due to the higher bone uptake of 89Zr as compared to that of 111In. The 
biodistribution study after dissection (72 h p.i.) revealed that femoral bone uptake of 89Zr 
in arthritic mice was significantly higher than that of 111In (32.4 ± 9.2 %ID/g vs. 5.1 ± 0.4 
%ID/g, p=0.0016) (Supplemental Data, Figure 3).
Interestingly, in mice injected with either 111In-28H1 or 89Zr-28H1, elevated uptake in the 
bone marrow was observed. 111In-28H1 showed a bone marrow uptake of 8.4 ± 0.9 %ID/g, 
whereas the uptake of 111In-DP47GS was significantly lower (4.8 ± 1.8 %ID/g, P=0.018), 
indicating that the bone marrow uptake was also FAP-mediated. Uptake of 18F-FDG in 
non-inflamed joints was low (mean 3.3 ± 2.4 %ID/g, range 1.8 – 7.5 %ID/g, Figure 4D), 
whereas uptake in more severely inflamed joints was higher; joints with scores of 1.75 
showed a mean uptake of 6.4 ± 2.6 %ID/g (range 3.5 – 10.2 %ID/g) and joints with a score 
of 2 showed a mean uptake was 9.1 ± 4.5 %ID/g (range 3.9 – 11.7 %ID/g).
Figure 5. High resolution 3D SPECT/CT scan of a knee joint (score 0.75) of an arthritic DBA/1J 
mouse i.v. injected with 111In-28H1 and scanned at 72 h p.i. Radioactivity was mainly localized to 
the synovial area of the femur-tibia and patella-femur region.
Localization of the radioactivity in the affected knee joints was demonstrated by a high 
resolution scan of an affected knee of a mouse 3 days p.i. of 111In-28H1. Figure 5 shows that 
the radioactivity in the joint is localized in the synovial area of the femur-tibia region as 
well as the patella-femur region.
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DISCUSSION
With SPECT and PET imaging, we demonstrated that radiolabeled anti-FAP antibodies 
specifically targeted to inflamed joints in an experimental model of rheumatoid arthritis. 
In addition, the present study showed that the uptake of the radiolabeled antibody 
correlated with the arthritis severity. 
Until now, targeting of FAP with radiolabeled antibodies has been studied exclusively in 
tumor models since FAP is abundantly expressed on carcinoma-associated fibroblasts in 
the tumor stroma. Good and specific targeting of tumour with 131I-labeled murine F199 
and 131I-labeled sibrotuzumab, a humanized version of the F19 antibody10, has been 
demonstrated. However, due to lack of therapeutic effect as well as the occurrence of 
human-anti-human antibodies (HAHA), further clinical development of sibrotuzumab was 
halted. Engineering human Fab fragments into fully human IgG1 led to the development 
of two anti-FAP antibodies, ESC11 and ESC14. These rapidly internalizing, 177Lu-labeled 
antibodies showed good tumor targeting as well as a significant therapeutic effect in 
melanoma xenografted mice11. 
Besides expression in tumour stroma and granulation tissue of healing wounds4, FAP 
also is abundantly expressed by fibroblast-like synoviocytes in rheumatoid arthritis2. It 
was also shown that expression of FAP was higher in RA than in osteoarthritis (OA). The 
authors speculated that the pronounced expression of FAP in RA might be related to the 
degree of synovial inflammation. Analyzing the gene expression profiles in inflamed paws 
of CIA mice confirmed that FAP expression was seven-fold increased in inflamed paws 
as compared to non-inflamed paws19. Therefore, we hypothesized that imaging of FAP 
expression with 28H1 might be a valuable tool to assess the severity of the inflammation. 
Here, we demonstrated that the uptake of the anti-FAP antibody 28H1 increased with 
enhanced severity of inflammation. It is therefore anticipated that anti-FAP imaging 
might be a new sensitive tool for scoring RA disease activity, and could possibly be of 
additive value to existing scoring systems such as DAS28. Most importantly, it might allow 
noninvasive early therapy response monitoring. 
The non-specific isotype-matched control antibody DP47GS also localized in inflamed 
joints, but the accumulation did not increase with increasing severity at higher scores. This 
led us to conclude that the major part of the uptake of 28H1 in inflamed joints was FAP-
mediated. Enhanced uptake of DP47GS in inflamed joints was due to locally enhanced 
vascular permeability at inflamed sites, resulting in extravasation of larger molecules such 
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as antibodies, also known as the enhanced permeability and retention effect20. This effect 
has been shown with 99mTc-labeled non-specific polyclonal IgG in a rat model of arthritis21.
In the present study, imaging was performed with both 89Zr and 111In-labeled FAP 
antibody 28H1. Although the image quality was similar for both radionuclides, 89Zr-28H1 
had the disadvantage of enhanced uptake in the bone, most likely caused by unbound 
89Zr, released from the radiolabeled antibody after metabolism in vivo. This phenomenon 
has been described in previous studies with 89Zr-anti-EGFR and anti-IGF1R antibodies22, 23. 
Also others reported elevated bone uptake of 89Zr compared to 111In23, 24. When imaging 
inflamed joints and bone-related disorders, this elevated bone uptake is unwanted and 
hampers the interpretation of the scans. Therefore, the use of 111In for imaging with anti-
FAP antibodies in rheumatoid arthritis is preferred over that of 89Zr. 
Radionuclide imaging in RA has been mainly focused on 18F-FDG PET/CT imaging25, 
but also  radiolabeled peptides such as IL-1-ra, annexin-V and small molecules such as 
folate, PK11195, and MMP- and E-selectin-targeting molecules have been investigated 
both clinically and/or preclinically26.  In addition, radiolabeled antibodies such as anti-
CD20 (rituximab) and anti-TNFα (infliximab) have been studied. Although these tracers 
accumulated specifically in affected joints, uptake could generally not be correlated 
with the severity of the inflammation. FDG has been studied extensively and joint 
accumulation has been proven to correlate with disease activity scores27, 28, and we 
therefore also included 18F-FDG in our studies as a reference. However, uptake of FDG in 
arthritic joints in the CIA model was relatively low and did not correlate with the severity 
of the inflammation, which is in line with previous preclinical studies29, 30, although one 
study reported a good correlation31. These differences might be explained by the use of 
various models, but also imaging might have been performed at various time-points after 
the onset of the arthritis. Therefore, 18F-FDG-PET imaging of experimental arthritis in mice 
is considered to be of limited value. Generally, neutrophils and activated macrophages 
mainly contribute to FDG uptake in inflammatory diseases. However, in rats with collagen-
induced arthritis it was shown that increased accumulation was mainly caused by uptake 
in activated fibroblasts in the pannus, rather than by neutrophils32. 
We noted an unexpectedly high bone marrow uptake of the 28H1 anti-FAP antibody, which 
was not observed with the isotype-matched control antibody DP47GS. This indicates that 
the uptake was specific and most likely FAP-mediated. These findings corroborate with 
a recent study in which it has been described that both mouse and human pluripotent 
bone marrow stem cells could be recognized by FAP-reactive T-cells33.
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CONCLUSION
SPECT/CT imaging with the anti-FAP antibody 111In-28H1 specifically visualized arthritic 
joints with high resolution, and accumulation correlated with the severity of the 
inflammation in murine experimental arthritis. Background uptake of the radiolabeled 
antibody was low, resulting in excellent image quality. Future studies will focus on the 
potential role of 28H1 as a tool to monitor therapy response early after the start of 
treatment.
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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder resulting in 
synovial inflammation. Fibroblast activation protein (FAP) is over-expressed by fibroblast-
like synoviocytes in arthritic joints. Radioimmunoimaging with an anti-FAP antibody 
might be used to monitor the response to therapy, thus enabling tailored therapy 
strategies and therapeutic outcomes. The aim of this study was to assess whether 
radiolabeled anti-FAP antibodies can be used to monitor the efficacy of treatment with 
long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a 
mouse model of arthritis. 
Methods: Collagen-induced arthritis (CIA) was induced in male DBA/1J mice. Mice 
were treated with a single injection (10 mg/kg) of PLP-LCL or empty LCL as control. 
Single photon emission computed tomography (SPECT) and computed tomography 
(CT) images were acquired 24 h after injection of 99mTc-labeled succinimidyl-
hydrazinonicotinamide (S-HYNIC)-conjugated anti-FAP antibody, 28H1, at 2, 5 and 9 
d after treatment. The uptake of 99mTc-S-HYNIC-28H1 in all joints was quantified and 
correlated with macroscopic arthritis scores. 
Results: Treatment of CIA with PLP-LCL significantly suppressed joint swelling. At just 
1 d after treatment, the macroscopic arthritis scores had decreased by 50%. Scores 
decreased further to only 10% of the initial scores at 5 and 9 d after treatment. In 
contrast, macroscopic arthritis scores had increased up to 600% in untreated mice at 9 
d after the injection of empty LCL. 99mTc-S-HYNIC-28H1 uptake ranged from 1.5 %ID/g in 
noninflamed joints to 22.6 %ID/g in severely inflamed joints. The uptake of radiolabeled 
28H1 in inflamed joints (%ID) correlated with arthritis score (Spearman ρ 0.77, p < 
0.0001). Moreover, the uptake of 99mTc-S-HYNIC-28H1 was slightly increased at 9 d after 
therapy, but was not seen macroscopically, indicating that SPECT/CT imaging might be 
more sensitive than the macroscopic arthritis scoring method. 
Conclusions: SPECT/CT imaging with 99mTc-S-HYNIC-28H1 specifically monitored 
the response to therapy and tracer accumulation correlated with the severity of 
inflammation. In addition, SPECT/CT imaging was potentially more sensitive than the 
macroscopic scoring method. This study showed that SPECT/CT with 99mTc-S-HYNIC-
28H1 could be used to noninvasively monitor the course of CIA in mice.
Keywords: Fibroblast activation protein, SPECT/CT imaging, collagen-induced arthritis, 
prednisolone phosphate-encapsulating PEG liposomes, therapy monitoring
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disorder that affects 0.5% - 1% of the European 
population1. It is characterized by inflammation of synovial joints and eventually leads 
to cartilage and bone destruction. At present, RA is treated mostly systemically (orally, 
intramuscularly, or intravenously) by combinations of non-steroidal anti-inflammatory 
drugs, disease-modifying antirheumatic drugs, biological agents or corticosteroids or 
sometimes locally (intraarticular corticosteroid injections)2, 3. All of these therapeutic 
treatments aim to relieve pain, reduce inflammation, and prevent irreversible damage. 
Unfortunately, therapeutic effects may take several months to occur, especially after 
treatment with disease-modifying antirheumatic drugs; in a subpopulation of patients, 
non-responsiveness to the drugs is seen. Therefore, there is a need for a noninvasive 
imaging method to objectively determine the severity of the symptoms, to monitor 
therapeutic efficacy, and to predict the occurrence of exacerbations during the course of 
the disease. At an early stage after treatment, specific and sensitive therapy monitoring 
could allow for alteration of the therapeutic strategy when therapeutic effects are shown 
to be insufficient, potentially decreasing the unwanted side effects of the ineffective drugs. 
In addition, an early switch to an effective drug could protect patients from irreversible 
damage due to RA.
The synovium of RA patients contains high levels of inflammatory cells, including 
macrophages and fibroblast-like synoviocytes4, 5. These cells are prominently present in 
areas with high inflammatory activity and have an aggressive, invasive character. When 
activated, macrophages produce proinflammatory cytokines, such as interleukin 1 and 
tumor necrosis factor α, triggering the production of proinflammatory cytokines6. After 
stimulation by interleukin 1 and tumor necrosis factor α, fibroblast-like synoviocytes 
produce proinflammatory cytokines and proteolytic enzymes, such as interleukin 6 and 
matrix metalloproteinases7, 8. These mediators stimulate and amplify the inflammation, 
contribute to degradation of the extracellular matrix, and exacerbate joint damage. 
Patients are often treated with corticosteroids, such as prednisolone phosphate (PLP), to 
suppress inflammation and reduce the levels of proinflammatory cytokines. PLP reduces 
accumulation of macrophages and irreversible cartilage damage9, 10. To increase efficacy 
and reduce toxicity, PLP can be given locally or encapsulated in drug delivery systems. 
In experimental arthritis models, the use of long-circulation liposomes (LCL) to target all 
inflamed joints at once with one intravenous injection created local persisting depots of 
steroids and increasing ratios of efficacy to safety11, 12. 
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Molecular imaging has already been proven successful in noninvasive and early response 
monitoring but, in most cases, is not specific for arthritis at a molecular level11, 13. Fibroblast 
activation protein (FAP) is a cell surface-bound, type II transmembrane glycoprotein 
belonging to the family of serine prolyl oligopeptidases. In arthritic joints, FAP is 
dominantly expressed by activated fibroblast-like synoviocytes and is found in human 
arthritis as well as experimental arthritis, such as the collagen-induced arthritis (CIA) 
model14. FAP plays a role in pannus formation and progression of disease in all stages15. 
The antibody 28H1 antibody is a noninternalizing antibody with high affinity for human 
and murine FAP16. The specificity of 28H1 was shown in an in vitro binding assay and by 
immunohistochemistry in arthritic joints. SPECT/CT imaging with 111In-labeled 28H1 as a 
tracer revealed a significant correlation with uptake of 111In-diethylenetriaminepentaacetic 
(DTPA)-28H1 in inflamed joints and the severity of arthritis16. To further improve this tracer, 
we examined the use of 99mTc for radiolabeling. Because of the shorter half-life of 99mTc (6 
h) compared to that of 111In (67 h), it is a better match with the relatively short circulation 
time of 28H1. Additionally, radiation dose per scan will be lower, 99mTc is less expensive and 
image resolution was expected to be even higher than with 111In-labeled tracers. 
In this study, we focused on the potential role of the antibody 28H1 as a specific and 
sensitive tool for early response monitoring after treatment with LCL containing PLP 
(PLP-LCL) in murine CIA. The CIA model is considered to be a suitable model for studying 
disease progression and the therapeutic effects of antirheumatic drugs.
MATERIALS AND METHODS
Preparation of the liposomes
LCL containing PLP at 2.1 mg/mL were prepared by injection of an ethanolic lipid solution 
into an aqueous dispersion medium and then extrusion as described earlier11, 17. In brief, 
dipalmitoylphosphatidylcholine (DPPC), 1,2-distearoyl-phosphatidylethanolamine-
methyl-polyethyleneglycol conjugate-2000 (mPEG2000-DSPE) (both from Lipoid GmbH, 
Ludwigshafen, Germany) and cholesterol (from BUFA, Uitgeest, The Netherlands) (molar 
ratio,1.85: 0.15: 1) were dissolved in ethanol. The aqueous drug solution contained PLP 
(from BUFA, Uitgeest, The Netherlands) at 100 mg/mL in water for injection. The ethanolic 
lipid solution was injected into the aqueous solution, and the resulting coarse dispersion 
was downsized by multiple extrusion steps (4 or 5 for each pore size) through polycarbonate 
filter membranes with decreasing pore sizes of 200, 100 and 50 nm (Whatman Nuclepore 
Track-Etch Membrane, Sigma-Aldrich, Zwijndrecht, The Netherlands). Size (111 nm) and 
Therapy monitoring with 99mTc-S-HYNIC-28H1 SPECT/CT
113
6
mean polydispersity (0.07) were determined by dynamic light scattering with a Malvern 
4700 system (Malvern Ltd, Malvern, UK). Nonencapsulated PLP was removed by dialysis 
against saline using Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, Etten-Leur, 
The Netherlands) with a molecular weight cutoff of 10  kDa. The dialysis medium was 
refreshed 4 times after at least 8 h.  
Antibody conjugation
Monoclonal anti-FAP antibody 28H1 (3.7 mg/mL) was conjugated with a 10-fold molar 
excess of succinimidyl-hydrazinonicotinamide (S-HYNIC) (Solulink, Inc. San Diego, CA, 
USA) in 1 M NaHCO3 (pH 8.2) for 1 h at room temperature. Nonconjugated S-HYNIC was 
removed by dialysis against ammonium acetate (0.25M; pH5.5) using Slide-A-Lyzer dialysis 
cassettes with a molecular weight cutoff of 10 kDa. The dialysis medium was refreshed 4 
times after at least 8 h. 
Radiolabeling procedure
SnSO4 (1mg/mL) was freshly prepared by adding 5 mg SnSO4 to 5 mL 0.1 M HCL. This solution 
was flushed with N2 (gas) for 10 min to prevent oxidation of SnSO4 during the labeling 
procedure. Tricine (100 mg per mL of phosphate buffered saline; pH 7; coligand), 0.02 mg 
of SnSO4 and 240 MBq of 
99mTcO4
- were added to 300 µg S-HYNIC-28H1 and, the micture 
was incubated at room temperature for 30 min. Radiolabeling efficiency was determined 
by instant thin-layer chromatography on ITLC-SG strips (Agilent Technologies, Santa 
Clara, CA), with 0.1 M citrate (pH 6.0) as the mobile phase. Labeling efficiency exceeded 
95% or, if it was less than 95%, then the labeled product was purified by gel filtration 
chromatography on a PD-10 column (GE Healthcare Life Sciences, Buckinghamshire, 
United Kingdom) to provide a preparation with a radiochemical purity greater than 95%. 
Animals
Male DBA/1J mice, 10-12 wk old, were purchased from Janvier Labs (le Genest-Saint-Isle, 
France). All mice were housed in filter-top cages under pathogen-free conditions. Food 
(SNIFF Voer, Soest, The Netherlands) and water were available ad libitum. All animals were 
allowed to become accustomed to the environment for at least 1 week before experiments 
were initiated. All in vivo experiments were approved by the Animal Welfare Committee of 
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the Radboud University, Nijmegen, The Netherlands, and were conducted in accordance 
with the principles of the revised Dutch Act on Animal Experimentation (1997).
CIA model
CIA was induced as described previously18. In brief, male DBA/1J mice were immunized 
with 100 µg of bovine type II collagen emulsified in Freund complete adjuvant (Difco 
Laboratories, Detroit, USA) and injected intradermally into the tail base. After 3 wk (day 
21), the mice received a booster injection of 100 µg of bovine type II collagen in saline. The 
onset of CIA occurred a few days after the booster injection. The onset and development 
of arthritis were macroscopically monitored by independent observers in a masked 
fashion and scored on a scale from 0-2 for each paw. Cumulative scoring was based on 
redness, swelling and ankylosis: 0, no sign of arthritis; 0.25, 1 or 2 toes red or swollen; 0.5, 
3-5 toes red or swollen; 1.0, swollen ankle; 1.5, swollen footpad; and 2.0, severe swelling 
and ankylosis16.
Liposomal treatment with PLP
Liposomal treatment was given 1 d after the booster injection. The treated mice received 
a single intravenous injection of PLP (10 mg/kg) in LCL, with a lipid dose of 100 µmol/
mouse, in a total volume of 200 µl. The control mice received empty LCL at the same lipid 
dose. 
SPECT/CT imaging and ex vivo biodistribution studies
Treated and untreated DBA/1J mice with CIA were intravenously injected with 50 µg 99mTc-
S-HYNIC-28H1 (specific activity, 800 MBq/mg, in 200 µl; n = 5 per group) at day 1, 4 or 8 
after therapy. At 24 h after tracer injection, mice were euthanized by CO2/O2 suffocation. 
Subsequently, images were acquired with a U-SPECT-II/CT scanner (MILabs, Utrecht, The 
Netherlands19). Images were acquired as 2 frames of 25 min with a 1.0-mm-diameter 
cylindrical pinhole mouse ultra-high sensitivity collimator. SPECT scans were followed 
by CT scans for anatomic referencing (spatial resolution, 160 µm; 65 kV; 615 µA). Scans 
were reconstructed with MILabs reconstruction software (which uses an ordered-subset 
expectation maximization algorithm), a voxel size of 0.2 mm, 16 subsets and one iteration.
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After image acquisition, relevant tissues were dissected to determine accumulation of the 
tracer in the organs and the joints. Tissues of interest (right wrist joint, left wrist joint, right 
ankle joint, left ankle joint) were dissected and weighed, and radioactivity was measured 
in a shielded well-type γ-counter (~7.7 cm [3in]; Perkin-Elmer, Boston, MA, USA). Injection 
standards (1%) were counted simultaneously with tissue samples to correct for physical 
decay and to allow calculation of the percentage injected dose (%ID) per gram tissue 
(%ID/g). 
Quantitative SPECT analysis
Reconstructed SPECT scans were coregistered with CT images. A gaussian filter of 0.8 was 
applied to the SPECT images and a 3-dimensional volume of interest was drawn around 
the arthritic joints with Inveon Research Workplace 4.1 software (Siemens Preclinical 
Solutions, Knoxville, TN, USA). Voxel intensity values were converted to %ID with decay 
correction and a standard curve (voxel intensity vs. kBq) acquired by scanning and 
reconstructing known 99mTc activities from 0 to 370 kBq under identical conditions as 
those during the animal scans. 
Statistical Analysis
Statistical analysis was performed with Graphpad Prism version 5.03 for Windows 
(Graphpad Software, San Diego, CA, USA).  Values are reported as mean ± SD. The data was 
analyzed with nonparametric Mann-Whitney U tests. All tests were 2-sided, and P values 
of less than 0.05 were considered to be significant.
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RESULTS
PLP-LCL therapy
Treatment with a single injection of PLP-LCL at 10 mg/kg was started after onset of 
arthritis and was effective, as macroscopic arthritis scores were lower in treated mice than 
in control mice (Figure 1). Visual arthritis scores were measured on a scale from 0 to 2 per 
paw and from 0 to 8 per mouse until 9 d after therapy. Arthritis scores were significantly 
lower in the treated group than in the control group at all time points. At day 2 after 
treatment, the arthritis scores had decreased in treated mice but had increased in control 
mice (P = 0.01). This effect was still seen at 5 d after treatment (P = 0.01) and at 9 d after 
treatment (P = 0.02). 
Figure 1. Changes in macroscopic arthritis scores over time after single treatment with PLP-LCL 
at 10 mg/kg (red circles) vs. empty LCL (blue squares). Values are mean ± SD for 5 mice per group. 
Mann-Whitney U tests show that differences between control and treated animals were significant 
at all time points (P = 0.01, P = 0.01 and P = 0.02 at 2, 5 and 9 d after treatment, respectively).
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SPECT/CT imaging
Inflamed joints were specifically visualized by SPECT/CT imaging with 99mTc-S-HYNIC-28H1 
at 2, 5 and 9 d after treatment (Figure 2). Images clearly showed preferential uptake of the 
anti-FAP antibody in inflamed paws, with low background accumulation in other tissues; 
even joints with minimal arthritis scores (0.25 on a scale of 0-2) were delineated. Increased 
uptake of radiolabeled anti-FAP antibody in inflamed joints of control mice was shown 
over time (Figure 2A-2C), whereas the joints of treated mice did not show enhanced 
uptake (Figure 2D-2F). 
Figure 2. 3-Dimensional SPECT/CT scans of control (A-C) and PLP-LCL-treated (D-F) CIA mice at 24 
h after injection of 99mTc-S-HYNIC-28H1 (50 µg). Image acquisition was performed 2 d (A and D), 5 
d (B and E) and 9 d (C and F) after therapy. All images are scaled equally.
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Quantitative SPECT Analysis
Tracer accumulation in each paw on SPECT/CT images was analyzed quantitatively. Analysis 
showed that tracer accumulation was lower in treated mice than in control mice and was 
significantly lower at 5 and 9 d after treatment (P < 0.02) (Figure 3A). Tracer accumulation 
in joints of treated mice was 4.1 ± 3.5, 1.9 ± 1.0, and 3.2 ± 1.1 %ID/g at 2, 5 and 9 d after 
treatment, respectively. For the untreated mice, the corresponding values were 3.5 ± 3.0, 
3.1 ± 2.8, and 6.9 ± 4.1 %ID/g at 2, 5 and 9 d after injection of empty LCL, respectively. A 
good correlation was found between the values obtained for 99mTc-S-HYNIC-28H1 uptake 
in the quantitative SPECT analysis and the arthritis score (Spearman ρ, 0.6830; P < 0.0001) 
(Figure 3B).
Biodistribution Studies 
Measurement of the activity concentration in dissected organs showed that the 
accumulation of 99mTc-S-HYNIC-28H1 in joints was lower in arthritic mice treated with PLP-
LCL than in control mice (P = 0.01) (Figure 4A). Tracer accumulation in joints of treated mice 
was 5.9 ± 3.1, 3.3 ± 1.4, and 4.1 ± 1.2 %ID/g at 2, 5 and 9 d after treatment, respectively. 
These values were lower than those for the control mice, in which tracer accumulation in 
joints was 7.2 ± 5.2, 5.1 ± 4.2, and 11.7 ± 5.6 %ID/g at 2, 5 and 9 d after injection of empty 
LCL, respectively. Whole-body distribution of radioactivity in treated mice did not differ 
significantly from that in control mice at all time points (data not shown). Additionally, 
in line with the quantitative SPECT analysis, a correlation was found between the values 
obtained for 99mTc-S-HYNIC-28H1 uptake in the biodistribution studies and the arthritis 
scores (Spearman ρ, 0.6699; P < 0.0001) (Figure 4B). Furthermore, the values obtained for 
99mTc-S-HYNIC-28H1 in the biodistribution studies correlated with the uptake values found 
in the quantitative SPECT analysis (Spearman ρ, 6.072, P < 0.0001).  
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Figure 3. (A) Tissue uptake-based quantitative SPECT analysis at 2, 5 and 9 d after treatment with 
PLP-LCL at 10 mg/kg. Mann-Whitney U tests showed significantly lower levels of tissue uptake 
after treatment with PLP-LCL than in control groups (P = 0.02). (B) Correlation between tissue 
uptake of 99mTc-S-HYNIC-28H1 at 24 h after injection and arthritis score (Spearman ρ, 0.6830; P < 
0.0001). Tissue uptake (%ID/g)  per individual paw (4 or 5 mice per group, 4 joints per mouse) is 
shown. 
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Figure 4. (A) Tissue uptake-based biodistribution studies at 2, 5 and 9 d after treatment with PLP-
LCL at 10 mg/kg  . Mann-Whitney U tests showed significantly lower levels of tissue uptake after 
treatment with PLP-LCL than in control groups (P = 0.01). (B) Correlation between tissue uptake 
of 99mTc-S-HYNIC-28H1 at 24 h after injection and arthritis score (Spearman ρ, 0.6699; P < 0.0001). 
Tissue uptake (%ID/g)  per individual paw (4 or 5 mice per group, 4 joints per mouse) is shown. 
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DISCUSSION
The present study demonstrated that SPECT images at 24 h after injection of a 99mTc-
labeled anti-FAP antibody reflected the severity of arthritis and therapeutic efficacy6, 11, 
12, 20. These data show that 99mTc-S-HYNIC-28H1 could be used for noninvasive monitoring 
of the therapeutic effects of PLP-LCL in a mouse model of arthritis. Our previous study 
showed that the uptake of 111In-DTPA-28H1 in inflamed joints was specific and correlated 
with severity of arthritis and that 111In-DTPA-28H1 SPECT/CT resulted in high-quality 
images16. The data indicated that molecular imaging with an anti-FAP antibody might 
provide added value for early and sensitive response monitoring.
Ideally, multiple images would be acquired within a short period of time, just before 
therapy and early after therapy. To allow for this schedule, repeated injections of the tracer 
would be necessary. High-quality images were obtained with 111In-DTPA-28H1 and the 
half-life (2.8 d) of 111In is suitable for antibody imaging but too long to allow repeated 
imaging of the same patient within a short period. Therefore, we radiolabeled 28H1 with 
a radionuclide that has a relatively short physical half-life. With a half-life of 6 hours, the 
radionuclide 99mTc is potentially suitable for repeated imaging at multiple time points at 
short intervals. To allow efficient and stable labeling of 28H1 with 99mTc, we conjugated the 
antibody with S-HYNIC and labeled it in the presence of tricine as coligand.
Because 28H1 is a humanized antibody that would induce a severe immune response with 
repeated exposure in mice, we were not able to image the mice repeatedly and monitor 
the therapeutic effects in the same animal. However, here we showed that 99mTc-S-HYNIC-
28H1 might be used to monitor therapeutic effects in RA patients at multiple time points. 
The potential ability of our construct to monitor therapeutic efficacy was examined using 
PLP-LCL therapy because it was shown to result in rapid, strong therapeutic benefits in 
experimental RA models6, 11, 12, 20. The therapeutic effects in mice were monitored by visual 
arthritis scoring; the score had already decreased 2 d after the administration of PLP-LCL, 
and almost complete remission of macroscopic signs of arthritis was observed at least 
until 9 d after treatment (Figure 1). 
With PLP treatment, lower levels of tumor necrosis factor α and interleukin 1 are 
produced in the inflamed joints, in turn leading to decreased activation of fibroblast-like 
synoviocytes, resulting in reduced production of FAP9, 10. We hypothesized that this effect 
could be visualized noninvasively with 99mTc-S-HYNIC-28H1 SPECT/CT. High image quality 
was obtained, and the activity of the radiolabeled antibody in background tissue was low 
(Figure 2). Over time, images showed increasing uptake in the joints of mice in the control 
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group and decreasing uptake in the joints of mice that received PLP-LCL. These findings 
demonstrated that the therapeutic effect of PLP-LCL could be visualized noninvasively 
with 99mTc-S-HYNIC-28H1 SPECT/CT. 
The findings were confirmed after quantification of the SPECT images (Figure 3A) and by 
the ex vivo biodistribution studies (Figure 4A). In both analyses, values correlated with the 
macroscopic arthritis scores (Figure 3B and 4B). This correlation was also observed with 
the 111In-labeled compound16. The correlation found between macroscopic arthritis scores 
and ex vivo biodistribution data was lower than that found between the macroscopic 
arthritis scores and quantitative imaging.  
Significant uptake of 99mTc-S-HYNIC-28H1 was observed in multiple joints of individual 
mice. These joints were considered in our macroscopic arthritis scoring system, so the 
uptake of 99mTc-S-HYNIC-28H1 resulted in a more complete representation of the severity 
of disease. Even paws with low arthritis scores were visualized by 99mTc-HYNIC-28H1 
SPECT, although the joints did not show obvious macroscopic symptoms, indicating the 
potentially high sensitivity of this imaging method for monitoring the onset of disease. 
These data suggest that this imaging method outperforms the macroscopic arthritis 
scoring method for identifying mildly involved joints and can measure inflammation in 
joints that cannot be scored macroscopically. 
Quantitative SPECT analysis at day 9 after therapy can also support the hypothesis of 
high sensitivity of imaging with 99mTc-S-HYNIC-28H1. The arthritis scores did not increase 
in the treated group, while the SPECT values increased, although not significantly. This 
finding can indicate an early decrease in the effect of PLP that was not yet detected 
macroscopically, emphasizing that molecular imaging might detect flare-ups at earlier 
time points than macroscopic arthritis scoring. However, we cannot rule out the possibility 
that the increase of tissue uptake was a result of variations between de groups. The mice 
that were imaged at day 5 were not the same as those that were imaged at day 9. The 
mice were divided into groups on the basis of macroscopic arthritis scores at the start of 
therapy, but because of the systemic and progressive character of the model, the groups 
were not equally affected at time of imaging. Although no significant differences were 
found in macroscopic arthritis scores between the mice in the day 5 groups and those in 
the day 9 groups at the start of therapy, the differences in tissue uptake could be explained 
by slightly more severely affected mice in the day 9 groups.
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CONCLUSION
99mTc-S-HYNIC-28H1 SPECT is a more specific and potentially more sensitive method for the 
early detection of exacerbations in RA and for therapy monitoring, relative to the arbitrary 
macroscopic arthritis scoring system. Therefore, this reliable, noninvasive method may be 
valuable for immediate therapy monitoring and further therapy planning in RA patients, 
with the aim of improving individual treatment strategies.
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ABSTRACT
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease leading to 
progressive destruction of cartilage and bone. RA patients show elevated levels of IL-22 
and the amount of IL-22-producing T helper cells positively correlates to more erosive 
disease, suggesting a role for this cytokine in RA pathogenesis. The purpose of this 
study was to determine the feasibility of SPECT/CT imaging with 111In-labeled anti-FAP 
antibody (28H1) to monitor the therapeutic effect of neutralizing IL-22 antibodies in 
experimental arthritis.
Methods: Mice with collagen-induced arthritis (CIA) were treated 3 times per week with 
anti-IL-22 antibodies (8 mg/kg), or with rat IgG1 isotype-matched control antibodies. 
To monitor therapeutic effects after 2 weeks of treatment, SPECT/CT images were 
acquired 24h after injection of 111In-labeled 28H1. Imaging results were compared with 
macroscopic, histologic, and radiographic arthritis scores.
Results: Blocking IL-22 before CIA onset was an effective approach to prevent arthritis 
development, reaching a disease incidence of only 50%, versus 100% in the control 
group. SPECT imaging showed that joint tracer uptake was significantly lower in 
mice treated early with anti-IL-22 antibodies compared to the control-treated group. 
Reduction of disease activity was confirmed by macroscopic scores, histological scores 
and radiographic bone damage scores, which were all reduced in those mice. However, 
when treatment was initiated in a later phase of CIA, progression of joint pathology 
could not be prevented.
Conclusions: These findings suggest that IL-22 plays an important role in the 
development of experimental arthritis, and neutralizing this cytokine seems an attractive 
new strategy in RA treatment. Most importantly, SPECT/CT imaging with 111In-28H1 can 
be used to specifically monitor response to therapy, and is potentially more sensitive 
in disease monitoring compared to the gold standard method of macroscopic arthritis 
scoring.
Keywords: SPECT-CT, anti-FAP, therapy monitoring, anti-IL-22, experimental arthritis
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting up to 1% of the world 
population. The synovial inflammation characterizing RA leads to destructions of cartilage 
and bone, thereby disabling patients in their daily life. Increasing evidence suggests an 
important role for T cells in RA pathology, in particular for the T helper (Th)17 cell subset1-3. 
Th17 cells produce various pro-inflammatory cytokines such as IL-17, IL-21, and IL-22, 
thereby protecting the host from bacterial and fungal infections, but also promoting 
the development of autoimmune diseases when present at elevated levels4-7. In the 
synovium and in the circulation in RA patients elevated levels of IL-22 are observed,8-10 
which positively correlates with disease activity score (DAS)2811, serum rheumatoid factor 
(RF),9-11 and anti-cyclic citrullinated peptide (CCP) antibodies9. Interestingly, reports on the 
role of IL-22 in various arthritis mouse models show that this cytokine can not only be 
pro-inflammatory, but also might exert anti-inflammatory activities during experimental 
arthritis. In collagen-induced arthritis (CIA) for instance, an IL-22-deficiency in the early 
phases of the disease reduced the susceptibility to arthritis development12, whereas 
absence of the cytokine during the later phases aggravated joint pathology13. Further 
insights into the role of IL-22 in experimental and rheumatoid arthritis are crucial when 
evaluating the potency of this cytokine as a new therapeutic target in RA treatment.
Since RA is characterized by disease exacerbations, not only early diagnosis is of utmost 
importance for an adequate treatment. In addition, monitoring of disease progression 
and early response monitoring after therapy are crucial for the prevention of progressive 
destruction. Considering that the response to therapy varies significantly among patients, 
personalized treatment based on accurate therapy response monitoring is essential. 
Molecular imaging of disease activity can be a valuable tool for immediate therapy 
monitoring. Specific tracer uptake can be quantified and can be assessed objectively. 
However, in most cases the tracer is not specific for arthritis at the molecular level14,15. 
Terry et al. were the first to demonstrate therapy response monitoring with tracers 
directed against targets which were specific biomarkers for arthritis16. One of the 
tracers used in their study was the radiolabeled anti-FAP antibody 28H1. 28H1 is a non-
internalizing antibody with high affinity for human and murine fibroblast activation 
protein (FAP). FAP is dominantly expressed by activated fibroblast-like synoviocytes in 
arthritic joints17, 18. Specificity of 28H1 for FAP was shown in an in vitro binding assay and 
by immunohistochemistry in arthritic joints. SPECT/CT imaging with 111In-labeled 28H1 
as a tracer showed a significant correlation between the uptake of the 111In-28H1 tracer in 
inflamed joints and the severity of arthritis18. 
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In this study, we investigated the feasibility of 111ln-28H1 SPECT/CT imaging of FAP-
expressing synovium to monitor the therapeutic potential of neutralizing IL-22 during 
various phases of experimental arthritis.
METHODS
Mice
Male DBA-1/J mice were purchased from Janvier-Elevage (Le Genest Saint Isle, France). 
Experiments were initiated when mice were between 10 and 12 weeks old. Mice were 
housed in filter-top cages under specific pathogen-free conditions. Mice had unlimited 
access to a standard diet and water. All animal procedures were approved by the animal 
ethics committee of the Radboud University Nijmegen.
Study design
Collagen-induced arthritis (CIA) was induced in DBA/1J mice, and animals were divided 
in six experimental groups. Arthritis development was evaluated as described in the ‘CIA 
induction’ section. Mice that did not develop arthritis were allocated to groups 1 and 2 
(‘before onset’), mice with an arthritis score of 0.5 to 1.0 to groups 3 and 4 (‘at onset’), 
and mice with an arthritis score of 1.5 or higher to groups 5 and 6 (‘established disease’). 
Mice in group 1, 3, and 5 were the control groups, and received rat IgG1 isotype-matched 
control antibodies (Pfizer), while mice in group 2, 4, and 6 were treated with rat anti-mouse 
IL-22 antibody (Pfizer, New York, NY, USA), while Antibodies (8 mg/kg) were administered 
intraperitoneally (i.p.) three times per week for a total period of 12 days. This regimen was 
based on previous studies19.
To monitor the therapeutic effect, SPECT/CT images were acquired at day 14, 24 h after 
injection of the 111In-28H1 tracer. After image acquisition, mice were euthanized, organs 
were isolated to determine tissue distribution of the tracer, and ankle joints were isolated 
for X-ray and histological analysis.
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CIA induction
Collagen-induced arthritis (CIA) was induced by intradermal injection at the base of the 
tail with 100 µg bovine type II collagen (CII; Radboud umc in house production, batch 03-
04-08) at a concentration of 2 mg/ml in 50 mM acetic acid, emulsified in equal volumes 
of Freund’s complete adjuvant (2 mg/ml of Mycobacterium tuberculosis strain H37Ra; 
Difco Laboratories, Detroit, MI, USA). After 21 days mice received an intraperitoneal 
(i.p.) injection of 50 µg CII dissolved in PBS. The onset of arthritis occurred around time 
of booster. Arthritis development was macroscopically scored three times a week, using 
an arbitrary scoring system from 0-2 per paw (0, no sign of arthritis; 0.25, 1-2 toes red 
or swollen; 0.5, 3-5 toes red or swollen; 1, swollen ankle; 1.5, swollen footpad; 2, severe 
swelling and ankylosis), resulting in a score of 0-8 per mouse.
Antibody conjugation and radiolabeling
The humanized monoclonal anti-FAP antibody 28H1 (3.7 mg/ml) was obtained from Roche 
(Schlieren, Switzerland) and has a picomolar affinity for both murine and human FAP. 28H1 
was conjugated with the chelator isothiocyanatobenzyl-diethylenetriaminepentaacetic 
acid (p-SCN-Bz-DTPA, Macrocyclics, Inc., Dallas, TX, USA). A 10-fold excess of p-SCN-
Bz-DTPA was added to 28H1 in 1 M NaHCO3 (pH 9.5) and incubated for 1 h at room 
temperature. Unconjugated p-SCN-Bz-DTPA was removed by dialysis against 0.25 M 
ammonium acetate (pH 5.5) in Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, 
Etten-Leur, The Netherlands) with a molecular weight cut-off of 10 kD. Five cycles of at 
least 8 h of dialysis were performed and after each cycle the medium was refreshed.
For radiolabeling, per mouse, 50 μg DTPA-28H1 was incubated with 15 MBq of 
111InCl3 in 0.5 MES buffer (pH 5.4) for 30 min at room temperature. After labeling, 
ethylenediaminetetraacetic (5 mM) was added to complex unincorporated 111In. Labeling 
efficiency was determined by thin-layer chromatography (ITLC) on ITLC silica gel strips 
(Agilent Technologies, Santa Clara, SA, USA), with 0.1 M acetate buffer, pH 5.4, as the 
mobile phase. Labeling efficiencies exceeded 99%.
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SPECT/CT imaging
All mice were injected intravenously with 50 μg of 111In-28H1 (15 MBq) in 0.2 mL. At 24 
h after tracer injection, image acquisition with the U-SPECT-II/CT (MILabs, Utrecht, The 
Netherlands) was performed20. Mice were scanned under general anesthesia (isoflurane 
and air) for 25 minutes while in prone position, using a 1.0 mm pinhole ultra-high 
sensitivity mouse collimator. SPECT scans were followed by CT scans for anatomical 
reference (spatial resolution of 160 μm, 65kV, 615 μA). SPECT scans were reconstructed 
with software from MILabs, using an ordered subset expectation maximization algorithm, 
with a voxel size of 0.375 mm.
Quantitative SPECT analysis
Reconstructed SPECT scans were coregistered with CT images using Inveon Research 
Workplace 4.1 software (Siemens Preclinical Solutions, Knoxville, TN, USA). The 
3-dimensional regions of interest were drawn on the CT images and transferred to the 
SPECT images to obtain mean voxel intensities of the SPECT data corresponding to those 
regions. The regions of interest included the joints of the ankles, knees, hips, wrists, elbows 
and shoulders. The mean voxel intensity values in these joints were converted to %ID/g 
using decay correction and a standard curve (mean voxel intensity vs. kBq) acquired by 
scanning and reconstructing known 111In activities.
Histology
Murine joints were fixed for at least four days in 4% formaldehyde, decalcified in 5% formic 
acid, dehydrated and embedded in paraffin. Frontal sections of 7 µm were mounted on 
SuperFrost slides (Menzel-Gläser, Braunschweig, Germany). To study pathologic features 
of the joints, haematoxylin and eosin (H&E) staining, and Safranin O (SafO) staining 
were performed. Arthritis severity in the joints was scored on an arbitrary scale from 0 
to 3, where joints without pathology were scored as 0, and with maximal pathology as 
3. Five different parameters (joint inflammation, cartilage proteoglycan (PG) depletion, 
chondrocyte death, cartilage surface erosion, and bone erosion) were analyzed as 
previously described21, on three semiserial sections of the joint spaced 70 um apart, in a 
blindfolded manner.
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X-ray analysis of knee and ankle joints
X-ray images from knee and ankle joints were taken using a Faxitron MX20 instrument 
(Faxitron Bioptics, Tucson, AZ, USA) and analyzed using Faxitron software. Bone destruction 
was scored on an arbitrary scale from 0 to 4 per paw, where joints without pathology were 
scored as 0, and with maximal pathology as 4. 
FAP Immunohistochemistry
Knee joint synovium pieces were fixed and frozen in Tissue-Tek® O.C.T.TM Compound 
(Sakura, Torrance, CA, USA) upon isolation. 7 µm sections were cut, and dried 30 minutes 
at room temperature (RT) on SuperFrost slides (Menzel-Gläser, Braunschweig, Germany). 
Subsequently, sections were stained with human anti-mouse/human FAP Ab (28H1-
IgG; 0.1 µg/ml; Roche, Indianapolis, IN, USA), or human IgG isotype-matched control 
Ab (DP47GS; 0.1 µg/ml; Roche) for 1 hour at RT, followed by an incubation period of 
15 minutes at RT with 3% H2O2 to block endogenous-peroxidase. Next, sections were 
incubated with biotinylated goat-anti-human secondary antibodies (BA-3000; Vector 
Laboratories, Burlingame, CA, USA) for 30 minutes, followed by labeling with streptavidin-
horseradish peroxidase (PK-6101; Vector Laboratories). Finally, peroxidase was developed 
with diaminobenzidine (DAB; D-5637; Sigma-Aldrich, Saint Louis, MO, USA), and 
counterstained with haematoxylin.
mRNA isolation and quantitative real-time PCR
For mRNA isolation, lateral and medial biopsies were isolated from murine knee synovium, 
using a 3 mm biopsy punch (Stiefel, Wachtersbach, Germany). The biopsies were immediately 
frozen in liquid nitrogen for further use. Thereafter, synovium pieces were disrupted and 
homogenized using the MagNA Lyser (Roche). RNA was isolated using TRIzol reagent 
(Sigma-Aldrich), according to manufacturers’ protocol, and obtained concentrations were 
quantified using the Nanodrop Spectrofotometer (NanoDrop Technologies, Wilmington, 
DE, USA). Samples were treated with 1x DNAse I buffer (Invitrogen, Carlsbad, CA, USA), and 
25 mM EDTA (Invitrogen) to prevent DNA contamination.
1 µg RNA was reverse-transcribed (RT) into complementary DNA (cDNA) using a mix of 
1x DNAse I buffer, 0.1M DTT (Invitrogen), dNTPs (12.5 mM each; Invitrogen), 0.5 µg/µl 
oligo dT primer (Invitrogen), 40 U/µl RNAsin (Promega, Madison, WI, USA), and 200 U/µl 
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Reverse Transcriptase (Invitrogen). The following protocol was used on the PTC-200 Peltier 
Thermal Cycler (Biorad, Hercules, CA, USA) for the RT reactions: 5 minutes at 25 °C, 60 
minutes at 39 °C, and 5 minutes 94 °C.
Synovium gene expression levels were determined by a quantitative real-time PCR 
(qPCR) reaction, determined on the StepOnePlus sequence detection system (Applied 
Biosystems, Foster City, CA, USA) using SYBR Green technology (Applied Biosystems). 2 
µM of murine FAP primers (Biolegio, Nijmegen, the Netherlands) were used in the reaction 
(5’-GTC-ACC-TGA-TCG-GCA-ATT-TGT-3’ (forward) and 5’-TCG-TAG-ATG-TAG-TAT-GTC-GCT-
GT-3’ (reverse)). The qPCR protocol was as follows: 2 minutes at 50 °C, 10 minutes at 95 
°C, 40 cycles of 15 seconds at 95 °C and 1 minute at 60 °C. Gene of interest expression 
levels were normalized for expression of the reference gene GAPDH (5’-GGC-AAA-TTC-
AAC-GGC-ACA-3’ (forward) and 5’-GTT-AGT-GGG-GTC-TCG-CTC-CTG-3’ (reverse)). To allow 
for statistical analysis, the –ΔCt value of samples with mRNA levels below detection limit 
was set at -30.
Statistics
To determine the level of statistical significance between the experimental groups, the 
Mann-Whitney or Spearman correlation test was applied, using GraphPad Prism version 5. 
P values less than 0.05 were considered significant. Results were expressed as bar graphs, 
Tukey boxplots, or correlation plots.
RESULTS
Severity of experimental arthritis positively correlates with synovial FAP 
expression
To determine the correlation between severity of experimental arthritis and FAP expression 
levels in the synovium, CIA was induced in DBA1/J mice. Mice were euthanized at various 
stages of the disease. Analysis of isolated synovium by qPCR and immunohistochemistry 
showed that both FAP mRNA and protein expression increased when disease severity 
increased (Figures 1A and 1B, respectively), indicating that FAP is a suitable marker of 
inflammation in the CIA model.
Monitoring therapeutic effects of anti-IL22
135
7
Figure 1. FAP expression increases in synovium of mice with more severe collagen-induced 
arthritis. mRNA expression levels depicted as -ΔCT levels as determined using qPCR (A), and 
immunohistochemistry slides (B) of synovium isolated from mice with various severities of 
collagen-induced arthritis, depicted as macroscopic scores (MS) on a scale of 0 to 2. Slides are 
stained with anti-FAP antibodies or appropriate isotype control antibodies (original magnification 
200x).
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Decreased synovial FAP expression after early anti-IL-22 treatment of mice 
with CIA
As previously reported, 111In-28H1 SPECT/CT is an excellent tool to noninvasively monitor 
synovial FAP expression18. In order to test the potency of this tracer in monitoring responses 
to arthritis therapy, mice in various stages of CIA (group divisions as depicted in Figure 
2) were treated with IL-22-neutralizing antibodies, and subsequently FAP expression was 
visualized using 111In-28H1 SPECT/CT. Arthritic joints were specifically visualized with 
111In-28H1 in all groups (Figure 3A-F). Images showed lower uptake of 111In-28H1 when 
mice received anti-IL-22 treatment before onset of macroscopic symptoms (Figure 3D), 
compared with mice that were treated around onset (Figure 3E), or in established disease 
(Figure 3F) with this IL-22 neutralizing antibody, or when mice received the control 
antibody (Figure 3A-C). Quantitative analysis of the SPECT images confirmed that tracer 
uptake in the joints was lower in joints after treatment with anti-IL22-antibodies before 
onset of disease (Figure 3G-I). For example, ankle joint uptake of 111In-28H1 (Figure 3G) 
was significantly higher (p=0.02) in control-treated mice than in anti-IL-22 treated mice. 
Additionally, a significant reduction in tracer uptake (p=0.03) was found in the knee joints 
of anti-IL-22-treated mice compared to control-treated mice, as depicted in Figure 3H. No 
significant differences were found for 111In-28H1 uptake in other joints, such as the wrists 
(Figure 3I), and for tissue uptake in joints of mice that were treated in a later stage of 
disease. 
Neutralization of IL-22 before disease onset reduces macroscopic arthritis 
incidence and severity, correlating with FAP-tracer uptake
In line with the reduced levels of 111In-28H1 uptake in synovium, we observed reduced 
clinical arthritis incidence (50% vs. 100% at day 12 after start of treatment) as well as 
severity (1.0 vs. 3.0 on a scale of 0 to 8, p<0.05) in mice treated with anti-IL-22 antibodies 
before disease onset as compared to mice that received control antibodies (Figure 4A and 
4B, respectively). As with SPECT/CT measured joint tracer uptake, macroscopically scored 
joint swelling was not inhibited in mice in which anti-IL-22 treatment was initiated during 
later phases of the disease in this arthritis model (Figure 4B). Of high interest, a strong 
positive correlation was found between synovial uptake of 111In-28H1 and macroscopic 
arthritis scores (Spearman r=0.7172, p<0.0001; Figure 4C). With macroscopic scoring, only 
the clinical signs of arthritis in wrists, ankles and digits of front and hind paws are included. 
As CIA is a systemic model also affecting larger synovial joints like the knee joints, hip, 
elbow and shoulders, not all affected joints can be scored using this system. Using FAP-
based SPECT-CT in vivo, those other affected area’s can be detected (Figures 3A-F).
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Figure 2. Macroscopic scores of the various experimental groups before treatment. Treatment 
with either IgG isotype control antibodies or anti-IL-22 antibodies was initiated when mice 
reached a macroscopic score of 0 (group 1 and 2), 0.5-1.0 (group 3 and 4), or higher than 1.5 
(group 5 and 6). Group division based on macroscopic scores at the time of treatment initiation 
depicted as Tukey’s boxplots (n=6 mice/group).
Early anti-IL-22 treatment reduces ankle histopathology and radiographic 
bone damage, correlating with synovial tracer uptake
In agreement with SPECT/CT and macroscopic data, reduced inflammation and cartilage 
damage of ankle joints was observed on a histological level in mice treated with anti-
IL-22 antibodies before disease onset, as compared to the control group (Figure 5A and 
5B). As with tracer uptake and macroscopically scored joint swelling, neutralization of IL-
22 could not prevent histological damage in ankles of mice with starting or established 
disease. Interestingly, again a strong correlation between joint damage and anti-FAP 
antibody uptake was apparent (Spearman r=0.7100, p<0.0001; Figure 5C). Additionally, 
radiographic ankle bone damage, as measured using X-ray, was significantly reduced in 
the ankle joints after early anti-IL-22 antibody treatment as compared to control treatment 
(0.4 vs. 1.5 respectively on a scale of 0-4, p<0.05; Figure 5D and 5E). No effect of the IL-22-
neutralizing antibody treatment was detected when treatment was initiated in mice with 
clinical signs of arthritis. Ankle tissue tracer uptake and radiological bone damage showed 
a strong, positive correlation (Spearman r=0.6993, p<0.0001; Figure 5F).
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Figure 3. Early anti-IL-22-treatment reduces tissue uptake of radiolabeled FAP-tracer, indicating 
reduced severity of collagen-induced arthritis. Whole body SPECT/CT images of mice injected 
with the FAP tracer 111In-28H1 24 h post injection (A-F) and tissue uptake based quantitative SPECT 
analysis in ankles (G), knees (H) and wrists (I). SPECT/CT imaging was performed after 2 weeks of 
treatment, either with an isotype control antibody (A-C) or with the IL-22 neutralizing antibody 
(D-F). IL-22 signaling was neutralized in mice either before onset (A +D, macroscopic start score 0), 
around onset (B + E, macroscopic start score 0.5-1.0), or in established CIA (C + F, macroscopic start 
score ≥1.5). Tissue uptake (%ID/g) per ankle, knee and wrist joints (n=6 mice/group) are shown (G, 
H,I; Tukey’s boxplot; *p<0.05; Mann Whitney test).
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Figure 4. Early anti-IL-22-treatment reduces macroscopically scored severity of collagen-induced 
arthritis, correlating with tissue uptake of FAP-tracer. IL-22 signaling was neutralized in mice either 
before onset (macroscopic start score 0), around onset (macroscopic start score 0.5-1.0), or in 
established CIA (macroscopic start score ≥1.5). Disease incidence of mice treated before onset 
(A), and disease severity in ankle joints (B) and wrists (C) of all experimental groups at day 12, as 
scored macroscopically on a scale of 0 to 2 per paw (Tukey’s boxplot; **p<0.01, Mann Whitney 
test; n=12 joints/group). Correlation between FAP-tracer uptake by the tissue as measured using 
SPECT-CT and macroscopic arthritis severity scores (D; n=72 ankle joints; Spearman correlation).
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Knee histopathology is potently reduced by early IL-22 neutralization, 
positively correlating with SPECT tracer uptake
In accordance with SPECT/CT images and observations in ankle joints, knee joint 
histopathology was reduced in mice treated with anti-IL-22 antibodies before disease onset, 
as compared to the control group (Figure 6A and 6B). Histopathological scores positively 
correlated with FAP-tracer uptake in the knee joints (Spearman r=0.6710, p<0.0001; Figure 
6C). As opposed to the significantly reduced bone damage in the knees as observed 
during histological analysis, radiological scored knee bone damage was unaffected after 
early anti-IL-22 antibody treatment (Fig. 6D and 6E). An effect of the anti-IL-22 antibody 
was detected neither on a histological, nor on a radiographic level when treatment was 
initiated in mice with starting or established disease. When linking tissue uptake of the 
tracer with radiological ankle bone damage, again a strong positive correlation between 
the readout parameters was observed (Spearman r=0.7206, p<0.0001; Fig. 6F).
Figure 5. Histopathology and radiographic damage of the ankle joint is reduced by treatment 
with IL-22-neutralizing antibodies before onset of collagen-induced arthritis, correlating to FAP 
protein expression. Mice received anti-IL-22-antibodies either before onset (macroscopic score 
0), around onset (macroscopic score 0.5-1.0), or during established CIA (macroscopic score ≥1.5). 
Frontal sections of the ankle joint were stained with haematoloxylin & eosin (H&E), or with Safranin 
O (SafO), to analyze histological inflammation, cartilage damage, and bone erosion, on a scale of 
0 to 3 per parameter (A; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images 
represent average group scores of mice treated before disease onset (B; original magnification H&E 
stained sections 50x, SafO stained sections 100x). Correlation between ankle FAP-tracer uptake 
and the sum of the three histologically scored parameters (C; n=72 joints; Spearman correlation). 
X-ray images were acquired using the faxitron, and bone damage was subsequently scored on 
a scale of 0 to 4 (D; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images 
represent average group scores of mice treated before disease onset (E). Correlation between 
ankle FAP-tracer uptake, and radiological bone damage (F; n=72 joints; Spearman correlation).
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Figure 6. Reduced histopathology of the knee joint by treatment with IL-22-neutralizing 
antibodies before onset of collagen-induced arthritis, correlating to FAP protein expression. 
Mice received anti-IL-22 antibodies either before onset (macroscopic score 0), around onset 
(macroscopic score 0.5-1.0), or during established CIA (macroscopic score ≥1.5). Frontal sections 
of the knee joint were stained with haematoloxylin & eosin (H&E), or with Safranin O (SafO), to 
analyze histological inflammation, cartilage damage, and bone erosion, on a scale of 0 to 3 per 
parameter (A; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images represent 
average group scores of mice treated before disease onset (B; original magnification H&E stained 
sections 50x, SafO stained sections 100x). Correlation between knee FAP-tracer uptake and the 
sum of the three histologically scored parameters (C; n=72 joints; Spearman correlation). X-ray 
images were acquired using the faxitron, and bone damage was subsequently scored on a scale 
of 0 to 4 (D; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images represent 
average group scores of mice treated before disease onset (E). Correlation between knee FAP-
tracer uptake, and radiological bone damage (F; n=72 joints; Spearman correlation).
DISCUSSION
We demonstrated, using 111In-28H1 SPECT imaging, that IL-22-neutralization only in the 
early phase of disease effectively suppressed the development of collagen-induced 
arthritis. Most importantly, we showed that this response to anti-IL-22 treatment can 
be monitored noninvasively, specifically and objectively using quantitative SPECT/CT 
imaging of the inflamed synovium using 111In-labeled anti-FAP antibody as a tracer.
Previous SPECT/CT studies with radiolabeled anti-FAP antibodies showed high quality 
images with low background uptake and absence of accumulation in joints of nonarthritic 
mice16, 18, 22. Additionally, a better correlation between tissue uptake of the imaging tracer 
and severity of disease was found compared to the correlation found with the widely-
used 18F-FDG-PET, which has been suggested as a tool to monitor therapeutic response 
in experimental arthritis14, 18, 23. These studies also emphasized the feasibility to use 111In-
labeled 28H1 SPECT to specifically monitor therapy response at a molecular level.
IL-22 is a cytokine to which both pro- and anti-inflammatory properties have been 
attributed. Even though most studies on the role of IL-22 in experimental arthritis 
hint towards a pro-inflammatory effect12, 19, 24, 25, the exact mechanism by which it is 
involved in RA pathology remains unclear. The therapeutic potential of targeting IL-22 
in experimental arthritis was clearly shown by the highly efficient reduction in disease 
incidence when treatment was initiated early in disease development. Additionally, 
disease severity was lowered as demonstrated by significantly reduced clinical arthritis, 
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histological damage, and radiographic bone damage. Of note, a minor discrepancy 
between histological and radiographic scored bone damage in ankle and knee joints was 
observed. On the histological level, ankle joint damage was not significantly reduced after 
IL-22 neutralization, while this was the case on a radiographic level. Knee joints on the 
other hand, showed significantly less histological bone damage after anti-IL-22 treatment, 
while no effects were observed on a radiographic level. This might appear contradictive, 
but the two different methods visualize different facets of bone damage. On a histological 
level, microscopic bone erosions can be detected, whereas bone density and larger areas 
of damage to the bone can clearly be observed using X-ray imaging. 
As this study was designed to investigate whether SPECT/CT imaging with 111In-labeled 
anti-FAP antibodies as a tracer could be used to monitor response to anti-IL-22 therapy, 
we did not focus on deciphering the mechanism of IL-22 in experimental arthritis. 
Nevertheless, the difference in effectiveness of IL-22-neutralization in reducing arthritis 
severity between treatment-initiation before disease onset versus at onset or during 
established disease is highly interesting. Based on results of our previous study, which 
showed efficacy of IL-22 neutralization during established disease in IL-1Ra-/- mice19, we 
hypothesize that the inadequacy of anti-IL-22 treatment in a later stage of disease is partly 
caused by the progressiveness and aggressiveness observed in the CIA model. Although CIA 
is considered to be the gold-standard animal model for rheumatoid arthritis, it is possible 
that disease development cannot be inhibited using IL-22-neutralizing antibodies once 
mice suffer from such a progressive form of experimental arthritis. Another explanation 
might be the changing role of IL-22 during disease development. As suggested previously 
by Pineda and colleagues13, the role of IL-22 might be pathogenic during the early, but not 
during later phases of CIA. Hence, neutralizing this cytokine later in disease development 
would not affect joint pathology. IL-22 has been shown to be pathogenic in the presence, 
and protective in the absence of IL-17 in an animal model for airway inflammation26, this 
cooperative mechanism with IL-17 or other pro- or anti-inflammatory cytokines might be 
present in experimental arthritis as well. This can provide a possible mechanism by which 
IL-22 exerts its pro- and anti-inflammatory activities respectively. Altogether, we conclude 
that IL-22 is an important mediator during the early phases of CIA and has potential as 
a target in treating early RA. Still, further studies into the exact mechanism are required 
before testing the druggability of anti-IL-22 treatment in the clinic.
Here, we showed the feasibility of 111In-28H1 SPECT/CT as a specific and quantifiable tool 
to assess therapy response after IL-22 neutralization in experimental arthritis. Due to the 
objectivity and specificity of this method, molecular imaging using radiolabeled anti-FAP 
antibodies as a tracer can be of additive value to existing methods of therapy monitoring 
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in patients such as clinical macroscopic scoring (DAS28), MRI, ultrasound or conventional 
radiography. Additionally, high sensitivity of 111In-28H1 SPECT/CT was shown, indicated 
by a relatively high tissue uptake of 111In-28H1 in joints that were macroscopically scored 
as 0, thus not showing any clinical signs. We suggest that the uptake of the tracer in the 
joints reflects increased FAP expression and that these joints might show symptoms of 
inflammation at later time points, indicating a potential predictive value of 111In-28H1 
SPECT/CT.
In conclusion, SPECT/CT imaging of the inflamed synovium using the 111In-labeled anti-
FAP antibody 28H1 can be used to specifically monitor response to therapy in an objective 
and quantitative way, and is potentially more sensitive in disease monitoring compared to 
the standard method of clinical arthritis scoring by macroscopic inspection.
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GENERAL DISCUSSION
Rheumatoid arthritis (RA) is an autoimmune disorder which affects 0.5% - 1% of the 
European population1. It is characterized by inflammation of synovial joints, eventually 
leading to cartilage and bone destruction. Glucocorticoids (GC) were among the first 
antirheumatic drugs and still have a prominent place in the treatment of RA2. However, 
poor accumulation at target sites, the occurrence of side effects and resistance to 
these drugs is limiting their application. High and frequent dosing is often required to 
treat severe inflammation, which might lead to severe adverse effects such as Cushing 
syndrome, induction of diabetes, osteoporosis, muscular atrophy and thinning of the 
skin3, 4.
Liposomes as a drug delivery system can be used to increase the efficacy of therapeutic 
agents by helping the agents overcome chemical, physical and biological hurdles and 
selectively direct and deliver them at the diseased target site. Improved delivery of the drug 
at the target may reduce side effects and therefore increase the efficacy safety ratio. The 
most straightforward way by which long-circulating liposomes (LCL) can achieve diseased 
site targeting is by means of a process called enhanced permeability and retention (EPR) 
effect, which involves gradual accumulation of the liposomes as a result of enhanced 
vascular permeability at the inflammatory sites provided the liposomes are small-sized 
(below 150 nm) and are of long-circulating nature when injected in the blood streams5, 6. 
Uncomplicated manufacturing and quality control, and excellent biodegradability 
and biocompatibility of the lipid excipients have rendered liposome technology a 
gold standard in the field of drug delivery. This resulted in the development of several 
liposomal drug products in late stage clinical development and on the market, including 
anti-infective (AmBisome®), anti-inflammatory (Nanocort®) and anticancer (Doxil/
Caelyx®, Myocet®, Depocyt®, Marqibo®) products7-10. Nanocort® contains the prednisolone 
phosphate and this liposomal GC has been proposed for the treatment of RA11-14.
While there are many drugs available for the treatment of RA, generally the classical 
disease-modulating antirheumatic drugs (DMARDs) take several months of treatment to 
become therapeutically active. Another problem with antirheumatic drugs, which also 
pertains to newer biologic drugs, is the significant fraction of the patients who become 
non-responsive. Therefore, there is a need for noninvasive methods that can monitor 
the response to treatment at an early stage. This could avoid the use of ineffective, but 
still toxic drugs and enable an early switch to a more effective drug that can quickly halt 
progression of disease, which is nowadays considered paramount in the treatment of RA. 
Molecular imaging can potentially be used to objectively determine the severity of the 
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symptoms, to monitor therapeutic efficacy early after therapy and to foresee hinder due to 
the occurrence of exacerbations during the course of the disease. Therefore, noninvasive 
imaging with a specific and sensitive radiotracer could favorably steer the therapeutic 
management of individual RA patients. The primary focus of the research described in this 
thesis was to select radionuclide imaging methods that could be used for early therapy 
response monitoring of RA in animal models.
Radiolabeled liposomes
Uptake of LCL in diseased tissue is primarily driven by the EPR effect: the liposomes will 
selectively accumulate in tissue with increased vascular permeability, such as inflamed 
and cancerous tissue. To track liposomes in vivo and to measure the accumulation of 
liposomes at diseased sites, liposomes can be radiolabeled with a range of radionuclides 
using various radiolabeling methods. An overview of the methods to label liposomes with 
radionuclides is given in chapter 2. Selection of the optimal labeling method depends on 
the application, the choice of radionuclide and the type of liposomes. In general, labeling 
of liposomes via a chelator incorporated in the lipid bilayer results in efficient labeling with 
high specific activity, good in vivo stability and unaltered in vivo behaviour. Additionally, 
this approach is relatively fast and easy to perform. Radiolabeled liposomes could be 
excellent tools to optimize therapy with drug-loaded liposomes. By radiolabeling the 
liposomal drug formulation, the pharmacokinetics and targeting to the diseased tissues 
can be noninvasively measured with molecular imaging techniques, such as PET and 
SPECT imaging. Such an approach would also allow for (semi)-quantitative determination 
of the quantity and retention time of the liposomal drugs in the diseased tissue. Based 
on the imaging results, the liposomal formulation may be further tuned for the particular 
application to maximize the exposure of the target tissue to the drug and to minimize the 
exposure of vulnerable healthy tissues. 
In chapter 3, three different methods to radiolabel liposomal formulations with 111In 
were compared in terms of labeling efficiency, stability and in vivo characteristics. Three 
liposomal formulations were used: 1. long-circulating liposomes (LCL) with DTPA accessible 
at the exterior of the liposomes (DTPA-DSPE LCL); 2. LCL with DTPA incorporated in the 
aqueous interior (DTPA LCL); 3. LCL without chelator. 
We found that the radiolabeling of LCL with 111In is more efficient when the chelator, DTPA, 
is incorporated in the lipid bilayer and is accessible at the surface of the liposomes. An 
additional advantage of this labeling strategy is that DTPA-DSPE-modified liposomes 
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can be labeled with 111In using 111InCl3 instead of 
111In-oxine, which is generally used if 
the chelator is encapsulated in the aqueous interior or if no chelator is present. 111InCl3 
has a 10-times higher concentration of radioactivity (370 MBq/mL) compared with 111In-
oxine (37 MBq/mL), which results in a smaller volume of the final radiolabeled product. 
Therefore, there is no need to concentrate your labeled product, which makes labeling 
with 111InCl3 faster and less laborious. Additionally, we showed that the presence of a 
chelator is essential for optimal radiolabel retention in time, since LCL devoid of chelator 
are less stably labeled with 111In. 
The in vivo properties of 111In-DTPA-DSPE LCL and 111In-DTPA LCL were compared in 
mice with a focal S. Aureus infection. The in vivo infection targeting properties of both 
formulations were similar, indicating that the presence of 111In and DTPA at the surface 
of LCL did not affect their in vivo behavior. Based on these results we propose that the 
labeling of DTPA-DSPE LCL with 111InCl3, a robust, easy and fast procedure, is preferred over 
the less efficient labeling of DTPA LCL. Liposomes without chelator can be labeled with 
111In-oxine, but the 111In label leaks from such LCL in human serum and therefore leakage 
in the bloodstream upon in vivo injection is expected. 
Theranostic liposomes
A theranostic agent is a single agent that can be used for diagnosis and therapy 
simultaneously. Theranostic agents can be designed for monitoring drug delivery, drug 
release and therapy response. This strategy has been developed to optimise therapeutic 
effectiveness and to predict adverse effects in a personalized manner. Potentially, 
theranostic agents can be used to identify the patients that are most likely to benefit 
from treatment15-18. Additionally, imaging of the theranostic agent after administration 
can be used to optimize the dose for that particular patient. Radiolabeled drug-loaded 
liposomes have the potential to be used as theranostic agents, by in vivo tracking of the 
formulation to identify affected tissue and to assess the quantity of the liposomes and 
the encapsulated drug in the diseased site(s). The use of liposomal drugs as a theranostic 
agent can steer the treatment of the patient by selecting the patient that could potentially 
benefit from treatment and by adjusting the dose of the liposomal drug based on its in 
vivo distribution. 
The therapeutic effects of drug-loaded liposomes are widely examined and the in vivo 
imaging properties of radiolabeled liposomes have been investigated as well. However, 
the theranostic application of radiolabeled drug-loaded liposomes has hardly been 
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explored18. Despite the promising results in animal studies, no radiolabeled drug-loaded 
liposomal formulation has been properly investigated in patients yet19, 20. The use of 
radiolabeled liposomes as theranostic agents in patients could accelerate the clinical 
development of this new class of drugs. When introducing theranostic liposomes in a 
clinical setting, some factors should be taken into account. Technical challenges such as 
batch-to-batch reproducibility, drug entrapment, specificity, (radio)chemical stability need 
to be examined. Batch-to-batch variation should be minimized to obtain reproducible 
results. Currently, lipid dose and the amount of (non-)encapsulated drug in the liposomal 
formulations may still differ from batch to batch. Another factor that has to be taken into 
account is the stability of the liposomal formulation. Physical stability and therapeutic 
effects after systemic administration have been much improved and side effects have been 
decreased with the development of PEGylated liposomes. Chemical stability was also an 
important issue, since hydrolysis of the ester bonds and oxidation of the acyl chains of 
the lipids could occur. However, in current formulations shelf lives of 3 years are typically 
seen and the excipient that is most vulnerable to chemical degradation is cholesterol. 
Additionally, the radiochemical stability and the dosimetry of the radiolabeled drug-
loaded liposomes should be assessed in a clinical setting, since until now only preclinical 
data are available. Furthermore, the toxicity of the formulation in an in vivo environment 
should be assessed.
Treatment of experimental arthritis with glucocorticoid-containing long-
circulating liposomes 
It has been shown that intravenous treatment of arthritis with glucocorticoid-containing 
LCL, is markedly more effective than pulse therapy or intra-articular injections of free 
glucocorticoids11, 13, 21. One of the most widely used immunosuppressive GC to treat 
RA is prednisolone. It is often administered as a prodrug, such as prednisone (in oral 
tablets) or prednisolone phosphate (PLP) in injectables, which was also found suitable for 
encapsulation in liposomes. Rats with adjuvant arthritis were treated with PLP-containing 
LCL after the first signs of disease. Therapeutic effects were compared with those of the 
same dose of free PLP or when free PLP is repeatedly injected on a daily base. Liposomal 
PLP showed complete and sustained remission of joint inflammation in this model and 
showed to be more effective than the other treatment strategies11. 
A similar experiment was performed in mice with antigen-induced arthritis, another 
established experimental arthritis model. Mice treated with liposomal PLP also showed 
suppressed joint swelling, as well as decreased synovial infiltrate and bone erosion. This 
treatment was more efficacious than that of multiple equidoses of free PLP13. 
General discussion
155
8
These studies showed that the required dose and frequency of dosing with GC can be 
reduced when the drug is encapsulated in liposomes. These liposomal preparations 
potentially can increase the therapeutic index of the GC, by increasing and prolonging 
their therapeutic effects and limiting the drug-related side effects. 
Therapy monitoring with 18F-FDG PET/CT
Although increased therapeutic efficacy of liposomal glucocorticoids has been shown, 
there is a need to develop noninvasive and quantitative methods for therapy monitoring 
early after therapy with PLP-containing LCL. In chapter 4, we investigated whether the 
development of arthritis in mice with antigen-induced arthritis can be monitored with 
18F-FDG PET/CT imaging. 18F-FDG accumulated in metabolically active cells, such as 
infiltrated immune cells in the inflamed knee joints in the mice. In this study, we have 
demonstrated that the course of the disease can be monitored noninvasively and 
quantitatively with 18F-FDG-PET. Moreover, the study showed that this imaging method 
can be used to visualize and quantify the therapeutics effect of PLP-containing liposomes 
(PLP-LCL). The therapeutic effects as assessed by 18F-FDG PET/CT were confirmed in 
biodistribution studies and by histological analysis. This study showed that noninvasive 
18F-FDG PET/CT imaging could be a useful tool to monitor the therapeutic effects of PLP-
LCL and potentially is superior to conventional methods to score arthritis (i.e. macroscopic 
or histological scoring). By acquiring a 18F-FDG PET/CT scan prior to therapy and early 
after onset of therapy, responsive patients may be discerned from unresponsive patients 
whose treatment can then be reconsidered in an early phase. 
However, the downside of using 18F-FDG PET in mice is that the uptake (in terms of %ID/
ml) in the mouse joints varies considerably and that it is of utmost importance to interpret 
18F-FDG uptake using a baseline scan as a reference. 18F-FDG cannot differentiate between 
arthritis or other processes with enhanced metabolic activity, in case of RA, the muscle 
uptake can impede the determination of tracer accumulation in the joints. Therefore, 
other more specific tracers, as described below, might be better suited.
SPECT/CT with anti-fibroblast activation protein (FAP) 
Multiple specific targets that represent inflammation in rheumatoid arthritis have been 
identified to increase the value of noninvasive imaging methods. For instance, studies 
with radiolabeled IL-1-ra, annexin-V, folate or TSPO, have been performed22, 23. Additionally, 
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radiolabeled antibodies that bind to over expressed in targets RA, such as CD-20 or 
TNFα, have been investigated. Although these tracers accumulated in inflamed joints, 
no significant correlation has been found with the severity of disease24. This makes these 
tracers less suitable to monitor the course of disease or therapeutic effects. To develop a 
better tracer with potential value for patient management, we examined the radiolabeled 
anti-FAP antibody 28H1. FAP is highly expressed by activated fibroblast-like synoviocytes 
that are present in arthritic joints, which makes FAP an attractive target for noninvasive 
imaging of RA. In chapter 5, the targeting properties of radiolabeled anti-FAP antibodies 
have been studied in a murine RA model. In this study, we used the 28H1 antibody, which 
is a non-internalizing anti-FAP antibody with picomolar affinity for both murine and 
human FAP. The Fc part of 28H1 carries a few mutations, preventing binding to the Fcγ 
receptors. 28H1 was conjugated with DTPA or desferal and radiolabeled with 111In or 89Zr, 
to allow for SPECT and PET imaging, respectively. The specificity of the accumulation of 
radiolabeled 28H1 in inflamed joints and extremely high quality images emphasize that 
anti-FAP imaging might be a new sensitive and specific tool for scoring RA disease activity, 
and could possibly be of additional value to existing scoring systems such as the disease 
activity score 28 (DAS28). Most importantly, accumulation of radiolabeled 28H1 correlated 
with the severity of disease, which might enable early therapy response monitoring when 
imaging is conducted prior and early after onset of therapy. Since PET/CT imaging with 
89Zr-28H1 showed elevated bone uptake of 89Zr, the use of 111In for imaging with anti-FAP 
antibodies in rheumatoid arthritis is preferred over that of 89Zr, at least as long as there are 
no chelators available that stably chelate 89Zr. 
Noninvasive early therapy response monitoring using radiolabeled anti-FAP 
SPECT/CT imaging
To further improve the properties of anti-FAP imaging for response monitoring in RA, we 
examined the use of 99mTc-labeled anti-FAP antibodies in a study described in chapter 6. 
Due to the shorter half-life of 99mTc (6 h), compared to that of 111In (67 h), it is a better match 
with the relatively short circulatory half-life of 28H1. Additionally, Buijs et al. estimated 
that the effective radiation dose per scan will be lower for 99mTc-labeled antibodies (6 mSv 
per 740 MBq administrated activity) compared with 111In-labeled antibodies (19 mSv per 
75 MBq administered activity)25. In addition, the use of 99mTc has the benefit of being a 
cheaper tracer that can be produced off the shelf in the majority of Nuclear Medicine 
departments. 
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Motivated by these arguments, mice with collagen-induced arthritis were treated with 
PLP-LCL to test the feasibility of 99mTc-HYNIC-28H1 SPECT/CT for early response monitoring. 
The therapeutic effects were clearly visualized in multiple joints. Enhanced tracer uptake 
was also observed in joints that were not taken into account in the macroscopic scoring 
system. Also, paws with low arthritis scores were clearly visualized with 99mTc-HYNIC-28H1 
SPECT, indicating the potential high sensitivity of this imaging method to monitor onset 
of disease and/or to predict exacerbations. This suggests that imaging with 99mTc-HYNIC-
28H1 is more sensitive than the conventional macroscopic arthritis scoring method. We 
hypothesize that SPECT/CT with 99mTc-HYNIC-28H1 can be used for immediate response 
monitoring to evaluate new treatment strategies. 
Both the 99mTc-labeled and the 111In-labeled 28H1 antibody can be used to visualize 
experimental arthritis. However, due the short half-life of 99mTc (6 h) only 6.25% of the 
injected activity is left at time of imaging (24 h after injection). This influences image 
quality and the amount of activity needed. Because of the high quality images obtained 
with the 111In-labeled 28H1 antibody when imaging is performed at later time points after 
injection, we preferred to use the 111In-labeled antibody over the 99mTc-labeled antibody in 
follow-up experiments.
Neutralizing IL-22 as a treatment strategy in RA
Elevated levels of IL-22 are observed in the synovia and circulation of RA patients26-28, 
positively correlating with DAS2829, serum rheumatoid factor (RF)27, 29, and anti-cyclic 
citrullinated peptide (CCP) antibodies27. Interestingly, reports on the role of IL-22 in 
various arthritis mouse models show that this cytokine can not only be pro-inflammatory, 
but also might exert anti-inflammatory activities in arthritis. In murine collagen-induced 
arthritis for instance, an IL-22-deficiency in the early phases of the disease reduced 
the susceptibility to arthritis development30, whereas absence of the cytokine during 
the later phases aggravated joint pathology31. Further insight into the role of IL-22 in 
experimental- and rheumatoid arthritis is crucial when evaluating the potency of this 
cytokine as a new therapeutic target in RA treatment. In the study described in chapter 
7 we evaluated the therapeutic effect of neutralizing IL-22 antibodies using 111In-DTPA-
28H1 SPECT/CT. Imaging showed that blocking IL-22 by the intravenous injection of an 
α-IL-22 antibody before CIA onset resulted in lower accumulation of 111In-DTPA-28H1 in 
inflamed paws. However, tracer uptake did not significantly differ between the treated 
and untreated groups when treatment was initiated in a later phase of CIA. This indicates 
that development of CIA can be prevented by neutralizing IL-22 antibodies only in an 
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early stage. Based on the imaging results, which were confirmed by macroscopic scores, 
histological scores and bone damage scores, it was suggested that IL-22 plays an important 
role in the development of experimental arthritis, and targeting this cytokine could be 
an attractive new strategy in RA treatment. Most importantly, SPECT/CT imaging with 
111In-DTPA-28H1 showed to be valuable to monitor the efficacy of this therapy. Enhanced 
uptake of the tracer in joints could be visualized, even before macroscopic signs became 
apparent, suggesting that 111In-DTPA-28H1 SPECT/CT can be used to detect flare-ups in an 
early phase. To evaluate this, repeated injection of the radiolabeled antibody in the same 
mouse will be necessary to enable imaging at different time points. Unfortunately, 28H1 
is a humanized antibody which induced mouse-anti-human antibodies (MAHA) upon 
repeated injection in mice. However, in patients repeated injections should be feasible. 
Research in RA has always had a strong focus on the ways to improve the balance between 
therapeutic efficacy and toxicity of antirheumatic drugs in patients. There is still a lot to 
learn and to optimize with regard to the potential theranostic application of radiolabeled 
drug-loaded liposomes. Nevertheless, the results so far are promising and suggest that 
radiolabeled liposomes could play a role in diagnosis and treatment of disease. Clinical 
studies are needed to demonstrate that the results obtained in animal models translate to 
patients and that clinical implementation is feasible. 
The use of radiolabeled anti-FAP antibodies showed promising results that suggest it 
could help steer patient management. The preclinical studies only focussed on 28H1-
based immunoSPECT. While preclinical SPECT imaging has a higher resolution, PET is the 
preferred imaging modality in patients because of its higher resolution and sensitivity. 
Therefore, the development of improved 28H1-based immunoPET for clinical studies is 
warranted.
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NEDERLANDSE SAMENVATTING
Reumatoïde artritis (RA) is een auto-immuun ziekte die wordt gekenmerkt door 
chronische ontstekingen in één of meerdere gewrichten. Deze ontstekingen kunnen 
leiden tot blijvende kraakbeen- en botschade en uiteindelijk tot invaliditeit. Ondanks dat 
de oorzaak van RA niet volledig bekend is, zijn er verschillende effectieve behandelingen 
beschikbaar. Het kan echter maanden duren voordat de medicijnen therapeutisch effectief 
blijken. Een ander probleem bij het behandelen van RA met klassieke reumaremmers 
(disease modifying antirheumatic drugs (DMARDs)), en ook met nieuwere biologische 
reumaremmers, is dat een significant gedeelte van de patiënten niet reageert op de 
behandeling. Om het gebruik van niet-effectieve medicijnen te voorkomen en om het 
behandelplan tijdig aan te kunnen passen, is het van belang om een methode beschikbaar 
te hebben om het therapeutisch effect van de behandeling in een vroeg stadium vast te 
stellen. 
Moleculaire beeldvormingstechnieken kunnen worden gebruikt om in reumatische 
patiënten op een objectieve manier de ernst van de ziekte te bepalen, het therapeutisch 
effect van een medicijn te monitoren en om exacerbaties van de ziekte tijdig te voorspellen. 
Om het behandelplan van een individuele patiënt te kunnen aanpassen dient zo’n 
methode specifiek en sensitief te zijn. Het primaire doel van het preklinische onderzoek 
beschreven in dit proefschrift, was het karakteriseren van beeldvormende technieken die 
gebruikt kunnen worden om therapeutische effecten te monitoren. 
Radioactief gelabelde liposomen
Liposomen zijn kleine vetbolletjes die farmaca, zoals glucocorticoïden (GC), kunnen 
bevatten. Bloedvaten in ontstoken weefsels bevatten grotere fenestra vergeleken met 
bloedvaten in gezond weefsel. Hierdoor kunnen liposomen op deze plaatsen uit de 
bloedbaan treden en ophopen in ontstoken gewrichten. Na uittreden uit de bloedbaan, 
worden ze gefagocyteerd door de aanwezige ontstekingscellen en komt het ingepakte 
farmacon vrij. 
Door liposomen te labelen met een radioactieve stof is het mogelijk om deze na 
injectie te volgen in het lichaam en dit zichtbaar te maken met behulp van moleculaire 
beeldvormingstechnieken zoals positron emission tomography (PET) of single photon 
emission computed tomography (SPECT). Deze technieken kunnen gebruikt worden 
om patiënten te selecteren die mogelijk baat kunnen hebben bij een behandeling 
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met liposomale medicijnen. Wanneer de liposomen bijvoorbeeld niet in de ontstoken 
gewrichten ophopen, zal het medicijn onvoldoende actief zijn in het aangedane gewricht 
en zal er geen therapeutisch effect optreden. In dit geval kan deze patiënt dus worden 
uitgesloten voor deze behandeling. Zo hoeven patiënten niet blootgesteld te worden aan 
bijwerkingen, en kunnen ze eerder overstappen op een effectieve behandeling waardoor 
er geen onnodige kosten gemaakt worden. Een samenvatting over de toepassing van 
radioactief gelabelde liposomen is te vinden in hoofdstuk 2. 
Voorwaarden om een radioactief gelabelde liposomale formulering voor beeldvorming te 
gebruiken is dat deze snel, efficiënt en relatief eenvoudig gelabeld kan worden. In hoofdstuk 
3 worden de labeling van drie verschillende liposomale formuleringen beschreven: 1. 
Lang-circulerende liposomen (LCL) met de chelator di-ethyleentriaminepenta-azijnzuur 
(DTPA) aan de buitenzijde van de liposomen (DTPA-DSPE LCL); 2. LCL met de chelator 
aanwezig in de waterige kern van de liposomen (DTPA LCL); 3. LCL zonder chelator. De 
chelator die hier gebruikt is, DTPA, kan metaalionen complexeren zoals het radioactieve 
metaalion Indium-111 (111In). Het voordeel van de chelator aan de buitenzijde van het 
liposoom is dat 111In niet door de lipide bilaag getransporteerd hoeft te worden. Hierdoor 
is het mogelijk 111InCl3 te gebruiken in plaats van het lipofiele 
111In-oxinaat complex. Wij 
hebben aangetoond dat de labeling het meest efficiënt werkt als de chelator aan de 
buitenzijde van de liposomen beschikbaar is. De aanwezigheid van een chelator bleek 
essentieel voor een efficiënte labeling en de stabiliteit van de gelabelde liposomen. Bij 
gebruik van LCL zonder chelator lekt het 111In label uit de liposomen en komt het vrije 
111In3+ ion in het serum terecht. Vervolgens hebben we het in vivo gedrag van de 111In-DTPA-
DSPE LCL en 111In-DTPA LCL met elkaar vergeleken in muizen met een S. Aureus infectie in 
de dijspier. Het in vivo gedrag van beide formuleringen was vergelijkbaar, wat aantoont 
dat de aanwezigheid van 111In en DTPA geen invloed heeft op de in vivo eigenschappen 
van deze liposomen. Deze studies toonden dus aan dat het labelen van DTPA-DSPE LCL 
met 111InCl3 een robuuste, makkelijke en snelle methode is die de voorkeur heeft boven de 
minder efficiënte labeling van DTPA LCL met 111In-oxinaat. 
Het monitoren van therapie met 18F-FDG PET/CT
Naar de therapeutische effecten van liposomaal GC is veel onderzoek gedaan in 
experimentele modellen van RA en hieruit is gebleken dat behandeling met liposomaal GC 
een snel en langdurig effect oplevert. Er wordt een groot therapeutisch voordeel gezien 
na behandeling met liposomaal GC ten opzichte van vrij GC. Ook wordt verwacht dat de 
ongewenste bijwerkingen verminderd zijn en dat de behandeling minder belastend is 
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voor de patiënt. Het is van belang om snel na de behandeling te weten of de behandeling 
aanslaat. In hoofdstuk 4 is onderzocht of dat gemeten kan worden met 18F-FDG PET/CT. 
In een muizenmodel onderzochten we of de non-invasieve en kwantitatieve methode 
18F-FDG PET/CT gebruikt kan worden om het verloop van de ziekte en het therapeutisch 
effect van liposomaal GC te monitoren. Daartoe werd de ontwikkeling van RA gevolgd in 
muizen met antigeen-geïnduceerde artritis (AIA) in de knie. 18F-FDG hoopt op in cellen 
met een verhoogd metabolisme, zoals ontstekingscellen, en de opname van 18F-FDG 
in de gewrichten was hoger naarmate de ontsteking ernstiger was. De muizen werden 
behandeld met liposomaal prednisolone phosphate (PLP-LCL). PET/CT scans toonden 
een lagere 18F-FDG opname in de aangedane gewrichten na behandeling met PLP-LCL. 
Door kwantitatieve analyse van de 18F-FDG PET/CT scans kon het therapeutisch effect 
van het liposomaal GC gemeten worden. Deze studies lieten zien dat 18F-FDG PET/CT 
een waardevolle methode kan zijn om snel na behandeling een therapeutisch effect te 
meten en dat deze methode potentieel beter is dan de conventionele macroscopische en 
histologische analyses. Wanneer een 18F-FDG PET/CT scan gemaakt wordt voor en na de 
therapie, kunnen de patiënten waarbij de therapie effectief is, worden onderscheiden van 
de patiënten die niet reageren op de behandeling. Voor deze laatste groep zou dan een 
alternatieve behandeling ingezet kunnen worden. 
De 18F-FDG opname in muizen liet echter een grote variatie zien. Het is daardoor belangrijk 
dat de 18F-FDG opname geïnterpreteerd wordt met een scan die gemaakt is voor aanvang 
van de behandeling (baseline) als referentie. 
SPECT/CT met radioactief gelabeld antilichaam tegen fibroblast activation 
protein (FAP)
Om het verloop van een ziekte, of een therapeutisch effect, te kunnen zien met een 
specifieke tracer moet de opname van de tracer in de ontsteking correleren met de ernst 
van de ziekte. Verschillende antilichamen gericht tegen CD-20 of TNFα, zijn gelabeld om 
de ernst van de ontsteking non-invasief te kunnen volgen. Hoewel deze antilichamen 
accumuleerden in de ontstoken gewrichten, werd er geen correlatie gevonden met de 
ernst van de ziekte en konden ze geen directe bijdrage leveren aan de behandeling van 
de patiënt. Fibroblast activation protein (FAP) komt tot overexpressie op geactiveerde 
fibroblast-like synoviocytes (FLS) in ontstoken gewrichten, wat het een geschikt target 
maakt voor moleculaire beeldvorming in RA. 28H1 is een IgG1 antilichaam dat specifiek 
gericht is tegen zowel humaan als murine FAP. Na conjugatie met DTPA of desferal, kan het 
antilichaam gelabeld worden met 111In voor SPECT imaging of met 89Zr voor PET imaging. 
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In hoofdstuk 5 zijn de in vivo eigenschappen van 111In-DTPA-28H1 en 89Zr-desferal-
28H1 in collageen-geïnduceerde artritis (CIA) in muizen beschreven en vergeleken met 
18F-FDG. Beeldvorming met SPECT toonde specifieke accumulatie van het radioactief 
gelabeld 28H1 in de ontstoken gewrichten aan en leverde kwalitatief goede beelden op, 
met minimale opname in andere organen. De opname van zowel 111In-DTPA-28H1 als 
89Zr-desferal-28H1 correleerde met de ernst van de ziekte, zelfs beter dan de correlatie 
van 18F-FDG met de ernst van de ziekte. Helaas was er verhoogde opname van 89Zr te 
zien in de botten na toediening van 89Zr-desferal-28H1. Dit bemoeilijkt de beoordeling 
van de beelden en daarom heeft, zolang er geen chelator is die 89Zr stabiel complexeert, 
111In-DTPA-28H1 de voorkeur. Dit maakt beeldvorming met 111In-gelabeld 28H1 een 
nieuwe, specifieke en sensitieve methode om het verloop van RA te monitoren en is het 
mogelijk een veelbelovende methode om respons op therapie in een vroeg stadium na 
behandeling te monitoren. 
Het monitoren van therapie respons met radiogelabeld anti-FAP antilichamen
Om te onderzoeken of beeldvorming met anti-FAP antilichamen waardevol kan zijn om de 
therapie respons te meten in RA, hebben we in hoofdstuk 6 28H1 gelabeld met 99mTc. We 
hebben voor 99mTc-gelabelde antilichamen gekozen vanwege (1) de lagere stralingsdosis 
in vergelijking met 111In-gelabelde antilichamen, (2) de lagere kosten van het 99mTc en (3) 
omdat 99mTc beter beschikbaar is. In deze experimenten zijn muizen met CIA behandeld 
met PLP-LCL, een behandeling waarvan we weten dat deze effectief is. Vergeleken met de 
gewrichten van behandelde muizen werd er verhoogde opname van 99mTc-HYNIC-28H1 
in gewrichten van onbehandelde muizen gemeten. De zwelling van de gewrichten werd 
ook macroscopisch gescoord. Opmerkelijk was dat ook in gewrichten met de laagste 
macroscopische artritis scores een duidelijke opname van 99mTc-HYNIC-28H1 werd gezien. 
Dit wijst erop dat deze techniek zeer sensitief is. Daarom zou beeldvorming met 99mTc-
HYNIC-28H1 niet alleen bruikbaar zijn voor het volgen van therapeutische effecten, maar 
mogelijk ook om progressie van de ziekte in een vroeg stadium te kunnen detecteren.
We hebben aangetoond dat zowel 99mTc-gelabelde en 111In-gelabelde antilichamen 
geschikt zijn om experimentele artritis in beeld te brengen. De korte halfwaardetijd van 
99mTc (6 uur) leidt tot beelden met een (te) lage count rate 24 h na injectie. Door hoge 
kwaliteit van de SPECT beelden na injectie van 111In-DTPA-28H1, heeft het 111In-gelabelde 
antilichaam onze voorkeur om te gebruiken in vervolgonderzoeken.
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Neutralisatie van IL-22 als behandeling in RA 
IL-22 is een cytokine dat in verhoogde mate aanwezig in de synovia en de circulatie van 
patiënten met RA. Deze IL-22 spiegels correleren met de DAS28 score, reumafactor in het 
serum en anti-cyclic citrullinated peptide (CCP) antilichamen. Het is nog onduidelijk welke 
rol IL-22 speelt in artritis. In vroege fases van CIA verlaagt een IL-22 deficiëntie de kans om 
artritis te ontwikkelen, maar in latere fases lijkt de afwezigheid van IL-22 de ziekte juist te 
verergeren. Meer inzicht in de rol van IL-22 in experimentele artritis is van cruciaal belang 
om te bepalen of IL-22 een therapeutisch target is. In hoofdstuk 7 evalueerden we met 
behulp van 111In-DTPA-28H1 SPECT/CT het therapeutisch effect van IL-22 neutraliserende 
antilichamen. SPECT/CT liet zien dat therapie met anti-IL-22 antilichamen, voordat er 
macroscopisch kenmerken van RA zichtbaar zijn, resulteert in verminderde ontwikkeling 
van de ontstekingen en een lagere opname van 111In-DTPA-28H1 in muizen met CIA. Er 
was echter geen verschil in opname van de tracer wanneer de behandeling gestart werd 
als de muizen macroscopische symptomen vertoonden. Op basis van de SPECT beelden, 
macroscopische scores, histologische scores, en radiologische botschade scores, kunnen 
we concluderen dat IL-22 een belangrijke rol speelt in de ontwikkeling van experimentele 
artritis. Deze resultaten gaven aan dat het neutraliseren van IL-22 een interessante 
benadering is om RA in een vroeg stadium te behandelen. Bovendien hebben we laten 
zien dat beeldvorming met 111In-DTPA-28H1 SPECT/CT een waardevolle methode is om de 
effecten van een nieuwe therapie in beeld te brengen, zelfs wanneer macroscopisch nog 
geen therapeutisch effect waarneembaar is. 
De veelbelovende resultaten van beeldvorming met radioactief gelabelde anti-FAP 
antilichamen wijzen erop dat deze non-invasieve methoden gebruikt kunnen worden 
voor het opstellen van een individueel behandelplan voor een patiënt. Hoewel we ons 
in de preklinische studies hebben gericht op immunoSPECT met radioactief gelabeld 
anti-FAP antilichamen, moeten deze resultaten nog in studies in RA patiënten bevestigd 
worden. 
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